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Abstract	  	  	  Neovascular	  Macular	  Degeneration	  is	  a	  significant	  cause	  of	  blindness	  world–wide.	  Anti-­‐Vascular	  Endothelial	  Growth	  Factor	  medication	  injected	  directly	  into	  the	  eye	  has	  halved	  the	  disease	  burden	  in	  recent	  years.	  	  	  Being	   able	   to	   adequately	   quantify	   the	   outcome	   of	   neovascular	   AMD	  treatment	   gives	   perspective	   not	   only	   on	   appropriate	   intervention	   for	  individual	   patients,	   but	   also	   the	   understanding	   of	   the	   science	   behind	   the	  disease,	  its	  therapeutics	  and	  design	  of	  future	  clinical	  trials.	  	  Assessment	  tools	  can	  be	  either	  subjective	  or	  objective,	  and	  often	  interrogate	  either	  efficacy	  or	  safety	  endpoints.	  Although	  patient	  reported	  Quality	  of	  Life	  utilities	  give	  the	  ultimate	  assessment	  of	  treatment	  success	  for	  an	  individual,	  surrogate	   biomarkers	   are	   more	   effective	   in	   judging	   short-­‐term	   response.	  Visual	  acuity	  assessment	  is	  useful	  in	  analyzing	  cohorts	  of	  individuals,	  but	  its	  subjective	   nature	   means	   that	   it	   is	   not	   particularly	   useful	   in	   determining	  individual	  retreatment	  decisions.	  An	  objective	  morphological	  assessment	  of	  the	  macular	  architecture	  does	  provide	  a	  good	  way	  of	  assessing	  short-­‐term	  response	   however.	   Retinal	   sensitivity	   also	   demonstrates	   usefulness	   as	   an	  endpoint	  for	  clinical	  trials,	  but	  as	  of	  yet	  is	  too	  cumbersome	  a	  technique	  for	  high	  volume	  clinical	  work.	  Functional	  imaging	  of	  the	  visual	  cortex	  remains	  a	  research	  tool	  at	  present,	  but	  provides	  promise	  as	  a	  new	  objective	  endpoint.	  Importantly	   this	   thesis	   has	   confirmed	   that	   that	   cortex	   is	   able	   to	   regain	  function	   after	   a	   short	   period	   of	   compromise	   due	   to	   neovascular	   macular	  degeneration.	  	  Measurement	   tools	   to	   assess	   the	   outcome	   of	   treatment	   are	   best	   selected,	  often	   in	  composite,	  with	  regards	  to	  the	  prime	  reason	  for	  assessment	  being	  undertaken.	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Preface	  	  Neovascular	  or	  ‘wet’	  macular	  degeneration	  is	  a	  devastating	  condition,	  which	  left	  untreated	   leads	  to	   irreversible	  and	  severe	  central	  visual	   loss.	  Although	  typically	  presenting	  in	  one	  eye	  it	  affects	  the	  fellow	  eye	  in	  around	  half	  of	  the	  time	  within	  5	  years.	  Thankfully	  injectable	  treatments	  into	  the	  eye	  that	  target	  the	   key	   chemical	   driver	   of	   the	   disease	   are	   available,	   and	   these	   often	   give	  partial	   visual	   recovery	   with	   long-­‐term	   stability.	   Blind	   registration	   has	  reduced	  by	  half.	  	  Being	  able	  to	  quantify	  the	  outcome	  of	  treatment,	  both	  in	  terms	  of	  safety	  and	  efficacy,	   are	   paramount.	   There	   are	   many	   ways	   of	   being	   able	   to	   assess	  treatment	  outcomes,	  the	  principle	  way	  being	  measuring	  of	  visual	  acuity.	  But	  is	  visual	  acuity	  a	  good	  representation	  of	  visual	  function?	  Ideally	  an	  outcome	  measure	  should	  be	  objective,	  reproducible,	  easy	  to	  acquire	  and	  relevant	   to	  those	   affected.	   A	   greater	   understanding	   of	   outcome	   tools	   will	   allow	   the	  clinical	   and	   scientific	   community	   to	   appropriately	   select	   a	   technique	   to	  assess	  current	  and	  future	  treatments.	  	  Through	   a	   series	   of	   6	   studies,	   each	   asking	   questions	   about	   the	   efficacy	   or	  safety	  of	  treatment	  of	  neovascular	  macular	  degeneration,	  different	  outcome	  measures	  are	  explored.	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Chapter	   1:	   An	   Introduction	   to	   Macular	   Degeneration	   and	   the	  
Assessment	  of	  Treatment	  of	  Neovascular	  Disease.	  
	  
1.	  Overview	  
	  Treatments	   for	   the	   blinding	   disease	   ‘Wet’	   Macular	   Degeneration	   took	   a	  significant	  step	  forward	  a	  decade	  ago	  with	  the	  introduction	  of	  a	  new	  class	  of	  ocular	  therapy,	  Vascular	  Endothelial	  Growth	  Factor	  Inhibitors.	  Being	  able	  to	  measure	   the	   response	   to	   treatment	   accurately	   not	   only	   increases	   our	  understanding	   of	   the	   science	   behind	   such	   treatments	   but	   also	   helps	  establish	  suitable	  treatment	  endpoints.	  	  After	   a	   brief	   introduction	   to	   essential	   ocular	   anatomy	   and	   the	   visual	  pathway	   this	  chapter	  details	  Macular	  Degeneration,	   its	  subtypes,	  diagnosis	  and	  treatments,	  all	  of	  which	  are	  topics	  essential	  to	  the	  understanding	  of	  this	  thesis.	   Furthermore,	   this	   chapter	   discusses	   the	   commonly	   used	   outcome	  measures	  of	  treatments	  and	  a	  selection	  of	  research	  tools,	  before	  formulating	  the	  aims	  of	  this	  thesis.	  
	  
1.1	  The	  Macula	  and	  vision	  
	  Essential	   aspects	   of	   both	   macro	   and	   microscopic	   anatomy	   core	   to	   the	  understanding	  of	  this	  thesis	  are	  detailed	  here.	  	  
1.1.1	  Macroscopic	  ocular	  anatomy	  	  The	  basic	  concept	  of	  the	  anatomy	  of	  the	  eye	  is	  similar	  to	  a	  camera	  with	  light	  rays	  being	  refracted	  at	  the	  optical	  surfaces	  of	  the	  eye,	  primarily	  the	  lens	  and	  cornea	   anteriorly,	   being	   focused	   on	   the	   light	   sensitive	   tissue,	   the	   retina,	  posteriorly.	   Between	   the	   lens	   and	   the	   retina	   lies	   the	   transparent	   vitreous	  gel,	  which	  is	  attached	  to	  the	  retina	  at	  the	  pars	  plana,	  3-­‐4	  mm	  posterior	  to	  the	  cornea.	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1.1.2	  Microscopic	  retinal	  anatomy	  
	  Principally	   three	   types	   of	   cell	   form	   the	   commencement	   of	   the	   visual	  pathways	  within	   the	  retina;	   the	  photoreceptors	   in	   the	  outermost	  aspect	  of	  the	  neurosensory	  retina,	  which	  synapse	  with	  the	  bipolar	  cells,	  which	  in	  turn	  synapse	   with	   the	   retinal	   ganglion	   cells	   at	   the	   innermost	   retina	   (Snell	   &	  Lemp,	   1998).	   In	   addition,	   horizontal	   and	   amacrine	   cells	   provide	   lateral	  connectivity	   between	   cells	   within	   layers,	   and	   Muller	   cells	   provide	   glial	  support	  across	  layers.	  	  Light	   energy	   is	   transduced	   into	   electrical	   signals	   by	   the	   retinal	  photoreceptors	   in	   the	  photo-­‐transduction	  cycle.	  The	  photoreceptors	  are	  of	  two	   types:	   rods	  which	  are	   located	  principally	   in	   the	  peripheral	  part	  of	   the	  retina	  and	  responsible	   for	  non-­‐colour,	  peripheral	  and	   low	   light	  vision,	  and	  cones	   which	   are	   located	   centrally	   and	   are	   responsible	   for	   vision	   in	   high	  illumination	   settings	   allowing	   high	   acuity.	   There	   are	   three	   types	   of	   cones	  which	  have	  maximal	  sensitivity	   in	  the	  short,	  medium	  and	   long	  parts	  of	   the	  visible	   electromagnetic	   spectrum	   often	   referred	   to	   as	   the	   blue,	   green	   and	  red	   cones.	   	   It	   is	   these	   cells	   that	   are	   responsible	   for	   colour	  perception	   at	   a	  retinal	  level.	  Horizontal	  cells	  work	  ‘laterally’	  in	  the	  retina	  providing	  support	  in	   the	   form	   of	   inhibition	   and	   immunomodulation	   between	   the	  photoreceptors	   and	   bipolar	   cells.	   Amacrine	   cells	   play	   a	   similar	   supporting	  role	  within	  the	  retina	  acting	  between	  the	  bipolar	  and	  retinal	  ganglion	  cells	  (Snell	  &	  Lemp,	  1998).	  	  There	   are	   a	   number	   of	   cells	   that	   support	   the	   neurosensory	   aspect	   of	   the	  retina.	   The	   Retinal	   Pigment	   Epithelium	   (RPE)	   lies	   external	   to	   the	  photoreceptor	  layer	  and	  has	  a	  number	  of	  functions	  including	  supporting	  the	  photo-­‐transduction	   cycle,	   light	   absorption,	   phagocytosis	   (engulfing	   foreign	  material)	   and	   ion	   buffering,.	   Beneath	   the	   RPE	   is	   a	   vascular	   layer,	   the	  choriocapillaris.	   The	   choriocapillaris	   supplies	   the	   oxygen	   and	   nutrient	  requirement	   to	   the	   outer	   layers	   of	   the	   retina.	   Its	   innermost	   layer,	   	   the	  basement	   membrane	   termed	   Bruch’s	   membrane,	   is	   shared	   with	   the	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outermost	   layer	   of	   the	   RPE	   and	   serves	   as	   a	   physical	   barrier	   between	   the	  vascular	  system	  and	  the	  retina	  (Snell	  &	  Lemp,	  1998).	  	  The	   macula	   is	   the	   central	   part	   of	   the	   retina,	   usually	   defined	   as	   the	   area	  located	  with	  the	  principle	  retinal	  vascular	  anatomy	  and	  is	  often	  mentioned	  in	  disease	  terminology.	  It	  is	  the	  central	  part	  of	  the	  macula,	  the	  fovea,	  that	  has	  the	  very	  highest	  density	  of	  cone	  photoreceptors	  and	   is	  responsible	   for	  our	  finest	  visual	  acuity	  enabling	  tasks	  such	  as	  reading	  (Snell	  &	  Lemp,	  1998).	  	  
	  
1.1.3	  The	  visual	  pathway	  
	  Following	   their	   synapse	  with	   the	  bipolar	   cells,	   the	  ganglion	   cells,	   of	  which	  there	  are	  approximately	  1	  million	  per	  eye	  at	  birth,	  form	  the	  nerve	  fibre	  layer	  on	  the	  inner	  most	  aspect	  of	  the	  retina.	  The	  axons	  of	  the	  ganglion	  cells	  form	  the	   optic	   nerve,	   which	   passes	   posteriorly	   through	   the	   orbit.	   At	   the	   optic	  chiasm	  the	  nasally	  located	  fibres	  decussate	  and	  with	  the	  temporal	  fibres	  of	  the	   fellow	   eye	   form	   the	   optic	   tracts,	   which	   then	   synapse	   in	   the	   lateral	  geniculate	   nuclei	   (LGN).	   	   The	  onward	  nerve	   fibres	   from	   the	   LGN	   form	   the	  optic	   radiations	   that	  ultimately	  pass	   into	   the	  visual	   cortex	   in	   the	  posterior	  aspect	  of	  the	  occipital	  lobe	  of	  the	  cerebral	  tissue	  (Snell	  &	  Lemp,	  1998).	  	  
1.1.4	  The	  visual	  cortex	  	  The	  visual	  cortex	  is	  the	  aspect	  of	  the	  cerebral	  tissue	  that	   is	  responsible	  for	  processing	   the	   input	   from	   the	   retina	   to	   establish	   visual	   perception.	   The	  primary	   visual	   cortex	   (which	   is	   also	   called	  V1	  or	   the	   striate	   cortex)	   is	   the	  region	  of	   the	   visual	   cortex	   that	   first	   receives	   information	   from	   the	  LGN.	  A	  cortical	  hierarchy	  of	  areas	  termed	  V2,	  V3,	  V4	  and	  V5,	  collectively	  known	  as	  the	   extrastriate	   cortex,	   then	   further	   processes	   the	   information.	   These	  cortical	   regions	   serve	   different	   purposes	   in	   interpreting	   the	   world.	   For	  example	   neurons	   in	   V1	   and	   V2	   respond	   selectively	   to	   bars	   of	   specific	  orientations	   and	   are	   believed	   to	   support	   edge	   and	   corner	   detection.	   In	  addition	  basic	  information	  about	  color	  and	  motion	  is	  processed	  here.	  (Jessel,	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Schwartz	   and	   James,	   2000).	   Other	   areas	   appear	   to	   establish	   specific	  functional	  roles	  in	  motion	  (V5)	  and	  colour	  perception	  (V4)	  (Born	  &	  Bradley,	  2005).	  	  	  	  
1.2	  Macular	  degeneration	  	  Macular	  degeneration	   is	  a	  pathological	  process	  affecting	  the	  central	  retinal	  tissues	   and	   encompasses	   a	   number	   of	   well-­‐defined	   diseases.	   The	   term	  ‘degeneration’	   refers	   to	   the	   ‘loss	   of	   specialist	   structure	   and	   function’	   of	   a	  tissue,	  and	   is	  a	  very	  broad	  definition	  that	  could	   incorporate	  most	  diseases,	  but	  is	  often	  used	  when	  the	  process	  is	  poorly	  understood	  and	  associated	  with	  ageing	  (Underwood,	  1992).	  As	  knowledge	  about	  macular	  degeneration	  has	  grown	  it	  transpires	  that	  there	  is	  a	  genetic	  explanation	  for	  some	  of	  its	  forms;	  in	   the	   age-­‐related	   type	   there	   are	   currently	   20	   known	   genetic	   loci	  responsible	   for	   approximately	   half	   of	   disease	   heritability	   (Fritsche,	   et	   al.	  	  2014).	   This	   calls	   into	   question	   the	   nomenclature	   ‘macular	   degeneration’,	  and	  indeed	  whether	  in	  the	  future	  it	  maybe	  be	  better	  suited	  to	  being	  labeled	  as	   a	   form	  of	   ‘macular	  dystrophy’,	   a	   term	  often	   reserved	   for	   a	   collection	  of	  macular	   pathologies	   that	   have	   a	   strong	   genetic	   influence	   (Kanski,	   1999).	  Nonetheless,	   macular	   degeneration	   is	   a	   condition	   with	   characteristic	  phenotypes.	  	  	  
1.2.1	  Classification	  of	  macular	  degeneration	  	  The	   commonest	   form	   of	   macular	   degeneration	   is	   Age-­‐related	   Macular	  Degeneration	  (AMD).	   It	   is	   the	  commonest	  cause	  of	  blindness	   in	  the	  elderly	  population	  in	  the	  western	  world,	  being	  a	  condition	  diagnosed	  over	  the	  age	  of	   50	   years	   (Ferris	   et	   al	   2013;	   Klien	   et	   al	   2007).	   The	   second	   commonest	  form	  of	  macular	  degeneration	  is	  Myopic	  Macular	  Degeneration	  (MMD),	  often	  occurring	   earlier	   in	   life.	   	   Table	   1	   illustrates	   a	   summary	   of	   macular	  degeneration	  classification	  detailed	  in	  the	  following	  sections.	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   Macular	  Degeneration	  A.	  Age-­‐related	  Macular	  Degeneration	   B.	  Non	  Age-­‐related	  Macular	  Degeneration	  e.g.	  Myopic,	  Hereditary,	  Inflammatory	  1.	  Dry	   2.	  Wet	  	  (or	  ‘neovascular’)	   1.	  Dry	   2.	  Wet	  (or	  ‘neovascular’)	  a.	  Early	   Late	  	  (a.	  Choroidal	  neovascular	  membrane,	  	  b.	  Retinal	  Angiomatous	  proliferation	  or	  c.	  Polypoidal	  choroidal,	  Vasculopathy)	  	  
	  	  Atrophic	  
	  	  Choroidal	  neovascular	  membrane	  
b.	  Intermediate	  (non	  central	  atrophy)	  c.	  Late	  (central	  atrophy)	  
	  
Table	  1.	  A	  summary	  of	  the	  classification	  of	  macular	  degeneration.	  	  
1.2.1.1	  Age-­‐related	  Macular	  Degeneration	  	  A	   common	   classification	   of	   AMD	   is	   into	   ‘Dry’	   and	   the	   less	   common	   ‘wet’	  forms.	  	  
1.2.1.1.1	  Dry	  Age-­‐related	  Macular	  Degeneration	  	  As	   we	   age	   a	   lipid-­‐protein	   rich	   byproduct	   of	   the	   photo-­‐transduction	   cycle,	  lipofuscin,	   causes	   thickening	   of	   Bruch’s	  membrane.	   As	   a	   part	   of	   the	   aging	  process	  this	  material	  accumulates	  beneath	  the	  RPE	  in	  bodies	  called	  Drusen;	  they	  are	  present	  in	  approximately	  two-­‐thirds	  of	  the	  population	  over	  the	  age	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of	   70	   years	   (Rickmen	   et	   al,	   2013).	   This	   accumulation	   is	   considered	   to	   be	  abnormal	   or	   ‘degenerative’	   if	   there	   are	   excessive	   drusen	   or	   additional	  ‘abnormalities’	   of	   the	   RPE.	   These	   abnormalities	   can	   be	   seen	   as	  hyperpigmentation	   of	   the	   RPE,	   which	   is	   noted	   as	   ‘stipulation’	   or	   larger	  ‘clumping’	  of	  pigment,	  or	  alternatively	  there	  can	  be	  loss	  of	  the	  pigmentation	  termed	   hypopigmentation.	   Drusen	   can	   resolve	   or	   can	   evolve	   to	   become	  larger	  or	  worse	  still	  cause	  loss	  of	  the	  associated	  photoreceptors	  and	  RPE	  in	  the	  process	  of	   atrophy	   (Rickmen	  et	   al,	   2013).	   	  Geographic	   atrophy	   (GA)	   is	  observed	   where	   there	   is	   a	   well-­‐defined	   area	   of	   visible	   loss	   of	   the	   RPE	  demonstrated	  by	  the	  clear	  visualization	  of	  the	  choriocapillaris	  blood	  vessels	  beneath	  (Sunness	  et	  al,	  1999).	  	  A	  well-­‐accepted	  classification	  of	  AMD	   is	   that	  described	  by	   the	  Age-­‐Related	  Eye	  Disease	  Study	  Research	  Group	  study	  (AREDS,	  2001a)	  and	  is	  based	  upon	  the	  aforementioned	  clinical	  appearances.	  	  A.	  No	  AMD	  (AREDS	  category	  1).	  No	  or	  a	  few	  small	  drusen	  (<63	  microns	  in	  diameter)	  	  B.	  Early	  AMD	  (AREDS	  category	  2).	  Any	  or	  all	  of	  the	  following:	  multiple	  small	  drusen,	   few	   intermediate	  drusen	   (63	   to	  124	  microns	   in	  diameter),	   or	  RPE	  abnormalities.	  	  C.	   Intermediate	   AMD	   (AREDS	   category	   3).	   Any	   or	   all	   of	   the	   following:	  extensive	  intermediate	  drusen,	  and	  at	  least	  one	  large	  druse	  (≥	  125	  microns	  in	  diameter),	  or	  GA	  not	  involving	  the	  centre	  of	  the	  fovea.	  	  D.	  Advanced	  AMD	  (AREDS	  category	  4).	  GA	  involving	  the	  fovea	  and/or	  any	  of	  the	  features	  of	  neovascular	  AMD	  (AREDs,	  2001a).	  	  Dry	  AMD	  is	  common	  in	  the	  western	  world.	  Estimates	  for	  the	  UK	  population	  are	  a	  prevalence	  of	  late	  AMD	  of	  4.8%	  (95%	  CI	  3.4%	  to	  6.6%)	  of	  those	  over	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65	  years	  of	  age	  and	  12.2%	  (95%	  CI	  8.8%	  to	  16.3%)	  of	  those	  aged	  80	  years	  or	  more	  in	  the	  UK	  (Owen	  et	  al,	  2003).	  	  Those	   affected	  may	   experience	   no	   visual	   symptoms	   in	   the	   early	   phases	   of	  dry	   AMD.	   Difficulty	   in	   reading	   is	   a	   typical	   early	   symptom	   with	   people	  requiring	   more	   light	   and	   having	   a	   reduced	   tolerance.	   Symptoms	   usually	  progress	   slowly	   over	   a	   period	   of	   many	   years.	   Late	   stage	   symptoms	   are	  characterized	  by	  central	  scotomata	  (holes	  in	  the	  vision),	  making	  tasks	  such	  as	  reading	  and	  the	  recognition	  of	  facial	  features	  difficult.	  	  The	   diagnosis	   of	   dry	   AMD	   is	   a	   clinical	   one,	   with	   typical	   changes	   being	  observed	   directly	   by	   ophthalmoscopy.	   It	   is	   usually	   a	   bilateral	   disease,	  although	  progress	  may	  be	  asymmetrical	  (AREDS,	  2001a).	  	  Although	   inhibitors	   of	   the	   pro-­‐inflammatory	   complement	   pathway	   have	  shown	  promise	  to	  slow	  the	  progression	  of	  GA	  in	  early	  phase	  clinical	  studies	  (Do	  et	  al,	  2014),	  currently	  there	  is	  no	  effective	  routine	  clinical	  treatment	  of	  dry	   AMD.	   Vitamin	   supplementation	   in	   the	   form	   of	   high	   dose	   combination	  has	  been	  shown	  to	  reduce	  the	  conversion	  of	   ‘dry’	   to	   ‘wet’	  disease	  however	  (AREDS,	  2001b).	  
	  
1.2.1.1.2	  Neovascular	  Age-­‐related	  Macular	  Degeneration	  	  Neovascular	   (new	   blood	   vessels)	   AMD,	   also	   termed	   ‘wet’	   AMD,	   is	   a	   less	  common	  but	  potentially	  more	  devastating	  form	  of	  the	  disease.	  The	  incidence	  has	   been	   estimated	   at	   450	   per	  million	   in	   the	   UK	   (Owen	   et	   al,	   2003).	   It	   is	  typically	   of	   unilateral	   onset	   with	   the	   second	   eye	   becoming	   involved	   in	  approximately	   25-­‐42%	   after	   5	   years	   (AREDS,	   2001a).	   Neovascular	   AMD	  (nvAMD)	  is	  of	  three	  principle	  types.	  	  	  A. Choroidal	   Neovascular	   Membrane.	   A	   choroidal	   neovascular	  membrane	  (CNV)	  occurs	  when	  there	   is	  a	  breach	  of	  Bruch’s	  membrane,	   the	  tissue	   directly	   beneath	   the	   RPE,	   and	   a	   fibrovascular	   network	   of	   blood	  
	   30	  
vessels	  arises	  from	  the	  choroidal	  circulation.	  A	  breach	  of	  Bruch’s	  membrane	  is	   not	   unique	   to	   AMD.	   It	   also	   occurs	   in	   trauma,	   shortsightedness	   and	  hereditary	   abnormalities	   of	   its	   constituent	   collagenous	   tissue	   such	   as	  pseudoxanthoma	  elasticum,	  but	  dry	  AMD	  is	  the	  commonest	  cause.	  The	  CNV	  enters	   either	   the	   sub	   RPE	   space,	   the	   sub	   retinal	   (neurosensory)	   space	   or	  both.	  These	  blood	  vessels	  are	  abnormal;	  being	  highly	  fenestrated	  they	  leak	  serum	  and	   lipids,	  and	  are	  prone	   to	  haemorrhage	  (Kanski,	  1999).	  Fluid	  can	  accumulate	  beneath	  the	  RPE,	  the	  neurosensory	  retina,	  within	  the	  retina	  and	  cause	  the	  RPE	  to	  detach	  from	  the	  underlying	  Bruch	  membrane	  (a	  so	  called	  ‘Pigment	  Epithelial	  Detachment’	  or	  PED).	  	  	  B. Retinal	   Angiomatous	   Proliferation.	   A	   Retinal	   Angiomatous	  Proliferation	  (RAP)	   lesion	   is	  a	  similar	  neovascular	  abnormality	   to	  CNV	  but	  the	  lesion	  arises	  from	  within	  the	  retina	  (stage	  1).	  The	  lesion	  may	  extend	  to	  below	  the	  neurosensory	  retina	  (stage	  2)	  and	  in	  the	  late	  stage	  of	  the	  disease	  (stage	   3)	   it	   anastomoses	   with	   the	   choroidal	   circulation	   when	   CNV	   then	  becomes	  present	  (Yannuzzi	  et	  al,	  2012).	  	  C. Polypoidal	   Choroidal	   Vasculopathy.	   Polypoidal	   Choroidal	  Vasculopathy	  (PCV)	  is	  also	  a	  form	  of	  wet	  AMD	  usually	  occurring	  at	  a	  slightly	  earlier	   age	   and	   more	   nasal	   in	   the	   macula	   than	   CNV,	   and	   typically	   with	   a	  blood	   filled	   ‘serosanguinous’	   PED.	   PCV	   is	   characterized	   by	   an	   arborizing	  network	   of	   choroidal	   blood	   vessels,	   with	   dilated	   vessels	   that	   are	   seen	   as	  ‘polyps’.	   These	   do	   not	   often	   enter	   the	   sub	   retinal	   space	   and	   are	   only	  associated	  with	  CNV	  in	  approximately	  10%	  of	  cases	  (Yannuzzi	  et	  al,	  1997).	  	  Wet	  AMD	  causes	  symptoms	  of	  acute	  loss	  of	  vision,	  often	  accompanied	  with	  distortion	   of	   lines	   that	   would	   otherwise	   be	   seen	   as	   straight,	   a	   symptom	  known	   as	   metamorphopsia.	   The	   natural	   history	   of	   wet	   macular	  degeneration	  is	  poor	  due	  to	  haemorrhage	  and	  fibrosis	  (scarring)	  ultimately	  disrupting	   the	   function	   of	   the	   retina.	   This	   typically	   leads	   to	   severe	   loss	   of	  central	  vision	  and	  blindness	  over	  a	  period	  of	  many	  months	  (Rosenfeld	  et	  al,	  2006).	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  Diagnosis	  of	  nvAMD	  relies	  on	  clinical	   judgment	  of	   typical	   features	   (AREDS	  2001a)	  at	  ophthalmoscopy	  supported	  by	  investigations.	  Fundus	  Fluorescein	  Angiography	   (FFA)	   is	   required	   to	   confirm	   the	   presence	   of	   CNV,	   whilst	  Indocyanine	   Green	   Angiography	   (ICG)	   confirms	   PCV.	   Both	   of	   these	  techniques	  are	  dynamic	  examinations	  of	   the	   circulation,	  FFA	  of	   the	   retinal	  and	   ICG	  of	   the	   choroidal	   systems.	  Following	   injection	  of	   the	   fluorescein	  or	  Indocyanine	  Green	  dye	  into	  a	  vein	  in	  the	  arm,	  photographs	  are	  taken	  of	  the	  posterior	  aspect	  of	  the	  retina	  (the	  Fundus)	  over	  a	  10-­‐15	  minute	  period.	  Two	  main	  forms	  of	  CNV	  are	  seen	  on	  FFA.	  Classic	  lesions,	  forming	  about	  15	  %	  of	  all	   CNV,	   are	   well	   defined	   in	   the	   early	   stages	   of	   the	   angiogram	   (within	   20	  seconds),	   often	   have	   a	   lacey	   pattern	   and	   demonstrate	   leakage	   in	   the	   later	  stage.	   Occult	   lesions	   are	   ill	   defined,	   are	   often	   described	   as	   having	   a	  ‘speckled’	   hyperfluorescence,	   and	   leak	   in	   the	   later	   stages.	   Commonly	   a	  combination	  of	   the	  two	  patterns	   is	  observed	  and	   lesions	  may	  be	  described	  as	   100%	   classic,	   predominantly	   classic	   (>/=	   50%,	   Figure	   1),	   minimally	  classic	   (<50%)	   or	   occult.	   A	   third	   rare	   description	   of	   ‘late	   leakage	   of	  undetermined	   origin’	   has	   been	  made,	  whereby	   leakage	   is	   not	   seen	   until	   2	  minutes	  or	  more	  after	  the	  dye	  has	  been	  injected	  (Macular	  Photocoagulation	  Study,	  1991).	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Figure	  1.	  A	  Fundus	  Fluorescein	  angiogram	  demonstrating	  a	  predominantly	  classic	  Choroidal	  neovascular	  membrane.	  This	  particular	  image	  of	  the	  FFA	  is	  in	   the	   arterio-­‐venous	   phase	   (the	   dye	   is	   in	   both	   arterioles	   and	   veins).	   It	  demonstrates	   a	   well	   defined	   hyperfluorescent	   area	   (white)	   with	   dark	  pigment	   encircling	   it	   (the	   classic	   component)	   with	   a	   less	   well	   defined	  	  hyperfluorescent	   area	   on	   the	   lower	   right	   border	   demonstrating	   the	   occult	  component.	  	  Optical	   Coherence	   Tomography	   (OCT)	   is	   a	   non-­‐invasive	   method	   of	  evaluating	   the	   retina	   used	   to	   complement	   the	   techniques	   of	   FFA	   and	   ICG.	  OCT	   is	   a	   non-­‐dynamic	   examination	   of	   the	   central	   macular	   region	  demonstrating	   the	   retinal	   and	   to	   a	   lesser	   extent	   adjacent	   choroidal	  architecture.	  OCT	  is	  based	  on	  the	  principle	  of	  analysis	  of	  reflected	  waves	  of	  laser	  light	  to	  from	  a	  2-­‐dimensional	  ‘A-­‐scan’.	  Tissue	  interfaces	  reflect	  the	  light	  allowing	   anatomical	   structures	   to	   be	   defined.	   A	   3-­‐dimensional	   image	   is	  formed	   when	   multiple	   A-­‐scans	   are	   taken	   to	   form	   a	   ‘B-­‐scan’.	   Using	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Fourier/spectral	  domain	  technology	  an	  image	  comprising	  of	  a	  few	  thousand	  cross	  sections	  can	  be	  performed	  in	  a	  few	  seconds	  (Figure	  2).	  	  	  	  
	  	  
Figure	   2.	   A	   spectral	   domain	  OCT	   image	   of	   normal	  macula	   anatomy.	   From	  http://586eyes.com/diagnostic-­‐center/spectralis/.	   Accessed	   23	   September	  2015	  	  	  
1.2.1.1.2.1	   The	   Treatment	   of	   Neovascular	   Age-­‐related	   Macular	  
Degeneration	  	  The	   treatment	   of	   nvAMD	   has	   rapidly	   evolved	   over	   the	   last	   15	   years	   with	  particular	  advancement	  during	  the	  last	  8	  years.	  	  One	   option	   for	   the	   treatment	   of	   CNV	   is	   thermal	   (or	   ‘hot’)	   laser	   therapy.	  Applied	   directly	   to	   the	   lesion	   the	   energy	   cauterizes	   the	   vascular	   network	  and	  so	  prevents	  further	  neovascularisation.	  Significant	  collateral	  damage	  to	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the	  associated	   retina	  and	  RPE	  occurs,	   effectively	  destroying	   the	   tissue	  and	  leaving	  a	  hole	  in	  the	  vision,	  a	  ‘scotoma’.	  Whether	  this	  scotoma	  is	  important	  or	   not	   depends	   on	   its	   location.	   If	   the	   laser	   is	   applied	   to	   a	   CNV	   in	   an	  extrafoveal	  location	  (that	  is	  >200μm	  from	  the	  centre	  of	  the	  fovea)	  then	  the	  induced	   scotoma	  may	  not	   be	   symptomatic	   as	   it	   leaves	   the	  photoreceptor/	  RPE	  complex	  required	  for	  functional	  vision	  unaffected.	  If	  the	  laser	  treatment	  is	   given	   in	   a	   juxtafoveal	   location	   (1-­‐200μm)	   there	   is	   a	   higher	   chance	   of	  symptoms.	   If	   the	   laser	   ‘burn’	   is	   subfoveal	   there	   is	   inevitably	   a	   sudden	  reduction	   in	   vision	   at	   the	   time	   of	   laser	   treatment	   as	   the	   central	   cone	  photoreceptors	   are	   destroyed.	   In	   this	   situation	   the	   resulting	   visual	   loss	   is	  often	   worse,	   at	   least	   initially,	   than	   the	   visual	   loss	   due	   to	   the	   CNV	   itself	  (Macular	   Photocoagulation	   Study,	   1991).	   Thermal	   laser	   is	   now	   only	  recommended	   for	   some	   extrafoveal	   lesions	   when	   other	   forms	   of	   therapy	  may	  not	  be	  in	  the	  best	  interests	  of	  the	  individual.	  	  Photodynamic	   therapy	   involves	   targeting	   the	   CNV	   with	   a	   different	  wavelength	   of	   (‘cold’)	   laser	   to	   try	   and	   minimize	   collateral	   damage.	   An	  ‘exciting’	   agent,	   verteporfin,	   is	   injected	   into	   the	   systemic	   circulation.	   After	  83	  seconds	  it	  accumulates	  in	  a	  higher	  concentration	  in	  the	  choroidal	  rather	  than	  the	  retinal	  circulation.	  The	  applied	  laser	  then	  induces	  a	  photochemical	  effect	   treating	   the	   CNV	   but	  minimizing	   damage	   to	   the	   surrounding	   retina.	  Although	   this	   had	   a	   statistically	   beneficial	   effect	   on	   reducing	   the	   speed	   of	  visual	  loss	  due	  the	  CNV,	  translated	  into	  clinical	  effect	  the	  results	  were	  often	  disappointing	  (TAP	  study,	  1999).	  	  The	  major	  breakthrough	  in	  treatment	  of	  nvAMD	  occurred	  when	  for	  the	  first	  time	   a	   treatment	   became	   available	   that	   enabled	   some	   restoration	   and	  stabilisation	  of	  vision.	  Vascular	  Endothelial	  Growth	  Factor	  (VEGF)	  is	  one	  of	  the	  principle	  chemical	  transmitters	  that	  promotes	  the	  growth	  and	  leakage	  of	  blood	  vessels.	  	  It	  is	  found	  in	  a	  particularly	  high	  concentration	  in	  association	  with	   neovascularisation.	   Anti-­‐Vascular	   Endothelial	   Growth	   Factor	   (anti-­‐VEGF)	  agents	  are	  commonly	  used	  to	  treat	  new	  blood	  vessel	  growth	  in	  cancer	  often	   being	   used	   as	   adjunctive	   chemotherapeutic	   agents.	   A	   trial	   of	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intravenous	   injection	  of	   bevacizumab	   (trade	  name	  Avastin,	  Genentech	   Inc.	  USA)	   in	   9	   patients	   with	   nvAMD	   demonstrated	   an	   improvement	   in	   visual	  acuity,	   reduction	   in	   leakage	   of	   CNV	   on	   FFA	   imaging	   and	   thinning	   of	   the	  retina	   using	   OCT	   (Michele,	   Rosenfeld,	   Puliafito,	   Marcus	   &	   Venkatrman,	  2005).	  A	  subsequent	  trial	  of	  injection	  of	  a	  small	  volume	  of	  bevacizumab	  into	  the	  vitreous	  body	  via	  the	  pars	  plana	  demonstrated	  resolution	  of	  subretinal	  fluid	   and	   visual	   improvement	   (Rosenfeld,	  Moshfeghi	  &	   Puliafito,	   2005).	   In	  parallel	   to	   this	   ‘off-­‐label’	   use	   of	   bevacizumab,	   ranibizumab	   (trade	   name	  Lucentis,	   Genentech	   Inc.	   USA)	   was	   being	   developed	   from	   just	   the	  monoclonal	   antibody	   fragment	   of	   bevacizumab,	   as	   a	   treatment	   specifically	  licensed	  for	  nvAMD.	  Ranibizumab	  is	  a	  humanised	  recombinant	  monoclonal	  antibody	   fragment	   targeted	   against	   human	   vascular	   endothelial	   growth	  factor	   A	   (VEGF-­‐A).	   It	   binds	   with	   high	   affinity	   to	   all	   the	   VEGF-­‐A	   isoforms	  thereby	   preventing	   binding	   of	   VEGF-­‐A	   to	   the	   receptors	   VEGFR-­‐1	   and	  VEGFR-­‐2.	  	  	  Landmark	   clinical	   trials	   (Brown	   et	   al,	   2006;	   Rosenfeld	   et	   al,	   2006)	   using	  fixed	  monthly	  injection	  of	  ranibizumab	  demonstrated	  a	  mean	  gain	  in	  visual	  acuity	   after	   3-­‐4	   injections	   with	   relative	   stability	   thereafter.	   Ranibizumab	  (marketed	   by	   Novartis	   Pharmaceuticals	   AG	   in	   Europe)	   was	   licensed	   in	  Europe	   in	   2006	   and	   approved	   for	   routine	   use	   in	   the	  NHS	   by	   the	  National	  Institute	  for	  Health	  and	  Clinical	  Excellence	  in	  August	  2008	  (NICE,	  2008).	  In	  the	  UK,	  due	  to	  its	  unlicensed	  nature	  and	  the	  NICE	  2008	  ruling,	  bevacizumab	  is	  rarely	  used,	  but	   in	  many	  other	  countries	   it	   is	  used	  more	  commonly	  than	  ranibizumab.	   It	   is	   worth	   noting	   that	   the	   same	   company,	   Genentech,	  manufactures	  both	  agents.	  The	  fact	  that	  Avastin,	  at	  the	  volume	  required	  for	  the	  eye,	  is	  significantly	  cheaper	  than	  ranibizumab	  and	  is	  not	  recommended	  for	   the	   use	   in	   the	   eye	   by	   Genentech	   has	   led	   to	   much	   controversy.	  Independent	  comparative	  trials	  for	  efficacy	  have	  led	  many	  commentators	  to	  describe	  similar	  efficacy	  with	  possible	  minor	  differences	   in	  systemic	  safety	  signals	   at	   a	   population	   level	   between	   the	   agents.	   The	   debate	   continues.	  (Martin,	   Maguire,	   Ying,	   Grunwald,	   2011;	   Chakravarthy,	   Harding,	   Rogers,	  Downes,	  Lotery,	  Wordsworth,	  et	  al	  2012).	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  In	  July	  2013	  the	  molecule	  aflibercept	  (trade	  name	  Eylea,	  Bayer	  HealthCare)	  was	   approved	   by	   NICE	   for	   use	   in	   nvAMD.	   Aflibercept	   is	   a	   fusion	   protein	  designed	  to	  bind	  multiple	  isoforms	  of	  Vascular	  Endothelial	  Growth	  Factor-­‐A	  (VEGF-­‐A)	   and	   Placental	   Growth	   Factor	   (PlGF).	   PlGF	   is	   another	   protein	  involved	  in	  the	  abnormal	  growth	  of	  new	  blood	  vessels.	  Visual	  acuity	  results	  have	   been	   similar	   to	   those	   in	   the	   clinical	   trials	   studying	   ranibizumab,	   but	  dosing	   is	   different.	   Both	   products	   are	   given	  monthly	   for	   three	   doses	   then	  aflibercept	   is	   given	  8	  weekly	   for	   the	   first	   year	   rather	   than	   the	  monthly	   as	  required	  schedule	  for	  ranibizumab	  (Schmidt-­‐Erfurth	  et	  al,	  2014).	  	  It	   has	   become	   clear	   that	   anti-­‐VEGF	   agents,	   for	   all	   their	   ability	   to	   restore	  some	   vision	   do	   not	   provide	   a	   cure	   for	   neovascular	   disease.	   By	   in	   large	  treatments	   simply	   suppress	   disease	   until	   the	   clinical	   effect	   is	   no	   longer	  apparent	   and	   treatment	   is	   re	   administered.	   Consequently	   the	   majority	   of	  those	  with	   neovascular	   disease	   need	   to	   be	  monitored	   for	   signs	   of	   disease	  activity	  and	  treated	  in	  the	  long	  term	  (Rofagha	  et	  al	  2013;	  Tufail	  et	  al,	  2014;	  Airody,	  Venugopal,	  Allgar	  &	  Gale,	  2014).	  	  	  The	  effect	  of	  introduction	  of	  anti-­‐VEGF	  agents	  for	  treatment	  of	  neovascular	  AMD	   has	   been	   truly	   remarkable:	   the	   burden	   of	   blindness	   has	   reduced	   by	  approximately	  50%	  over	  the	  last	  decade	  (Bloch	  et	  al,	  2012).	  	  
1.2.1.2	  The	  Pathogenesis	  of	  Age-­‐related	  macular	  degeneration	  
	  The	  pathogenesis	  of	  AMD	  is	  multifactorial.	   It	  can	  be	  thought	  of	   in	   terms	  of	  predisposing	  factors,	  and	  triggers	  /	  drivers	  of	  the	  disease	  ultimately	  leading	  to	  chronic	  destructive	  inflammation	  (Table	  2).	  A	  number	  of	  candidate	  genes	  have	   supported	   that	   notion	   that	   there	   is	   a	   strong	   genetic	   component	  predisposing	   to	   AMD.	   Complement	   factor	   H,	   being	   one	   of	   this	   first	   major	  genes	  to	  be	  identified	  with	  a	  mutation	  in	  C3,	  confers	  a	  2.6	  times	  greater	  risk	  of	   developing	   the	   disease	   (Thakkinstian,	   et	   al,	   2006).	   The	   complement	  pathway	   is	   one	   of	   the	   naturally	   occurring	   pro	   inflammatory	   pathways.	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Oxidative	  stress	  is	  the	  key	  mechanism	  in	  the	  development	  and	  progression	  of	  the	  disease	  through	  the	  production	  of	  free	  radicals	  and	  ultimately	  chronic	  inflammation	  of	  the	  retinal	  tissues.	  Oxidative	  stress	  occurs	  through	  disease	  triggers	  and	  drivers	  such	  as	  smoking,	  hyperglycemia,	  poor	  vascular	  disease,	  as	  well	  as	  the	  age-­‐associated	  accumulation	  of	   lipofuscin	  by-­‐products	  of	  the	  photoreceptor	   transduction	   cycle.	   	   As	   we	   age	   naturally	   occurring	   anti-­‐oxidants	   in	   the	   macula,	   such	   as	   the	   carotenoid	   pigments	   lutein	   and	  zeaxanthin,	  are	  less	  able	  to	  protect	  against	  these	  harmful	  stresses.	  The	  end	  result	   of	   all	   of	   these	   factors	   is	   an	   increased	   production	   of	   chronic	  inflammation	  with	  a	  reduced	  ability	  to	  be	  able	  to	  keep	  this	  in	  check	  (Pujol-­‐Lereis,	  SChlafer,	  Kuhn,	  Rohner,	  Pauly,	  2016)	  
	   Pathogenesis	  of	  AMD	  Predisposition	   Genetic	  mutations	  e.g.	  Complement	  factor	  H	  Triggers/	  Drivers	   e.g.	  	  Smoking	  Hyperglycemia	  Lipofuscin	  accumulation	  Retinal	  Destruction	   Chronic	  Inflammation	  
	  
Table	   2.	   A	   summary	   of	   the	   pathogenesis	   of	   Age-­‐related	   Macular	  
Degeneration	  	  
1.2.1.3	  Myopic	  Macular	  Degeneration	  	  Pathological	  myopic	  degeneration	  is	  the	  second	  commonest	  form	  of	  macular	  degeneration.	   It	   is	   diagnosed	   by	   characteristic	   ocular	   appearances	   in	  patients	   with	   at	   least	   6	   Dioptres	   of	   Myopic	   correction.	   It	   affects	  approximately	   2–4%	   of	   Caucasians	   and	   9–21%	   of	   Asian	   populations	  (Montero	  &	  Ruiz-­‐Moreno,	  2010;	  Soubrane,	  2008).	  In	  a	  similar	  way	  to	  AMD	  it	  can	  be	  divided	  into	  dry	  (atrophic)	  and	  wet	  (neovascular)	  forms.	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1.2.1.3.1	  	  Atrophic	  Myopic	  Degeneration	  	  A	  characteristic	   feature	  of	  dry	  degeneration	  due	  to	  myopia	   is	  peripapillary	  (adjacent	  to	  the	  optic	  disc)	  atrophy	  of	  the	  retina	  and	  RPE.	  This	  can	  progress	  to	  affect	  the	  central	  macula	  and	  fovea	  causing	  profound	  visual	  loss.	  	  
1.2.1.3.2	  Neovascular	  Myopic	  Degeneration	  	  The	  central	  vision	   loss	  that	  can	  occur	   in	  patients	  with	  pathological	  myopia	  (PM)	  most	  commonly	  results	  from	  CNV.	  It	  occurs	  in	  4–11%	  of	  affected	  eyes	  and	   predominantly	   in	   those	   younger	   than	   50	   years	   of	   age.	   The	   natural	  history	   dictates	   that	   almost	   90%	   of	   eyes	   will	   develop	   severe	   visual	   loss	  (20/200	   or	   less)	   after	   5–10	   years	   (Yoshida,	   Ohno-­‐Matsui	   &	   Yasuzumi,	  2003).	   The	   chance	   of	   the	   fellow	   eye	   being	   affected	   is	   high	  with	   around	   a	  third	   being	   affected	   within	   8	   years	   (Ohno-­‐Matsui,	   Yoshida	   &	   Futagami,	  2003).	  	  
1.2.1.3.2.1	  The	  Treatment	  of	  Neovascular	  Myopic	  Degeneration	  	  In	  a	  similar	  manner	  to	  Laser	  based	  therapies	  for	  CNV	  associated	  with	  AMD,	  thermal	   laser	   for	  pathological	  myopia	   is	   of	   limited	  value.	  Thermal	   laser	   to	  subfoveal	   lesions	  will	   cause	   severe	   and	   immediate	   visual	   loss.	  Whilst	   this	  does	   not	   occur	   with	   thermal	   treatment	   of	   juxta-­‐	   and	   extrafoveal	   lesions,	  expansion	  of	   the	   laser	   induced	   chorioretinal	   scar	   into	   a	   subfoveal	   location	  characteristically	  seen	  in	  myopia,	  and	  a	  high	  recurrence	  rate,	  dictates	  that	  it	  is	  rarely	  used.	  (Chan	  et	  al,	  2005;	  Secretan,	  Kuhn,	  Soubrane	  &	  Coscas,	  1997).	  	  	  Photodynamic	   therapy	   using	   verteporfin	   was	   the	   mainstay	   of	   treatment	  until	   injectable	  treatment	  started	  being	  used,	  but	  at	  best	  this	  slowed	  down	  the	  progression	  of	  visual	   loss.	  Data	  from	  a	  large	  multinational,	  randomized	  clinical	   trial	  demonstrated	  a	  significant	  benefit	   for	  PDT	  over	  sham	  therapy	  for	  the	  primary	  end	  point	  of	  what	  was	  considered	  to	  be	  clinically	  significant	  vision	  loss	  (72%	  versus	  44%;	  p	  <	  0.01),	  but	  this	  effect	  was	  lost	  after	  2	  years	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(64%	  versus	  49%	  p=0.01)	   (Blinder,	  Blumenkranz	  &	  Bressler,	  2003).	  Small	  case	  series	  using	  the	   ‘off-­‐label’	   intravitreal	  anti-­‐VEGF	  agents	  show	  promise	  in	  outperforming	  PDT	  (Cohen,	  2009).	  	  
1.3	   Measuring	   outcomes	   of	   treatment	   of	   neovascular	   macular	  
degeneration	  	  Having	   established	   there	   are	   now	   successful	   treatments	   for	   neovascular	  macular	   degeneration	   (nvMD)	   is	   it	   important	   to	   be	   able	   to	   quantify	   their	  outcome,	  not	  only	  from	  a	  clinical	  standpoint	  but	  also	  from	  a	  scientific	  point	  of	  view.	  Outcomes	  measurements	  can	  be	  broadly	  divided	  into	  the	  following	  categories:	  	  
A.	  Anatomical.	   A	   measure	   of	   anatomical	  restoration	  
B.	  Functional.	  	  	  	   i)	  Clinician	  /	  scientist	  measured.	   A	  measure	  of	  restoration	  of	  visual	  function	  	  
	   ii)	  Patient	  /	  participant	  reported.	  	  	   Patients’	   own	   perception	   of	  improvement	  	  
1.3.1	  	   Anatomical	   outcomes	   of	   treatment	   of	   neovascular	   macular	  
degeneration	  	  Restoration	  of	  the	  anatomy	  of	  the	  retina,	  RPE	  and	  choroid	  to	  its	  pre	  diseased	  state	  is	  a	  key	  goal	  of	  treatment	  of	  nvMD	  (Brown	  et	  al,	  2006;	  Rosenfeld	  et	  al,	  2006;	  Martin	  et	   al,	   2011;	  Chakravarthy	  et	   al,	   2012).	  The	  principle	  ways	  of	  measuring	  the	  anatomy	  have	  been	  introduced	  already:	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1.3.1.1	  Angiography	  	  FFA	  and	  ICG	  are	  excellent	  tools	  and	  are	  still	  considered	  the	  gold	  standard	  in	  diagnosis	  of	  nvMD.	  Leak	  of	  the	  fluorescein	  dye	  out	  of	  the	  abnormal	  vascular	  network	  on	  FFA	  is	  a	  marker	  of	  neovascular	  disease	  activity.	  The	  fluorescein	  or	   indocyanine	  dye	   is	  administered	   intravenously	  and	  although	  some	  form	  of	  abnormal	  reaction	  such	  as	  nausea,	  vomiting	  or	  rash	  is	  relatively	  common	  (5-­‐10%),	  anaphylactic	  reaction	  leading	  to	  death	  is	  very	  rare	  (1	  in	  250,000).	  Given	  the	  invasiveness	  of	  these	  techniques	  FFA	  and	  ICG	  are	  rarely	  routinely	  used	  to	  monitor	  disease	  progress	  at	  every	  patient	  visit	  and	  therefore	  limits	  its	  use	  as	  a	  high	  volume	  tool	  for	  assessment.	  
	  
1.3.1.2	  Optical	  Coherence	  Tomography	  derived	  outcomes	  	  The	  principles	  of	  OCT	  have	  been	  described	  above.	  It	  is	  a	  rapid,	  non-­‐invasive	  method	  of	  measuring	  single	  time	  point	  anatomy	  and	  therefore	  useful	  when	  high	  volumes	  of	  assessments	  are	  required.	  Common	  resolution	  of	  the	  OCT	  in	  a	  clinical	  based	   instrument	   is	  6μm	  (Cirrus	  OCT,	  Carl	  Zeiss	  Meditec,	  Dublin,	  CA).	  OCT	  is	  useful	  if	  defining	  normal	  anatomy	  and	  pathological	  changes	  such	  as:	  	  	  A. Tissue	   loss	   (for	   example	   atrophy	   of	   the	   inner	   and	   outer	   segment	  junction	   of	   the	   photoreceptors	   or	   loss	   of	   the	   contact	   cylinder	   of	  photoreceptor	  /	  RPE	  junction).	  B. New	  tissue	  (such	  as	  sub	  retinal	   fibrosis	  occurring	  secondary	   to	  a	  CNV.	  Fibrosis,	  haemorrhage	  and	  CNV	  all	  have	  similar	  reflectivity	  so	  distinguishing	  between	  these	   is	  not	  accurate	  and	  they	  are	  often	  grouped	  together	  as	   ‘Sub	  Retinal	  Highly	  Reflective	  Material’	  or	  SHRM).	  C. New	   spaces	   (which	   may	   be	   assumed	   to	   be	   fluid	   filled,	   such	   as	   intra	  retinal	   fluid	   or	   subretinal	   fluid	   associated	   with	   incompetent	   new	   blood	  vessels,	  or	  alternatively	  neuronal	  loss).	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OCT	  alone	  does	  not	  give	  a	  dynamic	  assessment	  of	  anatomy	  and	  so	  it	   is	  not	  possible	  to	  distinguish	  whether	  fluid	  seen	  on	  an	  image	  is	  a	  stagnant,	  inactive	  ‘pool’	   or	   a	   ‘leak’	   denoting	   active	   disease.	   Given	   the	   characteristics	   of	   CNV,	  assumptions	  are	  often	  made	  based	  on	  previous	  history,	  findings	  and	  clinical	  experience.	   OCT	   is	   also	   limited	   by	   its	   resolution.	   It	   follows	   that	   if	   higher	  resolution	  technology	  were	  available	  more	  detailed	  anatomy	  and	  pathology	  could	  be	  observed,	  which	  in	  turn	  may	  influence	  treatment	  criteria.	  	  
	  	  
Figure	   3.	   	   A	   Spectral	   domain	   OCT	   image	   through	   the	   central	   macula	  demonstrating	  neovascular	  age-­‐related	  macular	  degeneration.	  The	  left	  side	  of	   the	   image	   demonstrates	   elevated	   areas	   of	   the	   RPE	   (‘pigment	   epithelial	  detachments’)	   and	   fluid	   (dark)	   beneath	   retina	   and	   above	   the	   RPE	   (‘sub	  retinal	  fluid’).	  	  
1.3.2	   Functional	   outcomes	   of	   treatment	   of	   neovascular	   macular	  
degeneration	  	  Restoration	  of	  retinal	  anatomy	  does	  not	  necessarily	   lead	  to	  the	  restoration	  of	   function	   as	   ‘damage’	   to	   the	   integrity	   of	   the	   tissue	  may	   occur.	   Anatomy	  may	   therefore	   not	   be	   a	   good	   surrogate	  marker	   of	   function.	   The	   following	  section	   introduces	   the	   techniques	   of	   visual	   acuity,	   microperimetry,	  functional	  magnetic	   resonance	   imaging	   and	   patient	   reported	   outcomes	   as	  markers	  of	  functional	  outcomes	  of	  treatment	  of	  nvMD.	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1.3.2.1	  Visual	  Acuity	  	  Visual	  acuity	   is	  a	  measure	  of	  the	  spatial	  resolution	  of	  the	  visual	  processing	  system	   and	   is	   dependent	   of	   the	   entire	   visual	   pathway.	   Visual	   acuity	   is	  commonly	  measured	  by	  testing	  the	  ability	  to	  read	  high	  contrast	  black	  letters	  (optotypes)	   on	   an	   illuminated	   background	   at	   6	   metres,	   a	   distance	   that	   is	  assumed	   to	   be	   at	   infinity	   for	   optical	   purposes.	   The	   Snellen	   chart	   is	   a	  common	  example,	   and	  uses	   rows	  of	   letters	   that	  decrease	   in	   size	  down	   the	  chart.	   A	   person	   with	   normal	   vision	   would	   be	   assumed	   to	   able	   to	   see	   the	  letters	  on	  the	  row	  marked	  ‘6’	  at	  6	  metres,	  so	  called	  ‘6/6’	  vision.	  This	  gives	  an	  angle	  of	  resolution	  of	  1	  minute	  of	  arc.	  The	  less	  far	  down	  the	  chart	  is	  read,	  the	  higher	   the	   denominator	   resulting	   in	   a	   value	   that	   represents	  worse	   vision.	  The	   ability	   to	   read	   letters	   on	   a	   chart	   is	   influenced	   by	   a	   number	   of	   factors	  associated	   with	   the	   chart	   itself	   such	   as	   the	   contrast	   of	   the	   optotype	  compared	  with	  the	  background,	  the	  duration	  of	  presentation	  of	  the	   letters,	  the	   type	   of	   optotype	   and	   interaction	   effects	   from	   adjacent	   letters	   (the	  crowding	  effect	  of	  adjacent	  letters)	  (Kaiser,	  2009).	  	  The	   Bailey-­‐Lovie	   chart	   uses	   a	   constant	   number	   of	   letters	   per	   line	   with	   a	  constant	  amount	  of	   spacing	  and	  so	  overcomes	   the	   issue	  of	   spacing.	   It	  uses	  optotype	   that	   decreases	   in	   size	   in	   a	   logarithmic	   manner	   and	   so	   is	   often	  termed	   called	   a	   LogMAR	   chart.	   In	   1982	   the	   chart	   was	   adapted	   using	   the	  ‘Sloan’	  selection	  of	   letters	   from	  the	  alphabet,	   these	   letters	  all	  being	  equally	  recognisable,	   for	   the	   Early	   Treatment	   of	   Diabetic	   Retinopathy	   Study.	   The	  “ETDRS’	  chart,	  having	  20	  rows	  of	  5	   letters	  on	  each	  row	  has	  since	  been	  the	  standard	   for	   visual	   acuity	  measurement	   in	   clinical	   trials	   and	  gives	   a	   letter	  score	  of	  0-­‐100.	  (Ferris,	  Kassoff,	  Bresnick	  &	  Bailey,	  1982;	  Ferris	  and	  Bailey,	  1996).	  	  Although	   visual	   acuity	   remains	   the	   gold	   standard	   assessment	   tool	   for	  measuring	   visual	   function,	   it	   is	  widely	   recognized	   that	   these	  high	   contrast	  tests	  of	  vision	  underestimate	  the	  level	  of	  visual	   impairment,	  particularly	  in	  older	   patients	   (Scott,	   Schein	   &	   West,	   1994;	   West,	   Munoz	   &	   Rubin,	   1997;	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Mangione,	  Gutierrez,	  Lowe,	  Orav	  &	  Seddon,	  1999;	  Maclure,	  Hart	  and	  Jackson	  2000:	  Hazel,	  Petre,,	  Armstrong,	  Benson	  &	  Frost,	  2000).	  	  
1.3.2.2	  Retinal	  sensitivity	  as	  performed	  by	  Microperimetry	  	  Perimetry	   is	   a	   psychophysical	   method	   of	   assessing	   retinal	   sensitivity.	   A	  visual	   stimulus	   is	   presented	   to	   a	   subject	   in	   a	   part	   of	   their	   field	   of	   vision	  corresponding	  to	  the	  area	  of	  the	  retina	  under	  examination.	  If	  they	  perceive	  the	   stimulus	   a	   positive	   response	   is	   made.	   The	   size,	   intensity,	   type	   (for	  example	   a	   light,	   hand	  movements	   or	   coloured	   object)	   and	   location	   of	   the	  stimulus	   can	   be	   selected	   depending	   upon	   the	   question	   being	   asked	   of	   the	  subject.	   Two	   broad	   techniques	   are	   used	   the	   map	   the	   field	   of	   vision:	  movement	   of	   a	   constant	   stimulus	   from	   the	   least	   sensitive	   peripheral	   field	  towards	  the	  centre	  until	  it	  is	  seen	  (‘kinetic	  perimetry’),	  or	  the	  use	  of	  stimuli	  which	  are	  presented	  in	  a	  constant	   location	  but	   increasing	  in	   intensity	  until	  the	   threshold	   for	   identification	   is	  reached	  (‘static	  perimetry’).	   	  An	  example	  of	  kinetic	  perimetry	   is	   the	  Goldmann	  technique.	  The	  particular	   importance	  of	  this	  technique	  is	  that	  the	  size	  and	  intensity	  of	  the	  stimulus	  it	  uses	  have	  set	  standards	  used	  with	  other	  technologies.	  The	  stimulus	  size	  varies	  between	  0	  and	   V	   (roman	   numerals)	   and	   intensity	   between	   1	   and	   4	   (for	   each	   5dB	  increase),	  further	  refined	  by	  a	  to	  e	  for	  1dB	  increments.	  (Cohen	  &	  Kawasaki,	  1999).	  Typically	  I4e	  is	  used	  for	  a	  peripheral	  assessment	  and	  I2e	  for	  a	  central	  assessment.	  	  An	   automated	   process	   of	   perimetry	   enables	   the	   determination	   of	   retinal	  sensitivity	   in	   a	   numerous	   fine	   locations	   in	   a	   reliable	   and	   reproducible	  manner	   if	   so	   required.	   A	   key	   aspect	   of	   perimetry	   is	   ensuring	   the	   subject	  maintains	  fixation	  of	  vision	  in	  a	  constant	  place	  throughout	  the	  examination	  and	  hence	  eye	  movements	  are	  kept	  to	  a	  minimum.	  Automated	  perimetry	  is	  most	   commonly	   used	   to	   diagnose	   and	   monitor	   the	   effect	   of	   treatment	   of	  visual	   field	   defects	   in	   glaucoma,	   a	   condition	   affecting	   the	   optic	   nerve	   that	  characteristically	  produces	  peripheral	  visual	  defects.	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Microperimetry	  enables	   the	  determination	  of	   the	  map	  of	  retinal	  sensitivity	  in	   a	   much	   smaller	   field	   than	   conventional	   perimetry.	   This	   technique	   was	  first	   developed	   using	   a	  modified	   colour	   camera	   and	   subsequently	   using	   a	  scanning	  laser	  ophthalmoscope,	  a	  method	  using	  laser	  technology	  to	  view	  the	  retina	   in	  real	   time	  and	  therefore	  monitor	  the	  precise	  retinal	   localization	  of	  the	  stimulus	  and	  the	  ability	  of	  the	  patient	  to	  maintain	  fixation	  (Van	  de	  Velde,	  Timberlake,	   Jalkh	   &	   Schepens,	   1990).	   The	   Nidek	   MP-­‐1	   Microperimeter	  (Nidek	  Technologies,	  Padova,	  Italy)	  uses	  an	  infrared	  camera	  in	  conjunction	  with	   an	   automated	   eye-­‐tracking	   system	   that	   shifts	   the	   position	   of	   what	  should	   be	   constant	   stimulus	   locations	   to	   compensate	   for	   small	   eye	  movements.	  This	  allows	   for	  precise	  microperimetric	   assessment	  of	   central	  field	  sensitivities	  (Squirrel	  &	  Elrich,	  2012).	  	  Squirrel	   et	   al	   studied	   a	   small	   number	   of	   patients	   before	   and	   after	  commencing	   anti-­‐VEGF	   treatment	   for	   nvAMD.	   They	   used	   the	   MP-­‐1	  microperimeter	   with	   45	   Goldman	   III	   (medium)	   sized	   stimuli	   over	   a	   12-­‐degree	  macular	  area.	  After	  the	  first	  3	  doses	  of	  treatment	  there	  was	  a	  mean	  increase	   of	   6	   (-­‐15	   to	   +12)	   ETDRS	   letters	   and	   2.85	   (SD	   1.55)	   dB	   retinal	  sensitivity.	  Based	  on	  only	  1	  of	  10	  patients	  having	  an	  improvement	  in	  visual	  acuity	   but	   8	   of	   10	   having	   an	   improvement	   in	   retinal	   sensitivity,	   they	  concluded	   that	   visual	   acuity	   appeared	   to	   underestimate	   the	   functional	  improvement	  seen	  with	  retinal	  sensitivity	  (Squirrel,	  Mawer,	  Mody	  &	  Brand,	  2010).	  	  
1.3.2.3	   	   The	   BOLD	   response	   as	   measured	   by	   Functional	   Magnetic	  
Resonance	  Imaging	  	  Functional	  Magnetic	  Resonance	  Imaging	  (fMRI)	  is	  a	  neuroimaging	  technique	  that	  uses	  Magnetic	  Resonance	  Imaging	  (MRI)	  to	  measure	  functional	  changes	  in	   the	   brain	   based	   upon	   blood	   oxygenation	   (and	   probably	   volume).	   As	  neuronal	  activity	  increases	  there	  is	  an	  increase	  in	  the	  amount	  of	  oxygenated	  blood	  compared	  with	  deoxygenated	  blood.	  The	  additional	  oxygenated	  blood	  also	  enables	  the	  delivery	  of	  glucose	  to	  neurons	  so	  they	  can	  be	  repolarized,	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i.e.	   returned	   to	   their	   ready	   state,	   following	   previous	   activity.	   Neuronal	  activity	   causes	   a	   release	  of	   glutamate,	  which	  ultimately	   leads	   to	   release	  of	  nitric	  oxide,	  a	  powerful	  vasodilator,	  and	  so	  increases	  blood	  flow.	  	  Deoxygenated	   hemoglobin	   is	  more	  magnetic	   than	   oxygenated	   hemoglobin	  leading	  to	  an	  increase	  in	  the	  Magnetic	  Resonance	  (MR)	  signal	  detected.	  This	  improvement	   can	   be	   mapped	   to	   show	   which	   neurons	   (or	   in	   fact	   many	  thousands	   of	   neurons	   in	   a	   small	   volume	   called	   a	   voxel)	   are	   active	   at	   a	  particular	  time.	  This	  so	  called	  Blood	  Oxygenation	  Level	  Dependent	  (BOLD)	  contrast	  was	  taken	  advantage	  of	  by	  Ogawa	  in	  1990	  who	  pioneered,	  initially	  in	   rats,	   the	   now	   commonly	   used	   research	   technique	   of	   fMRI	   (Ogawa,	   Lee,	  Kay	   &	   Tank,	   1990).	   The	   BOLD	   contrast	   can	   be	   quantified	   and	   the	   three	  dimensional	  area	  that	  is	  studied	  divided	  into	  component	  parts	  or	  voxels	  to	  show	  detailed	  functional	  change	  in	  specific	  anatomical	  locations:	  Functional	  Magnetic	  Resonance	   Imaging	   is	   able	   to	   localise	  BOLD	   to	  within	  2-­‐3	  mm	  of	  the	  neuronal	  activity.	  	  The	   increase	   in	   oxygenation	   typically	   lags	   1-­‐2	   seconds	   behind	   neuronal	  activity	   and	   peaks	   at	   5	   seconds.	   Once	   the	   stimulus	   for	   brain	   activity	   is	  removed	   the	   level	   falls,	   overshoots	   below	   its	   original	   value	   slightly	   before	  returning	  to	  normal.	  	  	  Functional	   MRI	   is	   affected	   by	   unwanted	   signal,	   termed	   noise,	   from	   the	  scanner	  and	  random	  brain	  activity,	  which	  can	  be	  as	  big	  as	   the	  signal	   itself.	  To	  minimise	  this,	  fMRI	  studies	  repeat	  a	  stimulus	  presentation	  multiple	  times	  and	  a	  mean	  response	  is	  taken.	  	  Give	   its	   high	   retinal	   sensitivity	   the	   macula	   has	   a	   relatively	   large	  representation	  in	  the	  visual	  cortex	  compared	  with	  the	  peripheral	  retina.	  It	  is	  represented	  at	  the	  posterior	  pole	  of	  the	  cerebral	  cortex	  within	  the	  calcarine	  sulcus.	   This	  Region	  Of	   Interest	   (ROI)	   can	  be	  pre-­‐defined	  on	   an	   anatomical	  MRI	  scan	  for	  study	  and	  signal	  change	  within	  this	  area	  can	  be	  studied	  when	  the	  macula	  is	  stimulated	  with	  light.	  The	  amplitude	  and	  coherence	  of	  change	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of	   the	   fMRI	   activity,	   synchronized	   with	   the	   stimulus	   can	   be	   calculated	  (Baseler,	  2011a).	  	  Baseler	  et	  al	  studied	  a	  single	  case	  and	  reported	  improvement	  in	  fMRI	  signal	  in	  a	  patient	   treated	  with	  ranibizumab	   for	  neovascular	  Age-­‐related	  Macular	  Degeneration.	   Functional	   MRI	   was	   suggested	   as	   a	   sensitive	   and	   objective	  measurement	  of	  visual	  function	  as	  it	  does	  not	  rely	  on	  the	  patient	  to	  maintain	  good	   visual	   fixation	   that	   can	   interfere	   with	   techniques	   such	   as	   VA	   and	  microperimetry.	   Furthermore,	   the	   cortex	   appeared	   to	   remain	   responsive	  when	  vision	  was	  restored	  (Baseler,	  2011a).	  	  
1.3.2.4	  Patient	  reported	  outcomes	  
	  Patients	   can	   report	   their	   own	   perception	   of	   response	   to	   treatment.	   A	  number	   of	   different	   Patient	   Reported	   Outcomes	   (PRO)	   specific	   to	   eye	  disease	   or	   treatment	   exist	   enabling	   a	   structured	   response	   that	   individuals	  perceive	  to	  be	  recorded.	  	  	  	  	  The	   National	   Eye	   Institute	   Visual	   Function	   Questionnaire	   (NEI	   VFQ)	   is	   an	  example	   of	   a	   commonly	   used	  Patient	  Reported	  Outcome	  Measure	   (PROM)	  (Mangione,	  Berry	  &	  Spritzer,	  1998).	  It	  was	  initially	  developed	  as	  a	  51-­‐point	  scale	   that	   sampled	   different	   aspects	   of	   visual	   function	   with	   the	   help	   of	  patients.	   (Mangione	  et	  al,	  1998).	   It	  was	   further	  refined	   to	  a	  25	  point	  scale,	  which	  correlates	  well	  with	  the	  51-­‐pont	  scale	  and	  still	  being	  representative	  of	  visual	   function	   (Mangione	   et	   al,	   2001).	   The	   NEI	   VFQ	   has	   been	   used	   to	  provide	  insight	  into	  the	  quality	  of	  life	  change	  following	  anti-­‐VEGF	  treatment	  for	  nvAMD	  (Rakic	  et	  al,	  2013).	  	  The	  12-­‐item	  well-­‐being	  questionnaire	  (W-­‐BQ12),	  (Riazi,	  Bradley,	  Barendse,	  &	   Ishii,	   2006)	   was	   developed	   from	   the	   longer	   22-­‐item	   version	   and	  comprises	  3	  areas	  of	  assessment:	  Energy,	  positive	  well-­‐being	  and	  negative	  well-­‐being	  (Bradley	  &	  Lewis,	  1990;	  Bradley	  1994).	  Each	  of	  these	  3	  areas	  has	  a	   score	   of	   12	   points,	   making	   a	   total	   of	   36	   possible	   and	   a	   higher	   score	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indicates	  a	  better	  well-­‐being.	  Although	  the	  PROM	  was	  developed	  for	  use	  in	  patients	  with	  diabetes,	  it	  has	  been	  shown	  to	  be	  a	  useful	  and	  reliable	  tool	  in	  patients	  with	  macular	  disease	  (Mitchell	  &	  Bradley,	  2001).	  	  The	   treatment	   satisfaction	   questionnaire	   MacTSQ	   (Mitchell,	   Brose	   &	  Bradley,	  2007)	  was	  designed	  to	  assess	  treatment	  satisfaction	   in	  two	  areas:	  impact	  of	  treatment,	  and	  provision	  of	  information	  and	  convenience.	  Each	  of	  these	   scales	   can	   score	   a	   maximum	   of	   36	   points,	   making	   a	   potential	  maximum	  score	  of	  72	  with	  a	  higher	  score	  indicating	  better	  satisfaction.	  The	  MacTSQ	   was	   used	   in	   the	   IVAN	   trial,	   the	   results	   of	   which	   are	   awaited	  (Chakravarthy	  et	  al,	  2013).	  	  
1.3 	  Measuring	  the	  adverse	  effects	  of	  treating	  nvAMD	  	  All	   treatments	   have	   side	   effects	   and	   anti	   VEGF	   therapy	   of	   nvAMD	   is	   no	  exception.	   Side	   effects	   can	   be	   broadly	   considered	   as	   effects	   of	   the	  pharmacological	  agent	  and	  adverse	  effects	  of	  the	  procedure.	  	  
1.4.1	  Adverse	  effects	  of	  the	  pharmacological	  agents	  	  There	   has	   been	  much	   debate	   about	   the	   side	   effects	   of	   suppressing	   VEGF,	  particularly	   about	   potential	   systemic	   complications	   (Chakravarthy	   et	   al	  2012,	  Martin	   et	   al,	   2011).	   The	   SAILOR	   clinical	   trial	   studying	   the	   safety	   of	  ranibizumab	   therapy	   in	   nvAMD,	   warned	   of	   an	   increase	   in	   cardiovascular	  and	   cerebrovascular	   endpoints	   such	   as	   myocardial	   Infarction,	   arrhythmia	  and	   stroke	   (Boyer,	   Heier,	   Brown,	   Francom	  &	   Ianchulev,	   2008).	   Since	   then	  most	  studies	  have	  not	  convincingly	  proven	  any	  excess	  cardiovascular	  events	  but	   debate	   remains	   as	   to	   the	   possibility	   of	   slight	   excess	   of	   haemorrhagic	  stroke	  (Bressler	  et	  al,	  2012).	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1.4.2	  Adverse	  effects	  of	  the	  intravitreal	  injection	  procedure	  	  The	   intravitreal	   injection	   procedure	   can	   inadvertently	   cause	   retinal	   tears,	  vitreous	   haemorrhage	   or	   lenticular	   trauma.	   These	   are	   uncommon	   events	  occurring	  at	  a	   frequency	  of	   less	   than	  1	   in	  a	  1000.	   Introduction	  of	   infection	  into	  the	  vitreous	  cavity,	  an	  ideal	  culture	  medium	  for	  bacteria	  and	  fungi	  can	  lead	   to	   the	   complication	   of	   endophthalmitis.	   Endophthalmitis	   is	   a	   severe	  inflammation	  of	  the	  ocular	  structures	  that	  occurs	  at	  a	  rate	  of	  approximately	  1	   in	   3000	   injections	   often	   having	   a	   devastating	   outcome	   on	   final	   visual	  acuity	  (Boyer	  et	  al,	  2009;	  Hasler	  et	  al,	  2014).	  	  Typically	  a	  volume	  of	  0.05mls	  of	  an	  anti-­‐VEGF	  agent	  is	  administered.	  As	  the	  ocular	   structures	   are	   relatively	   rigid	   this	   leads	   to	   an	   intraocular	   pressure	  rise	  (Kim	  et	  al,	  2008).	  Intraocular	  pressure	  elevation	  is	  the	  main	  risk	  factor	  glaucoma,	  a	  condition	  characterized	  by	  damage	  to	  the	  optic	  nerve,	  with	  loss	  of	   retinal	   nerve	   fibres	   and	   consequently	   peripheral	   vision.	   The	   role	   of	  treatment	  to	  protect	  glaucoma	  patients	  from	  short-­‐term	  pressure	  spikes	  at	  the	  time	  of	  injection	  has	  not	  been	  well	  studied.	  	  
1.5	  The	  Aim	  of	  this	  Thesis	  	  Being	   able	   to	   adequately	   quantify	   the	   outcome	   of	   neovascular	   AMD	  treatment	   gives	   perspective	   not	   only	   on	   appropriate	   intervention	   for	  individual	   patients,	   but	   also	   the	   understanding	   of	   the	   science	   behind	   the	  disease,	  its	  therapeutics	  and	  design	  of	  future	  clinical	  trials.	  	  Commonly	  used	  methods	  of	  measuring	  VA	  using	  high	  contrast	  charts	  often	  underestimate	  visual	  function	  (Scott	  et	  al,	  1994;	  West	  et	  al,	  1997;	  Mangione	  et	   al,	   1999;	   Maclure,	   Hart	   and	   Jackson	   2000:	   Hazel,	   Petre,	   Armstrong,	  Benson	  &	  Frost,	  2000).	  The	  Study	  by	  Squirrel	  et	  al	  concluded	  that	  VA	  might	  underestimate	   the	   functional	   improvement	   in	   vision	   of	   nvAMD	   patients	  treated	   with	   ranibizumab	   (Squirrel	   et	   al,	   2010).	   It	   would	   be	   logical	   to	  assume	  that	  there	  is	  a	  strong	  correlation	  between	  the	  restoration	  of	  normal	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anatomy	   and	   the	   restoration	   of	   visual	   function;	   however	   this	   is	   not	  consistent	   finding	   (Munk	   et	   al,	   2013).	   	   Baseler	   et	   al	   suggested	   that	   fMRI	  might	  provide	  a	  functional	  measurement	  of	  visual	  function	  avoiding	  some	  of	  the	  problems	  with	  VA	  and	  microperimetry	  (Baseler,	  2011).	  	  	  Concluding	   from	   this	   introductory	   chapter,	   there	   is	   enough	   discussion	   to	  warrant	   further	   study	   of	   the	   common	  methods,	   and	   development	   of	   new	  techniques,	  which	  assess	  the	  outcomes	  of	  treatment	  of	  neovascular	  macular	  degeneration.	  	  This	   thesis	   aims	   to	   assess	   the	   common	   forms	   of	   outcome	   measures	   of	  treatment	   of	   macular	   degeneration	   such	   as	   visual	   acuity	   assessment	   and	  OCT	   imaging.	   It	   also	   aims	   to	   explore	   and	   develop	   the	   use	   the	   functional	  measures	  of	  patient	  reported	  outcomes,	  microperimetry	  and	  functional	  MRI.	  	  In	   line	   with	   this	   theme	   not	   just	   the	   positive	   aspects	   of	   therapy	   will	   be	  studied,	   but	   also	   a	   negative	   aspect	   in	   the	   form	  of	   the	  prevention	  of	   short-­‐term	   pressure	   spikes	   following	   intravitreal	   injection.	   These	   outcome	  measures	  will	   be	   evaluated	   in	   the	   context	   of	   a	   series	   of	   observational	   and	  interventional	   studies	   assessing	   new	   and	   existing	   treatments	   and	  techniques.	   Conclusions	   about	   these	   techniques	   and	   treatments,	   their	  advantage	   and	   pitfalls	   as	   well	   as	   their	   appropriateness	   for	   scientific	   and	  clinical	  use	  will	  be	  evaluated.	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Chapter	   2.	   Visual	   Acuity	   as	   an	   Outcome	   measure	   of	   anti-­‐VEGF	  
treatment	  of	  Neovascular	  Age-­‐related	  Macular	  Degeneration	  	  
2.1	  Introduction	  	  Following	  on	   from	   introducing	   some	  of	   the	   common	  methods	  of	   assessing	  outcomes	   of	   anti-­‐Vascular	   Endothelial	   Growth	   Factor	   (VEGF)	   treatment	   of	  Neovascular	  Macular	   Degeneration	   (nvMD)	   in	   chapter	   1,	   this	   chapter	  will	  study	  the	  value	  of	  using	  visual	  acuity	  (VA)	  as	  an	  assessment	  tool.	  A	  cohort	  of	  patients	   being	   treated	   with	   ranibizumab	   for	   neovascular	   Age-­‐related	  Macular	   Degeneration	   (nvAMD)	   was	   studied.	   The	   cohort	   initially	   had	   a	  longer	   than	   recommended	   follow	   up	   interval,	   but	   as	   a	   part	   of	   redesign	   of	  clinical	   services	   this	  was	   shortened	   to	   the	   required	   interval.	   Visual	   acuity	  was	  used	  to	  assess	  the	  impact	  of	  this	  change.	  	  
2.2	  Background	  	  In	  the	  developed	  world	  nvAMD	  is	  the	  commonest	  cause	  of	  severe	  visual	  loss	  in	   the	   retired	   population	   and	   accounts	   for	   more	   than	   half	   of	   all	   cases	   of	  those	  registered	  sight	  and	  severe	  sight	   impairment	   in	   the	  United	  Kingdom	  (Rostron	  &	  McKibbin,	  2012).	  The	   incidence	  of	  nvAMD	  rises	  with	  age	  being	  0.2%	  at	  age	  55-­‐64	  years	  and	  13%	  over	  the	  age	  of	  85	  years	  and	  equates	  to	  an	  estimated	  26,000	  new	  cases	  in	  the	  United	  Kingdom	  per	  year	  (Bunce,	  Xing	  &	  Wormold,	  2010;	  Owen,	  Jarrar,	  Wormald,	  Cook	  &	  Fletcher,	  2012).	  So	  with	  the	  knowledge	  that	  anti-­‐VEGF	  treatments	  by	  and	  large	  temporarily	  suppress	  the	  disease	  rather	  than	  providing	  a	  cure	  (Rofagha	  et	  al	  2013;	  Tufail	  et	  al,	  2014;	  Airody	  et	  al,	  2014)	  and	  that	  we	  have	  an	  aging	  population,	  the	  prevalence	  of	  treated	   nvAMD	   continues	   to	   rise.	   This	   has	   led	   to	   a	   substantial	   increase	   in	  capacity	  demand	  and	  many	  nvAMD	  treatment	  clinics	  are	  failing	  to	  meet	  this	  demand	  (Amoaku,	  Blakeney,	  Freeman,	  Gale,	  &	  Johnston,	  2012).	  	  Early	   treatment	   of	   nvAMD	   with	   anti	   vascular	   endothelial	   growth	   factor	  agents	   in	   order	   to	   prevent	   the	   natural	   history	   of	   rapid	   and	   progressive	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visual	   loss	   (Bressler,	   2001)	   is	   standard	   care.	   This	   is	   evidenced	   by	   the	  landmark	   studies	   ANCHOR	   (Anti-­‐VEGF	   antibody	   for	   treatment	   of	  predominantly	   classic	   choroidal	   neovascularisation	   in	   AMD)	   and	  MARINA	  (Minimally	  Classic/Occult	  Trial	   of	   the	  Anti-­‐VEGF	  Antibody	  Ranibizumab	   in	  the	   Treatment	   of	   Neovascular	   AMD)	   (Brown	   et	   al,	   2006;	   Rosenfeld	   et	   al,	  2006).	  Typically	  there	  is	  an	  initial	  gain	  in	  mean	  VA	  of	  7	  to	  9	  ETDRS	  letters	  with	  subsequent	  stabilisation.	  	  Studies	  have	  shown	  that	  equally	  important	  to	  early	   diagnosis	   is	   regular	   and	   long-­‐term	   follow	   up,	   enabling	   timely	   re-­‐treatment	  as	  required.	  These	  phase	  III	  clinical	  trials	  have	  demonstrated	  that	  regular	   treatment	   by	   either	   injection	   on	   a	   ‘fixed	  dosing’	   regimen	  or	   an	   ‘as	  required’	   (pro	   re	   nata	   or	   ‘prn’)	   regimen,	   with	   ranibizumab	   on	   a	   monthly	  basis	  leads	  to	  long	  term	  visual	  stability	  (Boyer	  et	  al,	  2009;	  Brown,	  2006	  et	  al;	  Martin,	   Maguire,	   Ying,	   Grunwald,	   2011;	   Martin	   et	   al	   2012;	   Lalwani,	  Rosenfeld,	   Fung,	   Dubovy,	  Michels,	   2009;	   Rosenfeld	   et	   al,	   2006).	   However,	  fixed	   dosing	   at	   a	   quarterly	   interval	   following	   three	   initial	   monthly	  ranibizumab	  injections	  leads	  to	  a	  gradual	  decline	  of	  the	  initial	  gain	  in	  visual	  acuity	  (Regillo	   et	   al,	   2008).	   Furthermore,	   the	  monthly	   regime	   studies	   also	  demonstrated	   less	   frequent	   severe	   visual	   loss	   (defined	   as	   greater	   than	   or	  equal	  to	  15	  ETDRS	  letter	   loss)	  and	  more	  significant	  visual	  gainers	  (defined	  as	  greater	  than	  or	  equal	  to	  15	  ETDRS	  letter	  gain)	  than	  either	  no	  treatment	  or	  treatment	  with	  photodynamic	  treatment	  (Brown	  et	  al,	  2006;	  Rosenfeld	  et	  al,	  2006).	  Mean	  visual	  acuity	  change	  and	  percentage	  of	  15	  ETDRS	  letter	  gainers	  or	  losers	  are	  two	  common	  parameters	  measure	  when	  evaluating	  treatments	  of	   vision	   threatening	   disease	   (Bressler,	   2001;	   Brown,	   2006;	   Rosenfeld,	  2006).	  	  With	   the	   knowledge	   that	   loss	   of	   vision	   is	   the	   consequence	   of	   not	   seeing	  patients	   in	   a	   timely	  manner	   and	   that	   long-­‐term	   therapy	   is	   required,	  many	  nvAMD	  treatment	  centres	  have	  needed	  to	  reconfigure	  services	  to	  be	  able	  to	  cope	  with	  continually	  rising	  demands.	  There	  are	  well-­‐documented	  solutions	  of	   how	   this	   may	   be	   achieved	   including	   ‘off	   site’	   closer	   to	   home	   models.	  (Amoaku	  et	  al,	  2012).	  In	  order	  to	  reduce	  follow	  up	  intervals	  in	  one	  nvAMD	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clinic	   (York	   Teaching	   Hospital,	   United	   Kingdom),	   a	   community	   eye	   clinic	  was	  established	  (The	  Eye	  Site	  Clinic,	  Bridlington,	  UK).	  
	  
2.3	  Aims	  	  The	   aim	   of	   this	   study	   was	   to	   evaluate	   the	   impact	   of	   reducing	   follow	   up	  intervals	   in	   a	   cohort	   of	   individuals	   with	   nvAMD	   being	   treated	   with	  ranibizumab,	  and	  evaluate	  the	  use	  of	  visual	  acuity	  as	  an	  outcome	  measure.	  	  	  
2.4	  Study	  Design	  
	  The	  National	  Institute	  for	  Health	  and	  Clinical	  Excellence	  (NICE)	  Technology	  Appraisal	  (TA)	  155	  for	  nvAMD	  recommends	  that	  patients	  are	  treated	  with	  3	  monthly	   initiation	   doses	   of	   ranibizumab,	   0.5	   mg,	   as	   part	   of	   the	   standard	  induction	   phase	   (NICE,	   2008).	   Patients	   should	   then	   be	   reviewed	  monthly	  and	  retreated	   if	   there	  are	  signs	  of	  disease	   in	  an	   ‘as	  required’	  phase	  (pro	  re	  
nata	  or	  prn).	  All	  patients	  at	  the	  ‘base’	  hospital	  (York	  Teaching	  Hospital,	  UK)	  were	   routinely	   managed	   in	   this	   way	   with	   signs	   of	   disease	   activity	   being	  similar	  to	  that	  used	  in	  Martin	  et	  al’s	  Comparative	  Anti-­‐VEGF	  Treatment	  Trial	  (CATT):	   reduced	  VA	  explained	  by	  nvAMD,	  presence	  of	   intra	   or	   sub	   retinal	  fluid	  on	  Ocular	  Coherence	  Tomography	  (OCT)	  or	  leakage	  on	  FFA	  (Martin	  et	  al,	   2011).	   Due	   to	   capacity	   limitations	   assessment	   intervals	   beyond	   the	   3	  initiation	  doses	  were	  often	  more	  than	  recommended.	  	  To	  help	  address	  the	  shortfall	  in	  capacity	  and	  enable	  care	  to	  be	  given	  closer	  to	  home	  154	  patients	  with	  189	   treated	  eyes	  were	   identified	  and	  had	   their	  care	  transferred	  from	  the	  base	  hospital	  (BH,	  York	  Teaching	  Hospital,	  United	  Kingdom)	  to	  the	  community	  eye	  clinic	  (CEC,	  The	  Eye	  Site	  Clinic,	  Bridlington,	  UK).	  The	  new	  facility	  enabled	  a	  strict	  28-­‐day	  follow	  up	  interval	  to	  be	  offered	  to	  all	  patients.	  	  	  
	   53	  
To	  be	  eligible	   for	   the	  study	  patients	  had	   to	  be	  at	   least	  50	  years	  of	  age	  and	  have	   and	   a	   fluorescein	   angiogram	   confirmed	   diagnosis	   of	   nvAMD.	   In	  addition	  to	  this,	  the	  patients	  must	  have	  been	  in	  the	  ‘stability	  phase’	  of	  their	  treatment	   defined	   as	   one	  month	   after	   having	   completed	   their	   3	   initiation	  treatments	  with	  ranibizumab.	  These	  three	  treatments	  must	  have	  been	  given	  at	   the	   BH	   each	   with	   an	   interval	   of	   between	   28	   and	   35	   days,	   this	   range	  enabling	   some	   routine	   flexibility	   in	   appointments.	   At	   the	   time	   of	   the	  commencement	  of	  the	  study	  the	  CEC	  had	  been	  operating	  for	  approximately	  6	  months	  enabling	  6	  visits	  at	  this	  location	  to	  be	  studied.	  To	  equate	  this	  study	  period	   and	   so	   to	   be	   included	   in	   the	   study,	   patients	  must	   have	   attended	   at	  least	  12	  consecutive	  visits	   in	   their	   stability	  phase	  comprising	  of	  6	  visits	  at	  the	  BH	  followed	  by	  6	  visits	  at	   the	  CEC.	   	   It	  was	  these	  visits	   that	   formed	  the	  study	  period.	  	  Some	   treatment	   centres	   perform	   the	   assessment	   at	   one	   visit	   and	   if	  treatment	   is	  required	  bring	  patients	  back	   for	   treatment	  on	  a	  different	  day.	  This	   so	   called	   ‘two-­‐stop’	   method	   enables	   better	   capacity	   planning	   for	   the	  host	   organization	   but	   is	   less	   convenient	   for	   patients	   and	   causes	   further	  delay	  in	  the	  treatment	  pathway.	  Both	  the	  BH	  and	  the	  CEC	  used	  a	  ‘one	  stop’	  model	  enabling	  assessment	  and	  re-­‐treatment	   to	  be	  performed	  at	   the	  same	  visit.	  	  To	   be	   consistent	   across	   sites,	   both	   locations	   used	   routine	   clinical	   VA	  measurement	  with	  the	  same	  type	  of	  standard	  ETDRS	  vision	  chart	  (Precision	  vision;	  Ferris	  &	  Bailey,	  1996).	  Vision	  was	  measured	  in	  the	  affected	  eye	  with	  the	   patient’s	   current	   spectacle	   correction	   to	   give	   Best	   Corrected	   Visual	  Acuity	   (BCVA).	   Consistent	   with	   routine	   clinical	   practice	   if	   the	   spectacle	  correction	  was	  considered	  out	  of	  date	  then	  pinhole	  visual	  acuity	  was	  used.	  Vision	  was	  measured	  at	  4	  metres	  in	  an	  illuminated	  room.	  If	  the	  patient	  was	  able	  to	  read	  4	  or	  more	  of	  the	  five	  letters	  on	  the	  first	  line	  they	  were	  asked	  to	  continue	   reading	  down	   the	   chart	   until	   they	   could	   read	   a	   fewer	   than	   three	  letters	   on	   a	   single	   line.	   At	   this	   point	   the	   total	   number	   of	   letters	   read	  correctly	  on	  the	  chart	  was	  recorded.	  Given	  that	  the	  measured	  distance	  was	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at	  4	  metres	   then	  an	  additional	  30	   letters	  was	  added	   to	   the	   score	   to	  give	  a	  total	  ETDRS	  letter	  count.	  If	  the	  patient	  was	  unable	  to	  read	  4	  letters	  correctly	  on	  the	   first	   line	   they	  were	  brought	   to	  1	  metre	  and	  were	  asked	  to	  continue	  reading	  down	  the	  chart	  until	  they	  could	  read	  fewer	  than	  3	  letters	  on	  a	  single	  line.	   No	   additional	   30	   letters	   were	   added	   in	   this	   circumstance.	   This	   total	  ETDRS	  score	  is	  routinely	  used	  as	  a	  clinical	  measurement	  and	  was	  the	  value	  used	   for	   the	   study.	   Although	  not	   using	   a	   refracted	   score,	   this	   technique	   is	  similar	  to	  that	  used	  for	  many	  clinical	  trials	  such	  as	  the	  REPAIR	  study	  (Tufail	  et	  al,	  2013b).	  	  	  An	  important	  point	  to	  discuss	  is	  that	  although	  an	  ETDRS	  letter	  score	  is	  not	  technically	  a	  measure	  of	  logarithmic	  acuity	  (it	  would	  need	  a	  multiplying	  by	  a	  quotient	  of	  0.02	  to	  give	  an	  equivalent),	  its	  use	  is	  commonplace	  and	  standard	  practice	  for	  clinical	  trial	  use	  since	  it	  1996	  (Ferris	  and	  Bailey,	  1996)	  	  To	  ensure	  consistency	  between	  the	  BH	  and	  CEC,	  the	  same	  model	  of	  OCT,	  the	  key	  piece	  of	  technology	  helping	  to	  determine	  disease	  activity	  and	  therefore	  governing	   retreatment	   decisions,	   was	   used	   at	   both	   sites	   (Cirrus	   HD	   OCT	  4000,	  Carl	  Zeiss	  Meditec).	  	  In	   addition	   to	   ETDRS	   visual	   acuity,	   the	   number	   of	   injections	   and	   the	   time	  interval	  between	  visits	  (in	  days)	  were	  collected.	  A	  paired	  t-­‐test	  was	  used	  to	  compare	   the	   mean	   BCVA,	   total	   number	   of	   injections	   and	   mean	   follow-­‐up	  time	  between	  sites.	  The	  BCVA	  at	  each	  visit	  within	  each	  centre	  was	  compared	  with	   a	   repeated	  measures	  ANOVA.	  The	  proportion	  of	   patients	  who	   gained	  and	  lost	  15	  ETDRS	  letters	  (a	  figure	  considered	  to	  be	  ‘significant’	  (MPS,	  1991)	  between	  sites	  was	  compared	  with	  a	  chi-­‐square	  test.	   	  The	  data	  analysis	  was	  undertaken	   on	   SPSS	   (v18,	   Chicago:	   SPSS	   inc.).	   A	   p-­‐value	   of	   <0.05	   was	  considered	  to	  indicate	  statistical	  significance.	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2.5	  Results	  	  After	  reviewing	  the	  records	  of	   the	  154	  patients	  72	  eyes	  of	  62	  patients	  met	  the	  criteria	  to	  be	  included	  in	  this	  study.	  There	  were	  45	  female	  eyes	  and	  27	  males	  eyes	  with	  mean	  age	  of	  82.0	  years	  with	  a	  range	  of	  60	  to	  96	  years.	  	  	  The	  mean	  follow	  up	  time	  between	  each	  visit	  in	  the	  period	  of	  study	  was	  56.8	  days	  (range	  21	  to	  288	  days)	  in	  the	  base	  hospital	  and	  31.8	  days	  (21	  to	  139)	  days	   in	   the	   community	   eye	   clinic.	   The	   mean	   difference	   in	   the	   follow	   up	  intervals	  between	  the	  base	  hospital	  and	  the	  community	  eye	  clinic	  was	  25.0	  days	  (SD:	  14.95)	  and	  was	  significant	  (t	  71=14.08,	  p<0.0001).	  	  Taking	   a	  mean	  of	   all	   the	  6	   visits	   in	   the	   base	  hospital	   the	  BCVA	  was	  54.49	  ETDRS	   letters	   (SD=14.02)	   and	   55.69	   ETDRS	   (SD=15.49)	   letters	   in	   the	  community	   clinic.	   This	   mean	   gain	   of	   1.19	   ETDRS	   letters	   (SD=5.57)	   after	  being	  moved	  from	  the	  BH	  the	  CEC	  was	  not	  significant	  (p=0.073).	  In	  the	  base	  hospital	  there	  was	  a	  trend	  of	  the	  BCVA	  to	  reduce	  however	  this	  did	  not	  reach	  significance	  over	  the	  6	  visits	  (-­‐1.13	  letters;	  repeated	  measure	  test:	  p=0.871),	  however	  in	  the	  CEC	  there	  was	  a	  significant	  increase	  in	  BCVA	  over	  the	  6	  visits	  (+4.61	  letters;	  p<0.001).	  This	  change	  is	  illustrated	  in	  Figure	  4.	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Figure	  4.	  	  Mean	  visual	  acuity	  with	  95%	  confidence	  intervals	  at	  the	  6	  visits	  in	  the	  base	  hospital	  and	   the	  6	  visits	   in	   the	  community	  eye	  clinic.	  The	  shaded	  area	   (TRANSFER)	   represents	   the	   time	   between	   the	   last	   visit	   at	   the	   base	  hospital	  and	  the	  first	  visit	  at	  the	  community	  eye	  clinic.	  	  	  The	   amount	   of	   significant	   visual	   gainers	   (15	   ETDRS	   letter	   or	   more)	   was	  statistically	   greater	   in	   the	   CEC	   compared	   with	   the	   BH,	   but	   the	   smaller	  number	   of	   patients	   experiencing	   severe	   visual	   loss	   (15	   ETDRS	   letters	   or	  more)	  did	  not	   reach	   significance.	   	   In	   the	  BH	  only	  1	  eye	  out	  of	   the	  72	  eyes	  (1.3%)	  had	  a	  gain	  of	  15	  ETDRS	   letters	  during	   the	   first	   six	  visits	   compared	  with	   9	   eyes	   (12.5%)	   in	   the	   community	   eye	   clinic	   (p=<0.001).	   Seven	   eyes	  (9.7%)	  lost	  15	  ETDRS	  letters	  in	  the	  base	  hospital	  compared	  to	  3	  eyes	  (4.1%)	  in	  the	  community	  eye	  clinic	  (p=0.170).	  	  	  The	  mean	  number	  of	  ranibizumab	  injections	  in	  the	  BH	  was	  3.69	  and	  3.39	  in	  the	  CEC.	  This	  was	  not	  significantly	  different	  (p=0.7).	  The	  mean	  percentage	  of	  patients	   requiring	   an	   injection	   at	   the	   BH	   was	   62%	   and	   at	   the	   CEC	   56%	  (Figure	  5).	  The	  study	  period	  was	  not	   the	  same	  duration	   in	   the	  BH	  and	   the	  CEC	  and	  so	  adjusting	  for	  this,	  the	  predicated	  mean	  number	  of	  injections	  over	  an	  equivalent	  6-­‐months	  period	  assuming	  the	  same	  injection	  rate	  and	  follow	  up	  intervals,	  was	  2.37	  at	  the	  BH	  and	  3.9	  at	  the	  CEC.	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Figure	  5.	   	  The	  percentage	  of	  patients	  receiving	  a	  ranibizumab	  injection	  for	  active	   nvAMD	   as	   a	   proportion	   of	   total	   assessments	   per	   month.	   For	  comparison	   the	  mean	  ETDRS	  visual	  acuity	   is	  plotted	   in	   the	  same	  axis.	  The	  shaded	  area	   (TRANSFER)	  represents	   the	   time	  between	   the	   last	  visit	  at	   the	  base	  hospital	  and	  the	  first	  visit	  at	  the	  community	  eye	  clinic.	  	  
2.6	  Discussion	  	  
2.6.1	  The	  implications	  of	  the	  Visual	  Acuity	  results	  	  The	  mean	  change	  in	  VA	  in	  anti-­‐VEGF	  treatment-­‐naïve	  patients	  demonstrates	  a	   very	   characteristic	   response	   curve	   (Brown	   et	   al,	   2006;	   Rosenfeld	   et	   al	  2006).	  It	  can	  be	  considered	  to	  have	  an	  ‘initiation	  phase’	  whereby	  there	  is	  a	  rapid	  gain	  in	  VA	  in	  response	  to	  the	  first	  3	  treatments,	  followed	  by	  a	  ‘stability	  phase’	   during	  which	   the	   VA	   remains	   stable	   or	   at	   least	   there	   is	   not	   such	   a	  dramatic	  change	  with	  monthly	  or	  prn	  dosing.	  	  The	  ANCHOR	  and	  MARINA	  studies	  provide	  good	  examples	  of	   this	   stability	  phase,	   in	   which	   there	   was	   a	   only	   a	   slight	   change	   of	   +1.3	   letters	   between	  month	  3	  and	  12	  when	   fixed	  monthly	  dosing	  was	  used	   (Brown	  et	  al,	  2006;	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Rosenfeld	  et	  al,	  2006).	  In	  the	  large	  randomized	  study	  of	  the	  use	  ranibizumab	  or	   bevacizumab,	   The	   Comparison	   of	   AMD	   Treatment	   Trial	   (CATT),	   a	   2.4	  letter	   gain	   in	   the	   fixed	   arm	   and	   1.2	   letter	   gain	   in	   the	   prn	   arm	   was	  demonstrated	  in	  the	  equivalent	  stability	  phase	  (Brown	  et	  al,	  2011).	  	  It	   is	   important	   to	   distinguish	   between	   the	   initiation	   and	   stability	   phases	  because	   the	  VA	   is	   influenced	  by	  different	   factors	   in	   these	  different	  phases.	  During	   the	   initiation	   phase	   the	   gain	   in	   VA	   is	   considered	   to	   be	   primarily	   a	  response	   to	   treatment.	   	   It	   is	   however,	   influenced	   by	   both	   patient	   and	  treatment	   factors.	   Patient	   factors	   include	   CNV	   lesion	   type,	   (as	   defined	   by	  angiography	  and	  demonstrates	  a	  greater	  increase	  in	  VA	  with	  classic	  lesions	  rather	  than	  occult	  ones)	  (Brown	  et	  al	  2006,	  Rosenfeld	  et	  al,	  2006),	  and	  delay	  in	   presentation	   (which	   may	   lead	   to	   more	   irreversible	   structural	   changes	  such	   as	   fibrosis)	   (Kelly	   &	   Barua	   2011).	   In	   fact	   delay	   is	   considered	   so	  important	  on	  the	  final	  outcome	  the	  Royal	  College	  of	  Ophthalmologists	  have	  developed	   guidelines	   recommending	   that	   time	   from	   presentation	   to	  treatment	   should	   be	   no	   longer	   than	   2	   weeks	   (RCOphth,	   2007).	   Ironically	  treatment	  of	  CNV	   lesion	  very	  early	   in	   their	  evolution	  may	   lead	   to	  a	  ceiling	  effect	  of	  VA	  gain:	  a	  patient	  with	  near	  normal	  starting	  VA	  will	  not	  have	   the	  same	  potential	  to	  gain	  as	  many	  letters	  as	  a	  patient	  with	  significantly	  reduced	  VA	  (Ross	  et	  al	  2014).	  Treatment	   factors	   include	   the	   type	  and	   frequency	  of	  anti-­‐VEGF	   used	   (slight	   numerical	   difference	   between	   ranibizumab	   and	  bevacizumab	   seen	   in	   the	   CATT	   trial,	   and	   between	   ranibizumab	   and	  aflibercept	   in	   the	   VIEW	   study)	   (Martin	   et	   al,	   2011;	   Schmidt-­‐Erfurth	   et	   al,	  2014).	  	  The	  VA	  change	  within	  the	  stability	  phase	  can	  be	  considered	  as	  a	  marker	  of	  disease	  control.	  Like	   the	   initiation	  phase	  outcomes,	   it	   is	  also	   influenced	  by	  patient	  factors	  such	  as	  lesion	  type	  (Brown	  et	  al,	  2006;	  Rosenfeld	  et	  al,	  2006)	  and	   smoking,	   (Klien,	   Knudtson,	   Cruickshanks.	   &	   Klein	   2008).	   Treatment	  factors	   are	   also	   particularly	   important,	   such	   as	   the	   regularity	   of	   follow	  up	  and	  how	  much	   tolerance	  of	   signs	  of	   activity	  of	   the	  nvAMD	   is	   allowed.	  The	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monitoring	  of	  VA	  in	  the	  stability	  phase	  can	  therefore	  reflect	  the	  quality	  of	  a	  wet	   macular	   degeneration	   service.	   The	   results	   of	   this	   study	   support	   this	  statement:	  there	  was	  an	  improvement	  in	  4.61	  letters	  over	  a	  6	  month	  period	  when	   the	   mean	   time	   interval	   between	   assessments	   was	   reduced	   from	  approximately	  8	  weeks	  to	  4	  weeks	  and	  so	  demonstrated	  an	  improvement	  in	  the	   quality	   of	   the	   service.	   The	   number	   of	   individuals	   with	   severe	   loss	   of	  vision	  can	  also	  be	  a	  marker	  of	  the	  quality	  of	  a	  service	  as	  discussed	  by	  Kelly	  in	   his	   review	   of	   safety	   incidents	   for	   vascular	   endothelial	   growth	   factor	  inhibitors,	  in	  which	  he	  reports	  43%	  of	  incidents,	  mainly	  of	  severe	  visual	  loss,	  were	   due	   to	   delay	   in	   treatment	   (Kelly	   &	   Barua,	   2012).	   Our	   study	  demonstrated	  fewer	  individuals	  losing	  15	  letters	  of	  more	  (7	  compared	  with	  3),	  although	  this	  did	  not	  reach	  statistical	  significance.	  ‘Significant’	  gain	  in	  VA	  also	  reflects	  the	  quality	  of	  a	  service;	  in	  our	  study	  a	  gain	  of	  15	  ETDRS	  letters	  in	  the	  2	  periods	  of	  study	  was	  more	  in	  the	  CEC	  than	  the	  BH	  (9	  versus	  1).	  	  The	   results	  of	   this	   study	   reflect	   conclusions	   that	   can	  be	  drawn	   from	  other	  studies	  that	  have	  discussed	  the	  importance	  of	  the	  follow–up	  or	  retreatment	  interval.	  Dagostar	  reported	  in	  a	  retrospective	  interventional	  cases	  series	  of	  131	  patients,	  that	  eyes	  receiving	  injections	  less	  than	  2	  months	  apart	  gained	  a	   mean	   of	   2.3	   lines	   of	   vision	   at	   month	   6	   compared	   with	   those	   receiving	  injections	   less	   frequently	   only	   gaining	   0.46	   lines.	   Similarly	   3.1%	   of	   the	  frequent	  group	  experienced	  severe	  visual	  loss	  compared	  with	  15.9%	  of	  the	  less	  frequent	  cohort	  (Dagostar,	  Ventura,	  Chung,	  Sharma	  &	  Kaiser,	  2009).	  The	  retrospective	  nature	  of	  this	  study,	  like	  ours,	  is	  open	  to	  bias	  but	  adds	  to	  the	  argument	   that	   fewer	   treatments	   result	   in	   worse	   VA.	   The	   prospective	  randomized	  controlled	  design	  of	  the	  PIER	  study,	  showing	  declining	  VA	  in	  the	  stability	  phase	  with	  a	  mean	   loss	  of	  0.2	   letters	   from	  baseline	  at	  12	  months,	  when	  quarterly	   injections	  of	   ranibizumab	   following	  3	   initiation	   treatments	  are	  given	  adds	  further	  weight	  to	  this	  argument	  (Regillo	  et	  al,	  2008).	  	  The	   results	   of	   our	   study	   revealed	   a	   surprisingly	   large	   range	   of	   follow	   up	  intervals	   in	   both	   groups.	   The	   reasons	   for	   this	   included	   patients’	   wishes,	  failure	  to	  attend	  and	  administration	  errors.	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  The	   percentage	   of	   patients	   requiring	   an	   injection	   per	   visit	   was	   reduced	  when	   the	   follow	  up	   interval	  was	   reduced	   to	  every	  4	  weeks.	  The	  predicted	  total	   number	   of	   injections	   over	   an	   equivalent	   6-­‐months	   period	   however,	  was	  higher	   at	   3.90	   in	   the	  CEC	   compared	  with	  2.37	   at	   the	  BH.	  This	   finding	  that	   a	   higher	   injection	   rate	   leads	   to	   a	   higher	   VA	   is	   again	   in	   keeping	  with	  Dagostar’s	  finding.	  (Dagostar	  et	  al,	  2009).	  	  	  Although	  this	  study	  is	  open	  to	  bias	  due	  to	  different	  members	  of	  the	  clinical	  staff	  performing	  assessments	  this	  bias	  is	  limited	  due	  to	  each	  member	  of	  staff	  having	   undertaken	   training	   by	   the	   same	   team	   and	  working	   cross-­‐site.	   	   To	  draw	  a	  more	  definitive	  conclusion	  on	  the	  benefit	  of	  following	  individuals	  at	  either	   4	   or	   8	   weekly	   intervals	   a	   prospective	   trial	   randomising	   to	   these	  groups	  after	  3	  initiation	  doses	  would	  be	  required.	  The	  cost	  involved	  in	  such	  a	   study	  and	   the	  realisation	   that	   the	  results	  would	  be	  non	   ‘real	  world’	  data	  would	  have	  to	  be	  taken	  into	  consideration	  if	  such	  a	  study	  were	  to	  go	  ahead.	  	  
2.6.2	  The	  use	  of	  visual	  acuity	  as	  a	  measurement	  tool	  	  	  	  Visual	  acuity	   is	  a	  measure	  of	  the	  spatial	  resolution	  of	  the	  visual	  processing	  system	  and	  is	  dependent	  of	  the	  entire	  visual	  pathway.	  The	  commonest	  way	  of	  measuring	  visual	  acuity	   in	   the	  clinical	   setting	   is	  with	  an	  optotype	  chart,	  usually	  of	  the	  Snellen	  type.	  The	  Early	  Treatment	  Diabetic	  Retinopathy	  Study	  (ETDRS)	   chart	   is	   now	   the	   recommended	   standard	   for	   measuring	   visual	  acuity	   in	   the	   clinical	   trial	   setting	   (Ferris,	  Kassoff,	   Bresnick	  &	  Bailey,	   1982;	  Ferris	   &	   Bailey,	   1996).	   Most	   clinical	   studies	   now	   use	   this	   modified	  logarithmic	   chart,	  which	   has	   Sloan	   letters	   equally	   spaced	   across	   the	   chart	  and	  5	  letters	  per	  line	  (Bressler	  et	  al,	  2001;	  Brown	  et	  al,	  2006;	  Rosenfeld	  et	  al,	  2006;	  Martin	  et	  al	  2011,	  Martin	  et	  al	  2012).	  	  	  The	   use	   of	   visual	   acuity	   as	   a	  measure	   of	   vision	   has	  many	   advantages	   and	  disadvantages.	  The	  principle	  advantages	  of	  the	  ETDRS	  chart	  are	  that	   it	   is	  a	  relatively	   quick	   and	   easy	   way	   of	   estimating	   visual	   performance,	   typically	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taking	   2-­‐3	   minutes	   in	   a	   literate	   individual	   and	   being	   performed	   by	   a	  member	   of	   staff	   that	   requires	   relatively	   little	   training.	   In	   addition	   a	   letter	  score	   gives	   a	   numerical	   value	  making	   descriptive	   and	   inferential	   statistics	  possible.	   It	   is	   possible	   therefore	   to	   perform	   power	   calculations	   to	   set	  endpoints	  and	  to	  perform	  statistical	  evaluations	  of	   interventions	   in	  clinical	  trials.	  	  Care	  should	  be	  given	  to	  measure	  Best	  Correct	  Visual	  Acuity	  (BCVA);	  the	  best	  possible	  measured	  vision	  with	   the	  use	  of	  spectacle	  correction	   if	  necessary.	  Most	   high	   quality	   clinical	   trials	   that	   use	   VA	   as	   an	   endpoint	   mandate	  refraction	   (that	   is	   the	   measurement	   for	   glasses)	   at	   each	   point	   of	   VA	  assessment	   (Brown	   et	   al,	   2006;	   Rosenfeld	   et	   al	   2006;	  Martin	   et	   al,	   2011).	  Refraction	   is	   not	   routinely	   performed	   at	   each	   visit	   in	   clinical	   practice	  though,	   as	   it	   takes	   approximately	   20	   minutes	   of	   an	   optometrist’s	   or	  ophthalmologist’s	   time.	   It	   follows	   on	   that	   ‘real	   world’	   studies	   do	   not	   use	  refracted	  VAs	  at	  each	  visit.	   In	  real	  world	  studies	   if	   the	  subject	  has	  recently	  been	  refracted	  then	  this	  prescription	  should	  be	  worn.	  In	  the	  unusual	  event	  when	  the	  subject	  has	  forgotten	  their	  glasses	  the	  use	  of	  pinhole	  vision	  can	  be	  tried.	  Looking	  through	  pinholes	  corrects	  some	  refractive	  error	  but	  can	  make	  measured	   vision	   worse	   in	   people	   with	   macular	   disorders	   so	   may	   be	   no	  better	  than	  unaided	  vision	  (Walker,	  Hall	  and	  Hurst,	  1990).	  	  Patients	  with	  vision	  on	  the	  borderline	  of	  being	  able	  to	  use	  the	  ETDRS	  chart	  at	   4	  metres,	   that	   is	  whether	   they	   can	   see	  4	   letters	   on	   the	   first	   line	   and	  or	  cannot	   and	   so	   have	   to	   be	   moved	   to	   1	   metre,	   often	   demonstrate	   widely	  fluctuating	  measured	  VA	  on	  successive	  visits	  when	  there	  is	  no	  symptomatic	  or	   anatomical	   evidence	   for	   this	   to	   be	   so.	   Experience	   from	   this	   study,	   and	  clinical	  practice,	  shows	  that	  when	  the	  1	  metre	  chart	  is	  used	  measured	  vision	  is	  often	  substantially	  worse	  and	  can	  therefore	  appear	  to	  ‘fall	  of	  a	  cliff’.	  This	  phenomenon	   requires	   further	   investigation,	   but	   may	   be	   explained	   by	   the	  additional	  effort,	  either	  on	  the	  part	  of	  the	  subject	  or	  the	  person	  assessing	  the	  VA,	   that	   is	  required	  to	  read	  more	   letters	  on	  the	  1	  metre	  chart	   to	  achieve	  a	  lower	  VA	  score	  than	  would	  be	  required	  for	  a	  higher	  score	  on	  the	  4m	  chart.	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This	   ‘cliff’	   effect	   could	   artificially	  magnify	   the	   gain	   in	   visual	   acuity	   arising	  from	   therapeutic	   agents	   and	   may	   have	   led	   to	   an	   overestimate	   of	   the	  proportion	   of	   patients	   gaining	   15	   ETDRS	   letters.	   As	   was	   discussed	   in	   the	  original	   description	   of	   the	  ETDRS	   chart	   by	   Ferris	   in	   1982,	   the	   chart	   could	  have	   been	   used	   at	   2	   metres,	   allowing	   for	   a	   range	   of	   acuities	   more	  appropriate	   to	  our	   cohort	   to	  be	   captured	  without	  having	   change	   the	   chart	  distance	  (Ferris	  et	  al,	  1982).	  	  	  The	   testing	   conditions	   should	   remain	   constant	   across	   multiple	   visits:	   the	  exact	   testing	  distance	   from	  patient	   to	  chart,	   the	   luminance	  of	   the	  chart	   (to	  ensure	  that	  contrast	  is	  consistent)	  and	  ambient	  lighting	  (which	  affects	  pupil	  size	  and	  therefore	  the	  degree	  of	  aberrations).	  	  	  Even	   with	   a	   very	   consistent	   testing	   environment	   there	   have	   been	   well-­‐documented	  variations	  in	  measured	  visual	  acuity.	  Patel	  et	  al	  reported	  on	  90	  fellow	   (non-­‐treated)	   eyes	   in	   patients	   undergoing	   treatment	   for	   CNV	   with	  bevacizumab.	  He	  stratified	  the	  extent	  of	  fellow	  AMD	  into	  early,	  intermediate	  and	   late	   categories;	   these	   categories	   were	   discussed	   in	   chapter	   1.	   It	   was	  demonstrated,	   by	   using	   coefficient	   of	   repeatability	   (CR,	   a	  measure	   of	   test-­‐	  retest	   repeatability	   defined	   by	   Bland	   and	   Altman	   as	   the	   mean	   +/-­‐1.96	  standard	  deviations),	  that	  a	  12-­‐letter	  difference	  was	  noticed	  over	  the	  study	  period	  of	  4	  measurements	  in	  12	  weeks.	  (Bland	  &	  Altmann,	  1986)	  This	  was	  refined	   to	   10	   letters	   after	   excluding	   patients	  who	  were	   tested	   at	   different	  distances.	   Worse	   visual	   acuity	   demonstrated	   a	   worse	   coefficient.	   The	  coefficient	  was	   similar	  when	  measured	  at	   an	   interval	   of	   a	  week	   compared	  with	  the	  4	  weeks.	  (Patel,	  Chen,	  Rubin	  &	  Tufail,	  2008).	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   All	  visits	  (n)	   Baseline	   and	   week	   one	  only	  (n)	  Early	  AMD	   9	  (29)	   9(29)	  Intermediate	  AMD	   10	  (36)	   8(36)	  Late	  AMD	   17	  (25)	   15(25)	  Total	   12	  (90)	   11(90)	  	  
Table	  3.	  The	  mean	  coefficient	  of	  repeatability	  by	  diagnosis,	  from	  Patel	  et	  al	  2008.	  	  Recently	  Aslam	  et	  al	  at	  has	  suggested	  that	  the	  repeatability	  may	  even	  be	  less	  than	  this,	  finding	  a	  coefficient	  of	  14.9.	  The	  test-­‐	  retest	  period	  was	  4	  weeks	  on	  this	   occasion	   and	   used	   similar	   methodology	   to	   Patel	   of	   low	   background	  luminance,	   ‘precision	   vision’	   charts	  with	   illumination	   tubes	   that	   had	   been	  ‘burnt	  in’	  for	  96	  hours	  and	  measured	  refracted	  VA	  (Aslam	  et	  al,	  2014;	  Patel	  et	   al	   2008).	   This	   discussion	   about	   the	   lack	   of	   repeatability	   of	   VA	  measurement	  is	  not	  a	  new	  one;	  an	  analysis	  of	  the	  Macular	  Photocoagulation	  study	  found	  a	  standard	  deviation	  of	  4.7	   letters	  between	  baseline	  and	  week	  one	  in	  a	  cohort	  of	  60	  nvAMD	  patients	  (Blackhurst	  &	  Maguire,	  1989).	  	  Our	  study	  did	  not	  use	  clinical	  trial	  standards	  but	  ‘real	  world’	  measurements.	  Optometrists	  did	  not	  perform	  visual	  acuity	  testing	  and	  refracted	  vision	  was	  not	   obtained,	   although	   there	   were	   as	   many	   constants	   as	   possible	   applied	  such	  as	  testing	  distance	  and	  background	  illumination;	   inevitably	  measured	  VA	   will	   not	   be	   as	   accurate	   as	   clinical	   trial	   standards.	   A	   higher	   degree	   of	  variability	   or	   reduced	   repeatability	   would	   therefore	   be	   anticipated.	   The	  coefficient	  of	  repeatability	  has	  yet	  to	  be	  studied	  in	  the	  ‘real	  world’	  situation.	  	  The	   reasons	   for	   the	   high	   variability	   between	   visits	   can	   be	   many	   fold:	  unexpected	  differences	   in	   the	   testing	  environment	   such	  as	   the	  vision	  alley	  and	  its	  background	  illumination,	  the	  subjects	  general	  health,	  how	  much	  the	  observer	   encourages	   the	   subject,	   and	   the	   visual	   ‘cliff	   effect’	   for	   example.	  Furthermore	   following	   damage	   to	   the	   fovea	   the	   development	   of	   new,	   or	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multiple	   or	   variable	   areas	   of	   preferred	   fixation	   (preferred	   retinal	   loci	   or	  PRL,	  which	  is	  different	  to	  the	  area	  of	  highest	  retinal	  sensitivity)	  could	  help	  to	  explain	   this	   variation	   (Shima,	   Markowitz	   &	   Reyes,	   2010).	   The	   concept	   of	  developing	   of	   new	   PRL’s	   in	   a	   short	   period	   of	   time	   has	   been	   disputed	  following	   a	   short-­‐term	   study	  observing	   for	   the	   area	   of	   fixation	  before	   and	  after	  3	  treatment	  with	  ranibizumab	  in	  previously	  treatment–naïve	  patients	  (Gonzalez,	  Tarita-­‐Nistor,	  Mandelcorn,	  Mandelcorn	  &	  Steinbach,	  2011).	  	  	  The	   documented	   coefficient	   of	   repeatability	  makes	   a	   single	   point-­‐to-­‐point	  visual	  acuity	  change	  in	  an	  individual	  difficult	  to	  interpret	  as	  a	  measure	  of	  an	  outcome	   of	   treatment.	   	   Therefore	   VA	   should	   not	   be	   used	   as	   an	   absolute	  measure	  in	  this	  circumstance.	  When	  cohorts	  are	  studied	  and	  mean	  VAs	  are	  calculated	   these	   fluctuations	  are	  decreased,	  and	  so	   it	   is	  appropriate	   to	  use	  VA	   as	   an	   outcome	   measure.	   The	   study	   of	   the	   cohort	   of	   patients	   in	   this	  chapter	   has	   demonstrated	   this.	   Furthermore,	   the	   use	   of	   mean	   change	   in	  visual	   acuity	   and	   the	   change	   in	   visual	   acuity	   in	   the	   stability	   phase	   is	  particularly	  useful.	  Mean	  VA	  is	  one	  of	  the	  commonest	  endpoints	  for	  clinical	  trials	  in	  this	  field.	  Some	  examples	  are	  the	  mean	  VA	  gain	  at	  12	  months	  in	  the	  ‘as	  required’	   treatment	  arms	  of	  the	  CATT,	   IVAN	  and	  PRONTO	  clinical	   trials	  being	   reported	  as	  6.8,	  7.2,	   and	  9.8	   letters	   respectively	   (Martin	  et	   al,	   2012;	  Chakravarthy	  et	  al,	  2012;	  Fung	  et	  al,	  2012).	  	  Similarly,	  mean	  VA	  is	  used	  as	  an	  outcome	   measure	   in	   ‘real	   world’	   studies:	   Querques	   reports	   +9.0	   at	   24	  months,	   Michalova	   +5.5	   at	   12	   months,	   Rostos	   +4.6	   at	   13.6	   months,	  Rothenbuhler	  +7.3	  at	  24	  months,	  Ross	  +2.4	  at	  24	  months,	  and	  Kang	  +7.9	  at	  12	  months.	  (Querques,	  et	  al	  2010;	  Michalova	  et	  al	  2009:	  Rostos,	  Patel,	  Chen	  &	  Tufail,	  2010;	  Rothenbuhler	  et	  al,	  2009;	  Kang	  &	  Roh,	  2009).	   	  Clinical	   trial	  reporting	  should	  also	  include	  change	  in	  visual	  acuity	  in	  the	  stability	  phase.	  	  Recently	  Ross	  and	  colleagues	  have	  questioned	  the	  use	  of	  the	  full	  cohort	  VA	  measurement	   as	   an	   appropriate	   VA	   outcome.	   Following	   a	   large	  retrospective,	   real	   world	   cohort	   that	   subdivided	   patients	   into	   starting	   VA	  categories,	  it	  was	  shown	  that	  those	  with	  worse	  baseline	  vision	  gained	  most	  vision,	  beyond	  the	  ‘ceiling	  effect’	  (Ross	  et	  al,	  2013).	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  So	   far	   these	   discussions	   have	   demonstrated	   that	   although	   there	   are	  advantages	   of	   using	   VA	   as	   an	   outcome	   measure	   for	   nvAMD	   treatment	  studies	  there	  are	  also	  significant	  difficulties	  especially	   for	   individual	  point-­‐to-­‐point	   measurement.	   A	   further	   point	   of	   discussion	   is	   how	   well	   visual	  acuity	  represents	  visual	  function.	  	  	  Mean	   distance	   VA	   outcomes	   do	   appear	   to	   broadly	   reflect	   what	   many	  patients	   informally	  communicate	   in	  the	  early	  part	  of	   their	  disease	   journey,	  that	   initially	   there	   is	   an	   improvement	   in	   vision	   and	   thereafter	   stability	   is	  reached.	  Once	  in	  the	  stability	  phase	  however,	  patients	  often	  do	  not	  report	  a	  change	  in	  vision	  when	  there	  is	  variation	  in	  point	  to	  point	  measured	  VA.	  This	  leads	   to	   discussion	   as	   to	   whether	   this	   measured	   change	   in	   VA	   is	   a	   true	  reflection	   of	   change	   in	   vision	   or	   visual	   function.	   Certainly	   there	   is	   good	  evidence	   that	   VA	   loss	   is	   associated	  with	   loss	   of	   day	   to	   day	   function:	   Scott	  reported	   on	   a	   cohort	   of	   86	   consecutive	   patients	   at	   the	   Wilmer	   Institute,	  Baltimore,	  of	  which	  51	  had	  normal	  visual	   acuity,	   and	  demonstrated	   that	  2	  quality	  of	  life	  questionnaires,	  the	  vision-­‐specific	  Sickness	  Impact	  Profile	  and	  the	   Community	   Disability	   Scale	   did	   independently	   predict	   visual	   acuity	  (Scott	   et	   al,	   1994).	   Similarly,	   a	   study	   of	   randomly	   selected	   participants	   in	  Maryland	  USA	   reported	   functional	   loss	   correlated	  with	  VA	   loss	   of	   6/12	  or	  more	  (West	  et	  al,	  1997).	  This	  loss	  of	  function	  is	  also	  observed	  when	  macular	  degeneration	  is	  the	  cause:	  Mangione	  reported	  on	  201	  participants	  with	  AMD	  and	  noted	   that	  AMD	  did	   reduce	  quality	  of	   life	  based	  upon	   the	  Activities	  of	  Daily	  Living	  scale,	  however	  concluded	   that	   the	  clinical	  grading	  of	   the	  AMD	  did	  not	  explain	   the	   significant	  variation	   in	  visual	   function	   (Mangione	  et	  al,	  1999).	  Hazel	   studied	  28	  participants	  with	   acquired	  macular	  disorders	   and	  concluded	   that	   although	   high	   contrast	   tests	   such	   as	   conventional	   distance	  VA	  measurement	  did	  correlate	  with	  performance	  loss	  as	  measured	  by	  vision	  related	   quality	   of	   life	   questionnaire,	   low	   contrast	   tests	   and	   reading	   speed	  better	   correlated	  with	   self-­‐reported	   problems	   and	   visual	   concerns	   (Hazel,	  Petre,	   Armstrong,	   Benson,	   Frost,	   2000).	   This	   finding	   was	   supported	   by	  McClure,	  who	  demonstrated	  in	  100	  patients	  with	  AMD	  that	  a	  combination	  of	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reading	   index	   and	   distance	   VA	   had	   the	   best	   correlation	  with	   ‘Daily	   Living	  Task	  Dependent	  upon	  Vision’	  visual	  function	  index	  (McClure,	  Hart,	  Jackson,	  Stevenson	   &	   Chakravarthy,	   2000).	   Adding	   weight	   to	   this	   argument,	  Bansback	  reports	  a	  better	  correlation	  of	  quality	  of	   life	  utility	  with	  contrast	  sensitivity	   than	   distance	   visual	   acuity	   in	   209	   participants	   with	   either	  unilateral	  or	  bilateral	  AMD	  (Bansback,	  et	  al	  2007).	  In	  the	  same	  cohort	  as	  he	  used	   to	   study	   the	   coefficient	   of	   variability	   of	   VA	  measurement,	   Patel	   also	  demonstrated	   that	   there	   was	   greater	   gain	   in	   contrast	   sensitivity	   using	   a	  Pelli-­‐Robson	  Chart	   than	  ETDRS	  VA	   in	   the	  bevacizumab	   treated	  arm	  (Patel,	  Chen,	  Da	  Cruz,	  Rubin	  &	  Tufail,	  2011).	  	  So	   there	   is	   good	   documentation	   that	   VA	   alone	   can	   underestimate	   visual	  function.	  Frisen	  provides	  a	  good	  neuro-­‐retinal	  explanation	  for	  this	  in	  a	  study	  of	  micropsia	  (perception	  of	   images	  to	  be	  smaller	  than	  they	  are)	  in	  macular	  oedema.	  Using	  quantitative	  assessment	  of	  micropsia	  as	  a	  sensitive	  indicator	  of	   photoreceptor	   displacement,	   it	   was	   estimated	   that	   only	   44%	   of	   the	  normal	   neuro-­‐retinal	   channels	   were	   required	   to	   give	   6/6	   (‘normal’)	   VA	  (Frisen	  &	  Frisen,	  1979).	  	  
2.7.	  Conclusion	  	  This	  chapter	  set	  out	  to	  assess	  the	  value	  of	  VA	  as	  an	  assessment	  tool	  for	  the	  outcome	   of	   treatment	   of	   nvAMD.	   It	   aimed	   to	   do	   this	   as	   a	   part	   of	   a	   study	  assessing	  the	  impact	  of	  normalising	  the	  re-­‐assessment	  intervals	  of	  a	  cohort	  of	  individuals	  in	  the	  process	  of	  a	  nvAMD	  clinical	  service	  redesign.	  	  The	   study	   demonstrated	   that	   during	   the	   stability	   phase	   of	   treatment	  reducing	   re-­‐assessment	   intervals	   from	   8	   to	   4	   weeks	   resulted	   in	   an	  improvement	  of	  VA	  and	  that	  more	  treatments	  were	  given.	  	  Using	  VA	  as	  an	  end	  point	  has	  advantages;	   it	   is	  quick	  and	  gives	  a	  numerical	  score	   that	   is	   easily	   interpreted	   statistically.	   The	   drawbacks	   are	   that	   it	   is	  tempting	  to	  translate	  the	  letters	  scores	  into	  accurate	  clinical	  outcomes.	  It	  is	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clear	  from	  the	  experience	  of	  study	  and	  the	  work	  of	  others	  (Patel	  et	  al,	  2008;	  Aslam	   et	   al,	   2014)	   that	   use	   of	   VA	   as	   a	   surrogate	   marker	   of	   visit-­‐to-­‐visit	  disease	   activity	   accurate	   enough	   to	   base	   retreatment	   decision	   upon	   is	  inappropriate.	   It	   is	   surprising	   that	   national	   clinical	   guidelines	   have	  recommended	   retreatment	   based	   upon	   a	   loss	   in	   measured	   visual	   acuity	  letters	   alone:	   the	   NICE	   retreatment	   guidance	   of	   a	   loss	   of	   5	   letters	   for	  treatment	   of	   nvAMD	   with	   ranibizumab	   following	   3	   initiation	   treatments.	  (NICE	   TA155).	   Visual	   acuity	   can	   be	   a	   very	   useful	   tool	   in	   estimating	   the	  outcome	  of	  treatment	  of	  nvAMD	  but	  needs	  to	  be	  selected	  appropriately	  for	  what	  it	  is	  intended	  to	  be	  a	  surrogate	  for.	  	  Assessing	  the	  mean	  response	  of	  VA	  in	  cohorts,	  where	  variation	  is	  balanced	  amongst	  the	  participants	   is	  a	  much	  more	  appropriate	  use	  of	  this	  outcome.	  	  With	   the	  knowledge	   that	  measuring	  VA	  change	  underestimates	   the	  change	  in	   visual	   function	   and	   the	   ability	   to	   perform	   visually	   dependent	   tasks	  (Mangiona	   et	   al,	   1999;	  Hazel	   et	   al,	   2000;	   Bansback	   et	   al	   2007:	   Patel	   et	   al,	  2011),	  better	  ways	  of	  assessing	  outcomes	  are	  required.	  This	  thesis	  goes	  on	  to	   explore	   some	   objective	   and	   subjective	   ways	   of	   assessing	   outcomes	   in	  order	  to	  address	  this	  need.	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Chapter	   3.	   Visual	   acuity	   and	   Ocular	   Coherence	   Tomography	   as	  
Outcome	   measures	   of	   anti-­‐VEGF	   treatment	   of	   Pathological	   Myopia	  
associated	  Neovascular	  Macular	  Degeneration	  	  
3.1	  Introduction	  
	  The	   previous	   chapter	   studied	   the	   effect	   of	   shortening	   reassessment	  intervals	  in	  patients	  receiving	  ranibizumab	  therapy	  for	  AMD	  complicated	  by	  a	  choroidal	  neovascular	  membrane	  (CNV).	  	  Visual	  acuity	  alone	  was	  used	  as	  an	   outcome	   measure	   of	   success	   of	   treatment	   and	   the	   merits	   and	  disadvantages	  of	  which	  were	  discussed.	  This	  chapter	   investigates	  the	  used	  of	  ranibizumab	  therapy	  to	  treat	  CNV	  secondary	  to	  myopia,	  and	  furthermore	  uses	  both	  visual	  acuity	  and	  OCT	  as	  measurement	  tools.	  	  	  
3.2	  Background	  	  Myopia,	   defined	   as	   a	   refractive	   error	   of	   -­‐0.5	   Dioptres	   or	   more	   affects	  approximately	  1	  in	  3	  people	  (Wolfram	  et	  al,	  2014).	  Myopia	  is	  only	  defined	  as	   pathological	   however,	   when	   the	   refractive	   error	   is	   greater	   than	   6	  Dioptres	  and	  is	  accompanied	  by	  characteristic	  clinical	  features	  giving	  rise	  to	  an	   increased	   risk	   of	   visual	   loss.	   Pathological	   myopia	   (PM)	   is	   a	   principle	  cause	  of	  blindness	  in	  developed	  countries	  affecting	  2–4%	  of	  Caucasians	  and	  9–21%	  of	   Asian	   populations	   (Montero	   et	   al,	   2010;	   Soubrane,	   2008;	   Chan,	  Ohji	  &	  Lai,	  2005).	  Choroidal	  neovascularization	  is	  the	  most	  common	  cause	  for	   the	   irreversible	   central	   vision	   loss	   that	   occurs	   in	   patients	   with	  pathological	  myopia.	  The	  natural	  history	  defines	  that	  approximately	  90%	  of	  patients	  with	  myopic	   CNV	   (mCNV)	  will	   have	   visual	   acuity	   at	   6/60	   or	   less	  within	   5-­‐10	   years	   of	   developing	   the	   complications,	   that	   the	   prevalence	   in	  PM	   is	   4-­‐11%	   and	   that	   those	   50	   years	   or	   younger	   will	   be	   predominantly	  affected.	   (Yoshida,	   Ohno-­‐Matsui	   &	   Yasuzumi,	   2003).	   The	   chance	   of	   the	  fellow	  eye	  being	  affected	  is	  high	  with	  around	  a	  third	  being	  affected	  within	  8	  years	  (Ohno-­‐Matsui,	  Yoshida	  &	  Futagami,	  2003).	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3.2.2	   Treatments	   for	   Choroidal	   Neovascular	   Membrane	   associated	  
Pathological	  Myopia	  	  
3.2.2.1	  Laser	  based	  therapies	  	  Thermal	   laser,	   typically	   administered	   with	   an	   argon	   laser,	   is	   no	   longer	  considered	   as	   a	   useful	   treatment	   in	   the	  majority	   of	   patients.	   Because	   the	  wavelength	   of	   the	   laser	   causes	   collateral	   damage	   to	   the	   neurosensory	  retina,	   retinal	   pigment	   epithelium	   and	   choroid,	   treatment	   of	   subfoveal	  lesions	   induces	   severe	   immediate	   visual	   loss.	   Treatment	   of	   juxtafoveal	  lesions	   (within	   200	   microns	   of	   the	   centre	   of	   the	   fovea)	   and	   extra-­‐foveal	  lesions	  (greater	  than	  200	  microns)	  is	  complicated	  by	  a	  high	  recurrence	  rate	  and	  long-­‐term	  expansion	  of	  the	  laser	  scar	  that	  can	  creep	  over	  many	  months	  and	  years	  to	  involve	  the	  fovea	  (Chan	  et	  al,	  2005;	  Secretan,	  Kuhn,	  Soubrane	  &	  Coscas,	   1997).	   Those	   lesions	   that	   are	   so	   extrafoveal	   that	   they	   are	  asymptomatic	  can	  often	  be	  observed	  and	  may	  do	  well	  without	  intervention.	  	  	  Transpupillary	   thermotherapy	   (TTT)	   uses	   diode	   laser	   and	   is	   less	  destructive	  to	  surrounding	  healthy	  tissues	  because	  its	  emission	  wavelength	  is	  close	  to	  infrared	  on	  the	  electromagnetic	  spectrum.	  It	  has	  low	  absorption	  by	   xanthophyll	   (a	   key	  macular	   pigment)	   and	   haemoglobin,	   so	  minimising	  nerve	   fibre	   layer	   damage,	   and	   allowing	   treatment	   through	   obscuring	  haemorrhage	  (Berger,	  1997).	  Initial	  studies	  using	  photocoagulation	  in	  age-­‐related	  CNV	  showed	  it	  to	  be	  effective	  demonstrating	  angiographic	  closure	  of	  the	  CNV	  in	  7	  or	  9	  eyes	  40	  weeks	  following	  1	  or	  2	  treatments	  (Ulbig,	  McHugh	  &	  Hamilton,	  1993).	  	  Specifically	  for	  PM	  associated	  CNV,	  it	  has	  been	  shown	  to	  stabilise	  vision	   in	  about	  2/3	  of	  74	  cases	  that	  were	  studied	  retrospectively,	  with	  only	  8%	  improving	  vision	  and	  the	  rest	  losing	  at	  least	  0.1	  LogMAR	  units	  of	   VA	   (Nabawi	   &	   Shaarawi,	   2001).	   Following	   further	   reports	   of	   safety	  concerns	  such	  as	  macular	  infarction	  and	  poor	  efficacy,	  the	  National	  Institute	  for	   Health	   and	   Clinical	   Excellence	   (NICE)	   have	   not	   recommended	   its	   use	  outside	  of	  special	  arrangements	  for	  research	  (Benner,	  Ahuja	  &	  Butler,	  2002;	  NICE,	  2004).	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3.2.2.2	  Verteporfin-­‐	  photodynamic	  therapy	  	  Photodynamic	   therapy	   (PDT),	   using	   verteporfin	   was	   the	   mainstay	   of	  treatment	  until	   injectable	  treatment	  started	  being	  used.	  As	  with	  the	  use	  of	  TTT,	   the	  majority	   of	   study	   of	   PDT	   has	   been	   in	   age-­‐related	   CNV,	   with	   the	  results	  being	  extrapolated	  to	  PM	  associated	  disease.	  	  In	  nvAMD	  at	  best	  PDT	  slowed	  down	  the	  progression	  of	  visual	  loss.	  Data	  from	  a	  large	  multinational,	  randomized	   clinical	   trial	   demonstrated	   a	   significant	   benefit	   for	   PDT	   over	  sham	  therapy	  for	  the	  primary	  end	  point	  of	  prevention	  of	  loss	  of	  8	  or	  more	  ETDRS	  letters	  (considered	  to	  be	  clinically	  significant	  vision	  loss,	  72%	  versus	  44%;	   p<0.01),	   but	   this	   effect	   was	   lost	   after	   2	   years	   (64%	   versus	   49%	  p=0.11,	  Blinder,	  Blumenkranz	  &	  Bressler,	  2003).	  	  Hayashi,	  when	  comparing	  bevacizumab	   with	   PDT	   in	   a	   consecutive	   group	   of	   75	   patients	   for	   mCNV	  demonstrated	   a	   significantly	   better	   VA	   in	   the	   former	   group	   at	   12	  months	  (Hayashi	  et	  al,	  2009).	  Similarly	  in	  31	  patients	  receiving	  either	  bevacizumab	  or	   PDT,	   the	   PDT	   group	   demonstrated	   a	   mean	   worsening	   of	   VA	   after	   12	  months	  with	   significantly	   worse	   vision	   at	   24	  months	   (Ikuno	   et	   al,	   2010).	  The	   results	   of	   the	   RETAIN	   study,	   a	   large	   multinational	   prospective	  randomised	  trial	  comparing	  ranibizumab	  and	  PDT	  is	  awaited.	  	  
3.2.2.3	  	  Anti-­‐	  Vascular	  Endothelial	  Growth	  Factor	  therapies	  	  Based	   on	   landmark	   trials	   (ANCHOR,	  MARINA,	   CATT,	   and	   ABC	   trials),	   and	  clinical	   experience	   of	   treating	   patients	   with	   CNV	   secondary	   to	   AMD,	  ophthalmologists	   began	   to	   use	   anti-­‐VEGF	   agents	   such	   ranibizumab	   and	  bevacizumab	  in	  an	  ‘off-­‐label’	  manner	  to	  treat	  CNV	  secondary	  to	  PM	  (Brown	  et	   al,	   2006;	   Rosenfeld	   et	   al,	   2006;	   Chakravarthy	   et	   al,	   2012;	   Tufail	   et	   al,	  2010).	   Small	   case	   series	   showed	   promise	   for	   these	   anti-­‐VEGF	   agents	   in	  being	  able	  to	  substantially	  outperform	  PDT.	  Although	  different	  designs	  and	  durations,	   they	   report	   gains	   in	  VA	   letters	  with	   ranibizumab	   therapy.	   Silva	  reports	  a	  mean	  improvement	  from	  20/100	  to	  20/50	  at	  6	  months	  in	  26	  eyes,	  15	   of	   which	  were	   treatment	   naïve.	   (Silva	   et	   al,	   2008).	   At	   the	   Jules	   Gonin	  University	  Eye	  Hospital	   a	   case	   series	  of	  14	  eyes	  demonstrated	  a	  mean	  VA	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imporvment	  of	  0.48	  log-­‐MAR	  (Konstantinidis,	  Mantel,	  Pournaras,	  Zografos,	  Ambresin,	  2009).	  Mones	  et	  al	   reported	  on	  23	  eyes	   treated	  with	  a	  mean	  of	  1.52	   ranibizumab	   injections	  over	  12	  months	   gaining	   a	  mean	  of	  9.5	   letters	  (Mones,	   Amselem,	   Serrano,	   Garcia	  &	  Hijano,	   2009).	   Another	   report	   on	   16	  eyes	   showed	   a	  mean	   gain	   of	   3	   letters	   at	   12	  months	   (Lai,	   Chan,	   Liu,	   Lam,	  2009).	  	  Reviews	  are	  supportive	  of	  anti-­‐VEGF	  therapy	  for	  CNV	  secondary	  to	  PM	  (Cohen,	  2009;	  Ng,	  Kwok	  &	  Chang,	  2012).	  	  
3.3	  The	  aims	  of	  this	  study	  	  The	   aim	   of	   this	   study	   is	   to	   evaluate	   the	   treatment	   of	   CNV	   secondary	   to	  pathological	   myopia	   with	   ranibizumab	   and	   to	   assess	   visual	   acuity	   as	   a	  functional	  measure	  and	  OCT	  as	  an	  anatomical	  measure	  of	  outcome.	  	  At	   the	   time	   of	   performing	   this	   study	   no	   randomised	   controlled	   trials	  comparing	  ranibizumab	  and	  the	  PDT	  existed.	  Although	  ideally	  randomized	  controlled	   trials	   were	   needed	   to	   confirm	   results	   many	   retina	   specialists	  perceived	   that	  a	  PDT	  arm	  would	  be	  clearly	   inferior.	   It	  was	   felt	   that	  a	  case	  series	   demonstrating	   an	   increase	   in	   visual	   acuity	   in	   the	   context	   of	   well-­‐documented	  natural	  history	  studies	  (Silva	  et	  al,	  2008;	  Konstantinidis	  et	  al,	  2009:	   Mones	   et	   al,	   2009,	   Lai,	   2009)	   showing	   that	   untreated	  myopic	   CNV	  results	  in	  a	  mean	  loss	  of	  VA	  would	  be	  a	  robust	  study	  design.	  	  
3.4	  Methods	  	  Approval	  was	  granted	  from	  the	  relevant	  ethical	  bodies	  for	  this	  study	  and	  it	  was	   performed	   in	   accordance	   with	   the	   Declaration	   of	   Helsinki	   and	   Good	  Clinical	   Practice.	   It	   was	   registered	   at	   ClinicalTrials.gov,	   identifier:	  NCT01037348.	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3.4.1	  Patient	  selection	  	  To	  be	   included	   in	  the	  study	  patients	  had	  to	  be	  aged	  18	  years	  or	  more	  and	  have	  active	  primary	  or	  recurrent	  CNV	  secondary	  to	  PM.	  The	  lesion	  could	  be	  either	   in	   a	   subfoveal	   or	   juxtafoveal	   location,	   but	   a	   best-­‐corrected	   visual	  acuity	  (BCVA)	  score	  of	  24–78	  Early	  Treatment	  Diabetic	  Retinopathy	  Study	  (ETDRS)	   letters	   was	   required.	   PM	   was	   defined	   as	   having	   a	   spherical	  equivalent	  of	  –6	  Dioptres	  or	  more	  (or	  an	  axial	  length	  of	  21mm	  or	  more	  on	  A-­‐scan	  if	  this	  was	  unavailable),	  with	  characteristic	  chorioretinal	  changes.	  	  	  	  In	  order	  to	  see	  the	  effect	  of	  the	  medication	  on	  the	  single	  pathology	  of	  CNV	  secondary	   to	   PM,	   patients	   were	   excluded	   if	   they	   met	   any	   of	   the	   criteria	  outlined	  in	  Table	  4.	  	   Surgical	   intervention	   in	   the	  study	  eye	  within	  2	  months	  of	   the	  screening	  visit	  Current	  or	  previous	  macular	  laser	  photocoagulation	  Treatment	   with	   intravitreal	   steroids,	   verteporfin-­‐PDT	   or	   anti-­‐VEGF	  agents	  in	  the	  study	  eye	  Prior	   treatment	   in	   the	   study	   eye	   with	   vitrectomy	   or	   transpupillary	  thermotherapy	  Those	  with	  current	  use	  or	  likely	  need	  for	  systemic	  medications	  known	  to	  be	  toxic	  to	  the	  lens,	  retina	  or	  optic	  nerve	  e.g.	  ethambutol,	  desferoximine	  Concurrent	   use	   of	   systemic	   anti-­‐VEGF	   therapy	   or	   previous	   treatment	  with	  intravenously	  administered	  bevacizumab	  Concurrent	   use	   of	   chronic	   non-­‐steroidal	   anti-­‐inflammatory	   drugs	  (NSAIDs)	  for	  more	  than	  7	  consecutive	  days	  Systemic	  or	  topical	  ocular	  corticosteroids	  for	  ≥	  3	  consecutive	  days	  within	  6	  months	  prior	  to	  baseline	  CNV	  from	  causes	  other	  than	  pathological	  myopia	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Table	  4.	  Patients	  were	  excluded	  from	  enrolment	  to	  the	  PM	  treatment	  study	  if	  they	  met	  the	  above	  criteria.	  	  At	  Visit	  1	  (Baseline)	  all	  criteria	  for	  inclusion	  and	  exclusion	  were	  confirmed.	  	  
3.4.2	  Ranibizumab	  dosing	  regimen	  	  All	   study	   participants	   received	   one	   initial	   intravitreal	   injection	   of	  ranibizumab	   at	   visit	   2.	   A	   qualified	   ophthalmologist	   experienced	   in	  intravitreal	   procedures	   administered	   this.	   A	   dose	   of	   0.5	   mg	   in	   0.05	   mL	  ranibizumab	   in	   solution	  was	   chosen	   as	   this	   reflected	   the	   product	   labeling	  for	   treatment	  of	  AMD	  (Summary	  of	  Product	  Characteristics	  (SmPC),	  2007)	  and	   that	   used	   the	   recent	   case-­‐series	   mentioned	   above	   (Silva	   et	   al,	   2008;	  Konstantinidis	  et	  al,	  2009;	  Mones	  et	  al,	  2009,	  Lai,	  2009).	  	  	  The	   need	   for	   re-­‐treatment	   was	   assessed	   at	   each	   subsequent	   visit	   (visit	  numbers	  3-­‐13)	  and	  was	  determined	  by	  a	  flow	  chart	  used	  set	  out	  in	  Figure	  6.	  This	   was	   an	   ‘as	   needed’	   (Pro	   Re	  Nata	  or	   prn)	   regimen	   with	   re-­‐treatment	  largely	   determined	   by	   BCVA,	   symptoms	   and	   spectral	   domain	   Optical	  Coherence	   Tomography.	   A	   reduction	   in	   BCVA,	   symptoms	   of	   increased	  blurred	   vision	   or	   increased	   metamorphopsia	   were	   used	   as	   surrogate	  markers	  of	  the	  activity	  of	  the	  CNV.	  Visits	  were	  no	  more	  frequent	  than	  every	  28	  days.	  	   1.	  Is	  there	  evidence	  of	  sub	  retinal	  or	  intra	  retinal	  fluid	  on	  the	  OCT?	  	  YES-­‐	  Retreat	  NO-­‐	  Go	  to	  question	  2.	  	   2.	   Has	   the	   patient	   had	   a	   decrease	   in	   BCVA	   by	   5	   letters	   or	   more	   or	  experience	  increased	  blurring	  or	  metamorphopsia?	  	  YES-­‐	  Go	  to	  question	  3.	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NO-­‐	  No	  treatment	  and	  monitor	  in	  1	  month	  	   3.	  Is	  there	  leakage	  on	  Fundus	  fluorescein	  angiography?	  	  YES-­‐	  Retreat	  NO-­‐	  No	  treatment	  and	  monitor	  in	  1	  month	  	  
Figure	  6.	  The	  algorithm	  used	  to	  determine	  retreatment	  in	  the	  PM	  treatment	  study.	  	  




3.4.4.1	  Primary	  endpoint	  
	  The	   mean	   change	   in	   BCVA	   from	   baseline	   to	   month	   12	   was	   the	   primary	  endpoint	  of	  this	  study.	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3.4.4.2	  Secondary	  endpoints	  	  The	  secondary	  endpoints	  were	  the	  evaluation	  of	  the	  mean	  change	  in	  central	  macular	   thickness	   from	   baseline	   to	   month	   12,	   the	   total	   number	   of	  treatments,	   the	   change	   in	   proportions	   of	   eyes	   with	   retinal	   fluid,	   and	   the	  safety	  of	  intravitreal	  injections	  of	  ranibizumab.	  	  	  As	   with	   all	   clinical	   trials,	   safety	   data	   were	   collected.	  With	   regards	   to	   the	  secondary	   endpoint	   only	   serious	   adverse	   events	   (SAEs)	   were	   analysed.	  Events	   which	   are	   life	   threatening,	   fatal	   or	   which	   result	   in	   persistent	   or	  significant	   disability	   including	   a	   congenital	   birth	   defect,	   or	   that	   require	  inpatient	  hospitalization	  constituted	  the	  definition	  of	  an	  SAE.	  
	  
3.4.5	  Statistical	  analysis	  	  The	   Mones	   study,	   reporting	   on	   the	   follow	   up	   of	   23	   eyes	   treated	   with	  ranibizumab	   at	   12	   months	   helped	   determine	   the	   required	   sample	   size	  (Mones	   et	   al,	   2009).	   To	   detect	   a	   difference	   in	  mean	  BCVA	   of	   10	   letters,	   a	  sample	  size	  of	  58	  was	  calculated	  to	  have	  90%	  power	  to	  detect	  mean	  change	  of	  10	  letters	  from	  baseline	  to	  month	  12.	  This	  assumed	  a	  standard	  deviation	  of	  differences	  of	  23,	  using	  a	  paired	  t-­‐test	  with	  a	  0.05	  two-­‐sided	  significance	  level.	   An	   expectation	   of	   approximately	   10%	   drop	   out	   was	   allowed	   for,	  requiring	  a	  total	  of	  64	  eyes	  of	  64	  patients	  to	  be	  enrolled.	  	  	  Data	   from	  all	   participants	  were	   analysed	   as	   long	   as	   they	   received	   at	   least	  one	  study	  injection	  of	  ranibizumab	  and	  had	  at	  least	  one	  further	  assessment	  of	   BCVA	   using	   the	   last-­‐observation-­‐carried-­‐forward	   and	   intent-­‐to-­‐treat	  principles.	   Likewise	   safety	   was	   assessed	   for	   all	   patients	   who	   received	   at	  least	  one	  application	  of	  study	  treatment	  and	  had	  at	  least	  one	  post-­‐baseline	  safety	  assessment.	  	  	  Descriptive	   statistics	   for	   absolute	   values	   and	   changes	   from	   baseline	  were	  reported	   for	   each	   endpoint.	   For	   the	   McNemar	   tests	   (used	   to	   analyse	   the	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qualitative	   aspects	   of	   the	   OCT)	   the	   category	   'Questionable'	   was	   included	  with	  the	  'Definite'	  category.	  Missing	  values	  (N/A)	  were	  excluded.	  	  Due	  to	  the	  infrequency	  of	  the	  disease,	  only	  7	  participants	  were	  expected	  to	  be	   recruited	   into	   the	   study	   locally.	  To	  enable	   the	   recruitment	   target	   to	  be	  met	  12	  sites	  across	  the	  UK	  participated	  in	  the	  study.	  Correlation	  coefficients	  were	  calculated	  between	  the	  local	  and	  UK	  cohorts.	  A	  two-­‐tailed	  probability	  was	  calculated	  an	  P	  <=	  0.05	  was	  taken	  as	  statistical	  significance.	  	  
3.5	  Results	  	  
3.5.1	  Demographic	  and	  baseline	  characteristics	  
	  In	  total,	  7	  participants	  were	  recruited	  locally	  and	  65	  throughout	  the	  UK.	  62	  patients	   completed	   the	   study,	   1	   withdrew	   due	   to	   an	   unsatisfactory	  therapeutic	  effect,	  1	  was	  withdrawn	  due	  to	  a	  protocol	  violation	  and	  1	  was	  lost	   to	   follow	   up.	   None	   of	   these	   3	   participants	   were	   in	   the	   local	   cohort.	  	  Demographic	   data	   are	   presented	   in	   Table	   5.	   Most	   participants	   were	  Caucasian	   (90.8%),	   female	   (70.8%)	   and	   aged	   younger	   than	   65	   years	  (76.9%).	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  Mean	  age,	  years	  (SD)	   55.5	  (14.97)	  Age	  distribution,	  n	  (%)	  <	  50	  years	  50	  to	  <	  65	  years	  65	  to	  <	  75	  years	  75	  to	  <	  85	  years	  >	  85	  years	  
	  21	  (32.3)	  29	  (44.6)	  10	  (15.4)	  3	  (4.6)	  2	  (3.1)	  Gender,	  n	  (%)	  Female	  Male	  
	  46	  (70.8)	  19	  (29.2)	  	   	  Predominant	  race	  n	  (%)	  Caucasian	  Other	  
	  59	  (90.8)	  6	  (9.2)	  	  	  
Table	  5.	  	  Participant	  demographic	  data	  in	  the	  PM	  treatment	  study.	  	  
3.5.2	  Primary	  endpoint	  
	  The	  mean	  BCVA	   increase	   for	   the	   local	   cohort	   of	   7	   participants	  was	   +16.5	  letters	   (SD	   =	   11.2,	   p	   <0.01,	   Paired	   T-­‐test)	   over	   12	   months	   (Table	   6	   and	  Figure	   7).	   The	   greatest	   improvement	   was	   seen	   following	   the	   initial	  treatment	  (+14.6	  letters).	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  Visit	  Number	   	  Mean	  VA	  (SD,	  ETDRS	  letters)	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Table	   6.	   The	   mean	   (standard	   deviation)	   BCVA	   (ETDRS	   letters)	   and	   CRT	  (micrometres)	   for	   the	   local	   cohort	   of	   7	   participants	   in	   the	   PM	   treatment	  study.	   Figures	   are	   given	   for	   assessments	   at	   baseline,	   the	   mandatory	  treatment	  and	  subsequent	  as	  required	  visits.	  	  
	  
	  
Figure	  7.	  The	  mean	  (standard	  deviation)	  visual	  acuity	  for	  the	  local	  cohort	  of	  7	  participants	   in	  the	  PM	  treatment	  study.	  All	  7	  participants	  contributed	  to	  the	  mean	  at	  each	  visit.	  Visit	  number	  is	  displayed	  on	  the	  X-­‐axis	  and	  absolute	  ETDRS	  BCVA	  on	  the	  Y-­‐axis.	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  Visit	  number	   	  Mean	  VA	  (SD,	  ETDRS	  letters)	  	  
	  Mean	   CRT	   (SD,	  μm)	  1	  (Baseline)	   59.5	  (13.6)	  	   384.7	  (130.9)	  2(Mandatory	  treatment)	   68.5	  (13.6)	  	   280.6	  (89.7)	  3	   70.3	  (13.0)	  	   277.1	  (87.2)	  4	   69.3	  (13.2)	  	   269.3	  (80.6)	  5	   71.0	  (13.7)	  	   252.3	  (77.3)	  6	   69.6	  (14.3)	  	   257.2	  (76.5)	  7	   70.7	  (15.5)	  	   256.7	  (82.7)	  8	   71.4	  (14.4)	  	   262.2	  (87.7)	  9	   72.2	  (13.9)	  	   253.6	  (83.8)	  10	   72.8	  (14.4)	  	   256.5(85.2)	  11	   73.5	  (13.3)	  	   249.8	  (79.5)	  12	   72.6	  (14.8)	  	   248.7	  (80.8)	  13	   73.0	  (13.3)	  	   251.4	  (78.1)	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Table	   7.	   The	   mean	   (standard	   deviation)	   BCVA	   (ETDRS	   letters)	   and	   CRT	  (micrometres)	   for	   the	   UK	   cohort	   of	   62	   participants	   in	   the	   PM	   treatment	  study.	   Figures	   are	   given	   for	   assessments	   at	   baseline,	   the	   mandatory	  treatment	  and	  subsequent	  as	  required	  visits.	  
	  	  
	  	  
Figure	  8.	  The	  mean	  (standard	  deviation)	  visual	  acuity	  for	  the	  UK	  cohort	  of	  62	  participants	  in	  the	  PM	  treatment	  study.	  Visit	  number	  is	  displayed	  on	  the	  X-­‐axis	  and	  absolute	  ETDRS	  BCVA	  on	  the	  Y-­‐axis.	  	  	  
























	   82	  
	  	  




































	   83	  
	  	  




































	   84	  
injection	   technique),	  which	  occurred	   in	   the	   local	   cohort.	   In	  addition,	   there	  were	  three	  non-­‐ocular	  SAEs.	  There	  were	  two	  hospitalizations,	  one	  because	  of	   joint	   dislocation	   and	   the	   other	   because	   of	   pre-­‐existing	   depression	   and	  anxiety,	  the	  latter	  occurring	  in	  a	  patient	   in	  the	  local	  cohort	  and	  was	  a	  pre-­‐existing	  condition.	  A	  termination	  of	  a	  partner’s	  pregnancy	  for	  social	  reasons	  was	  the	  third	  SAE.	  	  	  
Post	  hoc	  analysis	  of	  change	   in	  BCVA	  demonstrated	   that	  all	  but	  one	  patient	  avoided	  a	  loss	  of	  15	  letters	  or	  more,	  32	  (50.8%)	  gained	  10	  letters	  or	  more	  and	  24	   (36.9%)	   gained	  15	   letters	   or	  more.	  At	   baseline,	   the	   treatment	   eye	  was	  the	  worse	  seeing	  eye	  in	  73.8%	  and	  this	  reduced	  to	  59.4%	  at	  month	  12.	  	  	  	  
3.6	  Discussion	  	  
3.6.1	   The	   efficacy	   and	   safety	   of	   ranibizumab	   as	   a	   treatment	   for	   CNV	  
associated	  with	  Pathological	  Myopia.	  	  This	  local	  dataset	  of	  7	  participants	  showed	  an	  improvement	  in	  visual	  acuity	  and	  reduction	  in	  central	  retinal	  thickness.	  Because	  of	  the	  small	  sample	  size	  rendering	   it	   open	   to	   greater	   bias,	   most	   of	   the	   ensuing	   discussion	   will	   be	  based	  upon	  the	  larger	  national	  dataset.	  	  Ranibizumab	   treatment	   for	   CNV	   secondary	   to	   PM	   in	   a	   1	   +	   prn	   schedule	  improved	  VA	  and	  reduced	  CRT	  at	  12	  months	  compared	  with	  baseline.	  These	  improvements	  in	  vision	  were	  achieved	  with	  a	  low	  number	  of	  re-­‐treatments	  after	  the	  initial	  dose.	  Furthermore,	  very	  few	  SAEs	  were	  reported.	  	  These	   data,	   which	   at	   the	   time	   of	   study	   were	   the	   largest	   cohort	   to	   be	  prospectively	   studied	   show	   an	   improvement	   in	   VA	   of	   13.8	   letters	   at	   12	  months	  with	   a	  mean	   of	   3.6	   injections.	   Results	   from	   smaller	   case-­‐series	   of	  ranibizumab	  therapy	  in	  CNV	  secondary	  to	  PM	  also	  consistently	  demonstrate	  significant	   improvements	   in	   VA	   with	   an	   equivalent	   improvement	   of	   9-­‐19	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ETDRS	   letters	   (Silva	   et	   al,	   2008;	   Konstantinidis	   et	   al,	   2009:	   Mones	   et	   al,	  2009,	  Lai,	  2009).	  	  Based	  upon	  VA	  and	  CRT,	  the	  results	  add	  to	  the	  suggestion	  of	  ranibizumab’s	  superiority	  to	  verteporfin-­‐PDT	  with	  the	  VIP	  study	  (in	  age-­‐related	  disease)	  showing	  verteporfin-­‐PDT	  produces	  a	  loss	  of	  10	  letters	  at	  12	  months	   (VIP	   study	   group,	   2001).	   	   The	   awaited	   RADIANCE	   study	   results,	  reporting	  on	  a	  direct	   comparison	   in	  a	   randomised	   trial,	  will	  better	   inform	  us.	  	  	  The	  three	  reported	  SAEs	  did	  not	  reveal	  any	  safety	  concerns;	  all	  but	  the	  case	  of	   culture	  negative	  endophthalmitis	  were	   thought	  not	   to	  be	   related	   to	   the	  medication	   or	   the	   injection	   procedure	   (Lucentis	   SmPC,	   2007).	   These	  findings	   are	   consistent	   with	   the	   well	   characterized	   safety	   profile	  demonstrated	   by	   ranibizumab	   in	   this	   patient	   population	   in	   published	  smaller,	  less	  robustly	  designed	  case-­‐series	  (Silva	  et	  al,	  2008;	  Konstantinidis	  et	  al,	  2009:	  Mones	  et	  al,	  2009,	  Lai,	  2009).	  Given	  the	  significantly	  increased	  likelihood	   of	   retinal	   detachment	   in	   myopic	   eyes	   and	   eyes	   undergoing	  interventional	  procedures	   it	  was	  reassuring	  to	  observe	  that	  there	  were	  no	  reports	   of	   retinal	   detachment	   reported	   either	   in	   our	   study	   or	   the	  aforementioned	   studies.	   A	   much	   larger	   cohort	   of	   patients	   studied	   for	   a	  longer	  duration	  would	  be	  needed	  to	  more	  fully	  evaluate	  potential	  rare	  side	  effects.	  	  	  The	  single-­‐armed	  uncontrolled	  nature	  of	  this	  study	  limits	  its	  interpretation.	  The	  decision	  to	  have	  a	  singled	  armed	  open	  label	  design	  was	  taken	  as	  it	  was	  thought	   difficult	   to	   justify	   the	   allocation	   of	   patients	   to	   verteporfin-­‐PDT	   as	  what	   appears	   to	   be,	   from	   the	   above	   discussion,	   a	   clearly	   inferior	   a	  comparator	  arm.	  	  	  Although	  data	  from	  a	  multicentre	  study	  reduces	  the	  influence	  of	  single	  site	  bias	  the	  lack	  of	  a	  central	  reading	  centre	  leaves	  the	  interpretation	  of	  FFA	  and	  OCT	   images	   dependent	   upon	   the	   investigator.	   This	   may	   however,	   give	   a	  closer	  reflection	  of	  real	  world	  practice.	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3.6.2	  Visual	  acuity	  and	  OCT	  as	  outcome	  measures	  of	  the	  ranibizumab	  
in	  treatment	  of	  CNV	  secondary	  to	  pathological	  myopia	  	  This	   study	   confirms	   the	   notion	   that	   mCNV	   occurs	   predominantly	   in	   the	  work	   age	   group,	   and	   often	   in	   those	   age	   50	   years	   or	   younger	   (Chan	   et	   al,	  2005).	   It	   therefore	  has	  the	  potential	   to	  have	  a	  significant	  economic	   impact	  by	  limiting	  the	  ability	  to	  perform	  visually	  dependent	  tasks,	  and	  so	  on	  career	  progression,	  even	  forcing	  early	  retirement	  (Soubrane,	  2008).	  	  The	  question	  has	  to	  be	  asked	  whether	  high	  contrast	  VA	  or	  CRT	  as	  measured	  by	  OCT	  are	  the	  correct	  outcome	  measurements	  or	  a	  good	  proxy	  for	  visually	  dependent	  tasks?	  	  
3.6.2.1	  Visual	  acuity	  	  The	   arguments	   for	   and	   against	   using	   high	   contrast	   VA	   in	   a	   study	   setting	  have	   been	   made	   in	   Chapter	   2	   and	   concluded	   that	   measuring	   VA	   change	  often	   underestimates	   the	   change	   in	   visual	   function	   and	   ability	   to	   perform	  visually	  dependent	  tasks	  (Mangiona	  et	  al,	  1999;	  Hazel	  et	  al,	  2000;	  Bansback	  et	  al	  2007;	  Patel	  et	  al,	  2011).	  An	  additional	  point	  of	  discussion	  brought	  out	  by	   this	   study	   is	   which	   measurement	   of	   the	   change	   in	   VA	   is	   the	   most	  appropriate?	   This	   study	   used	   the	   mean	   change	   in	   VA	   from	   baseline	   to	  month	  12.	  That	   is	   the	  mean	  of	  the	  entire	  visits	  post	  baseline	  out	  to	  month	  12,	   and	   is	   an	   endpoint	   used	   in	   other	   studies	   (Ross	   et	   al,	   2013).	   Another	  alternative	  would	  have	  been	  to	  use	  the	  change	  in	  mean	  VA	  from	  baseline	  to	  month	   12	   as	   in	   the	   ANCHOR	   and	   MARINA	   studies	   (Brown	   et	   al,	   2006;	  Rosenfeld	   et	   al,	   2006).	   The	   former	  has	   the	   advantage	   in	   that	   it	  minimises	  the	  impact	  of	  a	  non-­‐representative	  result	  if	  the	  month	  12	  value	  is	  an	  outlier	  compared	  with	   the	   previous	   results	   as	   it	   would	   be	   expected	   to	   be	   in	   the	  stability	  phase	  of	  treatment	  (Tschour	  et	  al,	  2013).	  The	  latter	  method	  has	  the	  advantage	   in	   that	   the	   slower	   increase	   in	   VA	   in	   the	   initiation	   phase	   of	  treatment	  does	  not	  dilute	  the	  true	  gain	  at	  12	  months	  (Tschour	  et	  al,	  2013).	  As	  long	  as	  is	  appreciated	  that	  these	  two	  endpoints	  are	  different	  and	  either	  can	  be	  used.	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3.6.2.2	  Ocular	  Coherence	  Tomography	  	  The	   advantages	   of	   the	   use	   of	   OCT	   to	   assess	   the	   outcome	   of	   treatment	   of	  mCNV	  and	  nvMD	  in	  general	  are	  numerous.	  In	  a	  compliant	  individual	  an	  OCT	  image,	  even	  with	  high	  resolution,	   typically	   takes	  a	   few	  minutes	  to	  acquire.	  An	  automated	  calculation	  of	  central	  retinal	  thickness	  produces	  a	  numerical	  value	   enabling	   the	   benefits	   of	   statistical	   analysis.	   Repeatability	   and	  reproducibility	   of	   spectral	   domain	   OCT	   central	   thickness	   is	   high,	   Giana	  reporting	   a	   highly	   reproducible	   central	   retinal	   thickness	   even	   of	   -­‐6	   to	   +6	  microns	  using	  Bland-­‐Altmann	  plots	  even	  when	  using	  different	  density	  of	  A-­‐scan	   per	   B	   scan	   (Giana,	   Deiro	   &	   Staurenghi,	   2012).	   The	   interpretation	   of	  OCT	   images	   is	   subject	   to	   inter-­‐observer	   variability	  however.	   Patel	   reports	  on	   the	   study	   of	   278	   lines	   of	   73	   scan	   in	   patients	   with	   nvAMD	   prior	   to	  treatment.	   	   Two	   observers	   graded	   the	   images	   for	   the	   presence	   of	   intra-­‐retinal	  cysts,	  sub-­‐retinal	  fluid,	  diffuse	  retinal	  oedema,	  sub-­‐retinal	  tissue	  and	  pigment	  epithelial	  detachment	  with	  agreement	  only	   ranging	   from	  77-­‐91%	  (Patel	   et	   al,	   2009).	   Joeres,	   in	   a	   study	   of	   60	   images	   in	   AMD	   patients	  interpreted	   separately	   by	   2	   independent	   observers,	   demonstrated,	  however,	   that	  with	   training	   grading	   can	   be	   highly	   reproducible	  with	   only	  grading	  of	  sub	  retinal	  tissue,	  advanced	  CNV	  or	  RPE	  in	  the	  presence	  of	  poor	  visibility	  giving	  rise	  to	  the	  significant	  discrepancies.	  (Joeres	  et	  al,	  2007).	  	  	  The	  use	  of	  OCT	  does	  have	  a	  number	  of	  limitation	  and	  unknowns.	  Although	  the	   technology	   is	   advancing	   year	   upon	   year	   to	   give	   better	   resolution,	  caution	   has	   to	   be	   given	  when	   using	   automated	   interpretations.	   Firstly,	   to	  give	  an	  example,	  the	  Stratus	  (Carl	  Zeiss	  Meditec)	  time	  domain	  OCT	  does	  not	  give	  the	  same	  central	  retinal	  thickness	  measurement	  as	  its	  more	  advanced	  spectral	   domain	   successor,	   the	   Cirrus	   (Carl	   Zeiss	   Meditec).	   Grover	   and	  colleagues	  demonstrated	   that	  mean	  centre-­‐point	   thickness	   in	   the	  same	  36	  healthy	   eyes	   was	   166.9	   +/-­‐	   29µm	   using	   a	   Stratus	  machine	   but	   225.1	   +/-­‐	  17.1µm	  (p<0.0001)	  using	  the	  Cirrus	  (Grover,	  Murthy,	  Brar	  &	  Chalam,	  2010).	  This	   knowledge	   means	   that	   technology	   needs	   standardising	   within	   trials	  and	  caution	  given	  when	  interpreting	  across	  trials.	  Secondly,	  when	  OCT	  data	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from	   the	   ABC	   trial	   were	   being	   analysed	   it	   was	   remarked	   upon	   that	   the	  automated	  delineation	  of	  the	  retinal	  structures	  such	  as	  the	  internal	  limiting	  membrane	  and	  the	  RPE	  (the	  structures	  between	  which	  retinal	  thickness	  is	  calculated)	  were	  often	  misplaced	  and	  required	  manual	  placement	  (Keane	  et	  al,	  2012).	  As	  there	  was	  no	  central	  reading	  centre	  to	  verify	  the	  images	  in	  our	  study,	  errors	  in	  this	  figure	  are	  likely.	  	  There	   are	   a	   number	   of	   OCT	   acquired	   parameters	   that	   could	   be	   used	   to	  assess	  macular	  morphology.	  Our	  study	  chose	  to	  use	  centre	  point	  thickness	  as	   the	   CRT	   as	   myopic	   CNVs	   are	   often	   small.	   	   The	   term	   ‘CRT’	   or	   central	  retinal	  thickness	  differs	  between	  studies	  so	  again	  caution	  needs	  to	  be	  given	  when	   interpreting	   this	   value.	  Many	   studies,	   including	   those	   in	   chapters	   5	  and	  6	  use	  the	  mean	  thickness	  of	  the	  central	  1mm2	  subfield	  thickness,	  taken	  as	  a	  disc	   from	  the	  point	  of	   fixation	  as	  the	  CRT.	  This	   is	  because	  age-­‐related	  CNVs	  and	  so	  their	  sequelae	  of	  retained?	  fluid	  are	  often	  larger.	  	  Qualitative	  analysis	  of	  OCT	  images	  is	  also	  helpful.	  Our	  study	  demonstrated	  the	  proportion	  of	  eyes	  with	  intra-­‐retinal,	  sub	  retinal	  and	  DRE	  was	  reduced	  at	   12	  months	   compared	   with	   assessment	   prior	   to	   treatment.	   Keane	   et	   al	  correlated	  qualitative	  OCT	  features	  with	  VA	  in	  the	  ABC	  trial	  involving	  AMD	  patients	  and	  so	  gives	   justification	   for	   the	  use	  of	  change	  or	   the	  presence	  of	  these	  features	  as	  re-­‐treatment	  criteria	  (Keane	  et	  al,	  2012).	  In	  an	  analysis	  of	  the	  121	  treatment	  naïve	  patients	  randomised	  to	  receive	  either	  bevacizumab	  or	   standard	   of	   care,	   OCT	   determined	   reduction	   in	   diffuse	   retinal	   oedema	  correlated	  strongly	  with	  increase	  in	  VA	  (p	  =0.01).	  Surprisingly,	  as	  it	  is	  often	  used	   as	   re-­‐treatment	   criteria	   in	  many	   clinical	   trials	   such	   as	   the	  CATT	  and	  IVAN	  studies	  (Martin	  et	  al,	  2012;	  Chakravarthy	  et	  al,	  2012)	  sub	  retinal	  fluid	  did	   not	   (p=0.932).	   A	   larger	   volume	   of	   sub-­‐retinal	   tissue	   at	   baseline	   also	  strongly	   correlated	   with	   decreased	   VA	   at	   the	   54-­‐week	   study	   end	   point	  (p<0.001).	   Furthermore	   Schmit-­‐Urfuth’s	   group	   reported	   that	   the	   integrity	  of	  the	  External	  Limiting	  Membrane	  (representing	  the	  photoreceptor	  layer)	  is	  the	  most	  important	  spectral	  domain	  OCT	  biomarker	  correlating	  with	  VA	  at	  any	  point	  during	  the	  treatment	  of	  nvAMD	  with	  ranibizumab	  (Roberts	  et	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al,	  2014).	  	  Through	  the	  24	  months	  study	  of	  20	  treatment	  naïve	  patients	  the	  correlation	  was	  strong,	  but	  still	  did	  not	  serve	  as	  a	  predictive	  biomarker	  for	  visual	  prognosis	  prospectively.	  	  	  Central	   retinal	   thickness,	   an	   objective	   anatomical	  measure	   is	   used	   in	   this	  study	   as	   proxy	   for	   functional	   outcomes.	   Results	   show	   that	   there	   is	  justification	   for	   this	   in	   that	   there	   is	   a	   strong	   correlation	   between	   mean	  increase	   in	   VA	   and	   mean	   decrease	   in	   CRT	   (p<0.001).	   Unfortunately	   data	  was	  not	   collected	   to	   enable	   a	   qualitative	   change	   in	  OCT	  parameters	   to	   be	  correlated.	   	  As	  discussed,	  VA	  is	  not	  sufficient	  to	  inform	  about	  the	  ability	  to	  perform	  visually	  dependent	  tasks.	  The	  following	  chapter	  studies	  the	  use	  of	  patient	  reported	  outcome	  measures	  and	  correlates	  them	  with	  VA	  and	  CRT.	  	  
3.7	  Conclusion	  	  The	  results	  of	  this	  study	  show	  that	  ranibizumab	  used	  in	  an	  ‘as	  required’	  re-­‐treatment	   manner	   is	   an	   effective	   therapy	   for	   mCNV.	   It	   confirms	   the	  improvement	   in	   VA	   seen	   in	   smaller	   retrospective	   case	   series	   and	  supersedes	  performance	  of	  laser-­‐based	  therapies.	  Few	  SAEs	  were	  identified	  in	  line	  with	  other	  ranibizumab-­‐based	  studies.	  	  Central	   retinal	   thickness,	   as	   measured	   by	   OCT	   performed	   well	   with	   its	  decrease	   correlating	   well	   with	   improvement	   in	   VA.	   Quantitative	   changes	  thought	  to	  be	  markers	  of	  disease	  activity	  were	  used	  as	  re-­‐treatment	  criteria.	  As	  there	  is	  a	  paucity	  of	  literature	  on	  the	  treatment	  of	  mCNV,	  extrapolation	  is	  often	   taken	   from	   experience	   with	   nvAMD.	   The	   results	   of	   this	   study	   are	  consistent	  with	  that	  found	  with	  AMD,	  with	  improvement	  in	  VA	  possibly	  out	  performing	   its	   age-­‐related	   counterpart.	  There	   is	   still	   a	   lack	  of	   information	  about	   how	   well	   the	   change	   in	   the	   surrogate	   markers	   of	   VA	   and	   CRT	  represent	   visually	   dependent	   function.	   Nonetheless	   the	   National	   Institute	  for	   Health	   and	   Clinical	   Excellence	   recently	   approved	   its	   used	   in	   the	   NHS	  (NICE	  TA298,	  2013).	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Chapter	   4.	   Patient	   Reported	  Outcomes	   as	  Outcome	  Measures	   of	   anti-­‐
VEGF	   treatment	   of	   Pathological	   Myopia	   associated	   Neovascular	  
Macular	  Degeneration	  	  
4.1	  Introduction	  	  Chapter	   3	   reported	   on	   the	   use	   of	   Visual	   Acuity	   (VA)	   and	   Central	   Retinal	  Thickness	  (CRT)	  as	  outcomes	  measures	  of	  anti-­‐Vascular	  Endothelial	  Growth	  Factor	  (VEGF)	  treatment	  of	  myopic	  Choroidal	  Neovascularisation	  (mCNV).	  It	  concluded	  that	  there	  are	  benefits	  with	  the	  use	  of	  both	  of	  these	  biomarkers,	  in	   particular	   their	   use	   in	   parallel	   being	   of	   synergistic	   value	   in	   validating	  findings.	   It	   also	   discussed	   their	   limitations	   especially	   that	   they	   may	   not	  represent	  visual	  function	  or	  quality	  of	  life.	  	  It	   could	   be	   argued	   that	   the	   ultimate	   goal	   of	   any	   treatment	   of	   non-­‐life	  threatening	   disease	   is	   to	   restore	   the	   effect	   of	   disease	   on	   an	   individual’s	  quality	  of	  life.	  Although	  surrogate	  markers	  of	  disease	  activity	  are	  important	  in	   measuring	   immediate	   response	   to	   therapy,	   or	   indeed	   can	   help	   with	  retreatment	   decision	  making	   it	   is	   also	   prudent	   to	  measure	   an	   individual’s	  perception	   of	   disease	   effect.	   The	   National	   Institute	   of	   Health	   and	   Clinical	  Excellence	   bases	   funding	   arrangements	   not	   just	   on	   efficacy	   of	   treatments	  but	  also	  cost	  effectiveness	  using	  quality	  of	  life	  health	  utilities.	  An	  example	  of	  this	   is	   the	   decision	   of	   the	   NHS	   to	   fund	   ranibizumab	   for	   nvAMD	   (NICE	   TA	  155).	  Quality	  of	   life	  measurements	  aim	  to	  give	  a	  more	  holistic	  approach	   in	  assessing	   treatment	  response.	  These	  measurements	  should	  be	  reported	  by	  patients	   themselves,	   and	   in	   fact	   the	   use	   of	   the	   self-­‐reported	   status	   of	  healthcare	  has	  been	  suggested	  by	  some	  as	  to	  be	  of	  greater	  importance	  than	  any	   other	   outcomes	   that	   are	   clinical,	   physiological	   or	   carer-­‐given	  (Deshpande,	   Rajan,	   Sudeepthi	   &	   Nazir,	   2011).	   Patient	   Reported	   Outcomes	  (PROs)	  as	  defined	  by	  the	  US	  Food	  and	  Drug	  Administration	  are	  any	  report	  of	  the	   status	   of	   a	   ‘patient’s	   health	   condition	   that	   comes	   directly	   from	   the	  patient	  (i.e.	  without	  interruption	  of	  the	  patient’s	  response	  by	  the	  physician	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or	  anyone	  else’	  US	  FDA,	  2006).	  This	  chapter	  assesses	   the	  use	  of	  PROs	  as	  a	  measurement	  of	  response	  to	  anti-­‐VEGF	  treatment	  for	  mCNV.	  	  	  
4.2	  Background	  
	  Pathological	   Myopia	   (PM)	   is	   a	   common	   disease	   with	   a	   significant	   risk	   of	  visual	   loss	   due	   to	   CNV	   (Montero	   et	   al,	   2010;	   Soubrane	   2008;	   Chan	   et	   al,	  2005;	   Yoshida	   et	   al,	   2003).	   The	   study	   in	   Chapter	   3,	   the	   second	   largest	  prospective	   cohort	   at	   the	   time,	   showed	   that	   intravitreal	   anti-­‐VEGF	  treatment	   of	   mCNV	   improved	   and	   then	   stabilised	   vision	   in	   this	   situation	  (Tufail	  et	  al,	  2013a;	  Tufail	  et	  al	  2013b).	  Of	   the	  62	  eyes	   that	  completed	   the	  study	   the	   mean	   change	   in	   VA	   was	   13.8	   ETDRS	   letters	   at	   12	   months,	  requiring	   a	   mean	   of	   3.6	   ranibizumab	   injections.	   The	   RADIANCE	   study,	  comparing	  photodynamic	   therapy	   to	   ranibizumab	   in	   a	   randomised	   clinical	  trial	  has	  now	  reported	  and	  also	  describes	  a	   significant	  mean	  gain	   in	  VA	  of	  13.8	  and	  14.4	  letters	  at	  12	  months	  in	  the	  2	  ranibizumab	  only	  arms	  (Wolf	  et	  al,	  2014).	  	  	  There	   are	   a	   number	   of	   different	   Patient	   Reported	   Outcome	   Measures	  (PROMs)	  that	  can	  assess	  vision	  related	  outcomes,	  each	  of	  which	  have	  been	  validated.	   The	   National	   Eye	   Institute	   Visual	   Function	   Questionnaire	   (NEI	  VFQ)	  is	  an	  example	  of	  a	  very	  commonly	  used	  one.	  With	  the	  help	  of	  patients	  with	   visual	   impairment,	   NEI	   VFQ	   was	   developed	   as	   a	   51-­‐point	   scale	   that	  sampled	  different	  aspects	  of	  visual	   function	   (Mangione	  et	  al,	  1998).	   It	  was	  later	   refined	   to	   a	   more	   convenient	   25	   point	   scale,	   the	   NEI	   VFQ-­‐25,	   with	  correlations	  to	  its	  51	  point	  predecessor	  showing	  it	  was	  still	  valid	  (Mangione	  et	  al,	  2001).	  The	  NEI	  VFQ	  has	  subsequently	  been	  used	  to	  provide	  insight	  into	  the	   quality	   of	   life	   changes	   following	   anti-­‐VEGF	   treatment	   for	   nvAMD.	   For	  example,	   it	   was	   used	   in	   a	   24-­‐month	   open	   label	   study	   of	   ranibizumab	   in	  nvAMD	   where	   baseline	   vision	   was	   maintained	   at	   month	   12	   and	   then	  declined,	  despite	  a	  mean	  of	  7.6	  (SD	  4.1)	  injections.	  	  On	  this	  occasion	  the	  NEI	  VFQ-­‐25	   score	   improved	   at	   6	   months	   (p=0.03)	   and	   was	   subsequently	  maintained	   out	   to	  month	  24	   (Rakic	   et	   al,	   2013).	   The	  NEI	  VFQ-­‐25	  has	   also	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been	   used	   to	   study	   quality	   of	   life	   in	   mCNV	   in	   the	   RADIANCE	   study	   and	  demonstrated	   greater	   improvements	   in	   vision	   related	   function	   in	   the	  ranibizumab	  treated	  group	  (Wolf	  et	  al,	  2014).	  	  The	  MacDQoL	  is	  another	  example	  and	  is	  a	  22-­‐stem	  questionnaire	  designed	  to	  assess	  the	  impact	  of	  age-­‐related	  macular	  degeneration	  on	  quality	  of	  life	  of	  individuals	  with	  the	  AMD.	  It	  sampled	  159	  individuals	  at	  a	  single	  time	  point	  and	   after	   removing	   4	   questions	   from	   the	   original	   26	   (mainly	   due	   to	  redundancy)	   analyses	   demonstrated	   it	   had	   excellent	   internal	   consistency	  and	   reliability.	   Furthermore	   the	   results	   demonstrated	   that	   AMD	   has	   a	  significant	  impact	  on	  independence,	  leisure	  activities,	  the	  ability	  to	  deal	  with	  personal	  affairs	  and	  mobility	  (Mitchell	  et	  al,	  2005).	  It	  was	  further	  evaluated	  in	   a	   longitudinal	   study	   in	   135	   individuals	   with	   AMD	   and	   demonstrated	  excellent	  test	  re-­‐test	  reliability	  over	  12	  months	  (Mitchell	  et	  al,	  2007).	  	  The	  domains	  of	  well-­‐being	  and	  treatment	  satisfaction	  have	  not	  been	  studied	  in	  the	  context	  of	  treatment	  of	  mCNV	  and	  so	  this	  chapter	  focuses	  on	  two	  tools	  to	  assess	  these	  aspects	  of	  care.	  	  
4.2.1	  The	  W-­‐BQ12	  Well-­‐being	  questionnaire	  	  The	  12-­‐item	  well-­‐being	  questionnaire	  (W-­‐BQ12,	  Riazi,	  Bradley,	  Barendse	  &	  Ishii	  2006)	  was	  developed	  from	  the	  longer	  22-­‐item	  version	  and	  comprises	  3	  areas	   of	   assessment:	   Energy,	   positive	   well-­‐being	   and	   negative	   well-­‐being	  (Bradley	  &	  Lewis,	  1990;	  Appendix	  A).	  Each	  of	  these	  3	  areas	  has	  a	  score	  of	  12	  points,	  making	  a	  total	  of	  36	  possible;	  a	  higher	  score	  indicates	  a	  better	  well-­‐being.	  Although	  the	  PROM	  was	  developed	  for	  use	  in	  patients	  with	  diabetes,	  it	  has	  been	  shown	  to	  be	  a	  useful	  and	  reliable	  tool	   in	  patients	  with	  macular	  disease.	  Mitchell	  and	  Bradley	  analysed	  results	  from	  a	  self-­‐completed	  survey	  of	   1421	   members	   of	   the	   then	   called	   Macular	   Disease	   Society	   and	  demonstrated	   consistency	   with	   its	   use	   in	   those	   with	   diabetes	   and	   worse	  scores	  in	  those	  registered	  as	  partially	  sighted	  or	  blind	  compared	  with	  those	  who	  were	  not.	  They	  concluded	  that	  ‘The	  W-­‐BQ12	  will	  be	  useful	  in	  measuring	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outcomes	   in	   rehabilitative	   and	   medical	   interventions	   and	   in	   researching	  factors	  affecting	  adjustment	  to	  MD’	  (Mitchell	  &	  Bradley,	  2001).	  	  
4.2.2	  The	  MacTSQ	  Treatment	  satisfaction	  questionnaire	  	  The	   treatment	   satisfaction	   questionnaire	   MacTSQ	   (Mitchell,	   Brose	   &	  Bradley,	   2007)	   was	   designed	   to	   assess	   treatment	   satisfaction	   of	   macular	  disorders	  using	  scales	  separated	  into	  two	  broad	  areas:	  impact	  of	  treatment,	  and	   provision	   of	   information	   and	   convenience.	   There	   are	   12	   questions	   in	  each	  of	  these	  2	  areas,	  with	  the	  maximum	  of	  36	  points	  in	  each	  area	  giving	  a	  potential	  overall	  maximum	  score	  of	  72	  points	  (Appendix	  B).	  A	  higher	  score	  indicates	   a	   better	   satisfaction.	   In	   a	   similar	   manner	   to	   the	   W-­‐BQ12,	   the	  MacTSQ	  questionnaire	  was	  based	  upon	  a	  retinopathy	  treatment	  satisfaction	  questionnaire	  (Woodcock	  et	  al,	  2005).	  The	  MacTSQ	  has	  been	  used	  to	  assess	  the	  outcome	  of	  treatment	  of	  AMD	  with	  anti-­‐VEGF	  therapy	  in	  the	  IVAN	  trial,	  however	  the	  results	  are	  still	  awaited	  (Chakravarthy	  et	  al,	  2013).	   It	  has	  not	  been	  used	  to	  study	  response	  in	  those	  with	  mCNV	  so	  far.	  	  
4.3	  Methods	  
	  This	   study	  used	   the	   same	  participants	   as	  described	   in	  Chapter	  3.	   In	   short,	  the	   aim	  was	   to	   recruit	   65	   participants	  with	  mCNV	   and	   treat	   them	  with	   a	  single	   administration	   of	   ranibizumab	   followed	   by	   further	   treatments	   on	   a	  monthly,	  as	  required	  basis	  out	  to	  12	  months.	  This	  was	  a	  single	  armed,	  open	  label	  design.	  	  Both	   the	  W-­‐BQ12	  and	   the	  MacTSQ	  were	  completed	  at	  months	  1,	  6	  and	  12	  with	  the	  W-­‐BQ12	  also	  being	  completed	  at	  baseline	  prior	  to	  treatment.	  It	  was	  given	   to	   the	   participants	   to	   complete	   independently	   but	   if	   required	   help	  from	  a	  research	  nurse	  was	  allowed.	  The	  questionnaire	  was	  administered	  at	  the	  study	  visits	  before	  the	  patients	  had	  ocular	  examination	  or	  treatment.	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4.3.1	  Statistical	  analysis	  
	  A	  full	  analysis	  set	  approach	  (all	  patients	  that	  had	  at	  least	  one	  treatment	  and	  one	  assessment	  following	  baseline)	  was	  used	  to	  analyse	  the	  full	  data	  set.	  The	  local	  cohort	  was	  not	  analysed	  separately	  due	  to	  the	  analysis	  of	  such	  a	  small	  data	   set	  being	   invalid	   (Riazi	   et	   al,	   2006;	  Mitchell	   et	   al	  2007).	  Missing	  data	  was	   handled	   by	   using	   a	   last	   observation	   carried	   forward	   method.	   Mean	  differences	  over	  time	  were	  tested	  using	  analysis	  of	  covariance.	  Mean	  change	  from	  baseline	   to	  month	   12	   in	   general,	   positive	   and	  negative	  well-­‐being	   as	  well	   as	   energy	   was	   pre-­‐planned.	   Correlations	   (Pearson	   product-­‐moment	  correlation	  co-­‐efficient)	  were	  used	  to	  study	  the	  relationship	  between	  VA,	  W-­‐BQ12	   general	   well-­‐being	   and	   MacTSQ	   overall	   score..	   For	   the	   W-­‐BQ12,	  analyses	  was	  performed	  to	  compare	  participants	  when	  the	  treated	  eye	  being	  the	  better	  seeing	  eye	  (BSE)	  with	  participants	  when	  the	  treated	  eye	  was	  the	  worst	  seeing	  eye	  (WSE).	  A	  better	  seeing	  eye	  was	  defined	  as	  seeing	  5	  or	  more	  ETDRS	  letters	  better	  than	  the	  worse	  at	  baseline.	  The	  W-­‐BQ12	  was	  also	  sub	  analysed	  by	  groups	  dependent	  upon	  change	  from	  baseline	  VA	  (<0,	  0-­‐4,	  5-­‐9	  and	   10	   or	   more	   ETDRS	   letters	   gained).	   For	   the	   MacTSQ,	   sub	   analyses	  compared	  the	  BSE	  versus	  WSE	  and	  groups	  depending	  upon	  the	  number	  of	  treatments	  given	  in	  12	  months	  (1,	  2-­‐3,	  or	  more	  than	  3).	  Because	  these	  were	  exploratory	  end	  points,	  results	  were	  reported	  as	  descriptive	  only.	  P	  values	  were	  calculated	  using	  a	  paired	  t-­‐test	  and	  a	  value	  of	  less	  than	  or	  equal	  to	  0.05	  was	  considered	  statistically	  significant.	  	  
4.4	  Results	  
	  The	   VA	   and	   CRT	   results	   are	   described	   in	   detail	   in	   chapter	   3,	   but	   to	  summarise	   in	   the	   cohort	   of	   62	   participants	   there	   was	   a	   mean	   VA	  improvement	   of	   13.8	   letters	   (SD=14.0,	   p<0.001),	   and	   a	  mean	   reduction	   in	  central	   retinal	   thickness	   of	   135µm	   (SD=109µm,	   p<0.001)	   at	   12	   months	  (Tufail	  et	  al	  2013a,	  Tufail	  et	  al	  2013b).	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4.4.1	  W-­‐BQ12	  Well-­‐being	  questionnaire	  
	  The	  mean	  general	  well-­‐being	  score	  was	  25.6	  at	  baseline.	  Table	  8	  shows	  the	  change	   in	   general	   and	   sub-­‐scales	   of	   well-­‐being	   over	   time	   indicating	   a	  numerical	   increase	   in	   general	   well-­‐being,	   positive	   well-­‐being	   and	   energy,	  with	  a	  fall	  in	  negative	  well-­‐being.	  	  	   	   Mean	   (SD)	  general	   well-­‐being.	  	  
Mean	   (SD)	  positive	  well-­‐being.	  	  
Mean	   (SD)	  negative	  well-­‐being.	  	  
Mean	  (SD)	  energy.	  	  Baseline	  	  (n	  =	  65)	   25.6	  (6.96)	   8.3	  (2.74)	   2.3	  (2.80)	   7.6	  (2.54)	  Month	  1	  	  (n	  =	  59)	   26.8	  (5.03)	   8.6	  (2.59)	   1.4	  (1.95)	   7.6	  (2.30)	  Month	  6	  (n	  =	  61)	   27.2	  (6.08)	   8.9	  (2.61)	   1.7	  (2.47)	   8.0	  (2.48)	  Month	  12	  (n	  =	  61)	   27.3	  (6.35)	   8.7	  (2.66)	   1.5	  (2.60)	   8.1	  (2.44)	  Change	   from	  baseline	   to	  month	  12,	  	  p	  value	  	  
	  	  0.03	   0.150	   0.053	   0.102	  
	  
Table	   8.	  The	  baseline	  and	   time	  point	  scores	  of	   the	  general	  well-­‐being	  and	  subscales.	  	  The	  change	  in	  general	  well-­‐being	  from	  baseline	  to	  month	  12	  was	  significant	  (25.6	   to	   27.3,	   p=0.03)	   but	   the	   change	   in	   the	   subscales	   did	   not	   reach	  statistical	  significance.	  	  When	   analysing	   patients	   who	   had	   treatment	   to	   their	   BSE,	   the	   change	   in	  general	  well-­‐being,	  energy,	  positive	  well-­‐being	  and	  negative	  well-­‐being	  at	  12	  months	  were	  +2.1,	  +0.4,	  +0.2	  and	  -­‐1.5.	  When	  patients	  who	  had	  treatment	  to	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their	   WSE	   was	   studied	   the	   changes	   were	   +1.7,	   +0.5,	   +0.8	   and	   -­‐0.5	  respectively.	  Data	  for	  the	  general	  well-­‐being	  is	  shown	  in	  Table	  9.	  	   	   Mean	  W-­‐BQ12	   score	  BSE	  (n=15)	   Mean	   W-­‐BQ12	  score	  WSE	  (n=44)	  Baseline	   23.2	   27.2	  Month	  1	   24.8	   28.0	  Month	  6	   25.9	   28.2	  Month	  12	   25.3	   28.9	  	  
Table	   9.	  The	  baseline	  and	  time	  point	  general	  well-­‐being	  scores	  depending	  on	  whether	  the	  treated	  eye	  was	  the	  better	  and	  worse	  seeing	  eye.	  Note	  that	  there	  were	  6	  eyes	  where	  the	  baseline	  was	  neither	  better	  nor	  worse	  than	  the	  fellow	  eye	  (within	  5	  ETDRS	  letters	  of	  each	  other)	  and	  so	  total	  analysis	  was	  performed	  on	  59	  participants.	  	  	  At	   12	   months	   participants	   who	   had	   achieved	   an	   increase	   in	   VA	   had	   an	  increase	   in	   general	   well-­‐being	   but	   those	   who	   lost	   VA	   demonstrated	   a	  worsening	  of	  well-­‐being	  (Table	  10).	  Note	  this	  was	  not	  the	  case	  at	  6	  months	  for	  those	  that	  had	  lost	  vision.	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   Mean	  general	  well-­‐being	  score	  (number)	  ETDRS	   letter	  change	   from	  baseline	  (number	   of	  participants)	  
<0	  (8)	   0-­‐4	  (16)	   5-­‐9	  (10)	   >	  9	  (28)	  
Baseline	   23.4	   25.6	   24.6	   26.6	  Month	  1	   20.9	   26.0	   26.5	   28.7	  Month	  6	   26.1	   25.4	   28.0	   27.5	  Month	  12	  (change	  from	  baseline)	  
22.6	  (-­‐0.8)	   29.1	  (+3.5)	   27.0	  (+2.4)	   28.7	  (+2.1)	  
	  
Table	   10.	   	   General	   well-­‐being	   score	   over	   the	   course	   of	   the	   study,	   sub-­‐grouped	  by	  improvement	  from	  baseline	  VA.	  	  	  
4.4.2	  MacTSQ	  Treatment	  satisfaction	  questionnaire	  
	  The	   mean	   treatment	   satisfaction	   at	   month	   1	   was	   55.	   This	   increased	  significantly	  at	  12	  months	  to	  64.9	  (p<0.001)	  as	  did	  both	  impact	  of	  treatment,	  and	  information	  provision	  and	  convenience	  subscales	  (Table	  11)	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   Mean	   (SD)	  treatment	  satisfaction	  
Mean	   (SD)	  impact	   of	  treatment	  
Mean	   (SD)	  information	  provision	   and	  convenience	  Month	  1	  (n	  =	  62)	   55	  (17.88)	   26.2	  (7.87)	   28.7	  (10.85)	  Month	  6	  	  (n	  =	  59)	   58.8	  (16.21)	   29.6	  (7.31)	   29.2	  (9.73)	  Month	  12	  (n	  =	  61)	   64.9	  (9.23)	   32.0	  (4.88)	   32.9	  (6.03)	  Change	   from	  baseline	   to	  month	   12,	   p	  value	  
<0.001	   <0.001	   0.014	  
	  
Table	   11.	   The	   baseline	   and	   time	   point	   changes	   in	   overall	   treatment	  satisfaction	  and	  subscales	  scores.	  	  There	  was	   a	   similar	   increase	   in	  MacTSQ	   for	   both	   the	   BSE	   and	  WSE	   at	   12	  months	   (55.4	   to	   65.4,	   and	  54.8	   to	   64.4)	   but	   at	   6	  months	   only	   treating	   the	  WSE	  showed	  an	  improvement	  (54.8	  to	  60.0	  at	  6	  months	  and	  55.4	  to	  55.4	  at	  12	   months).	   Patients	   receiving	   2-­‐3	   injections	   had	   a	   numerically	   higher	  increase	  in	  MacTSQ	  (51.0	  to	  66.8)	  from	  month	  1	  to	  12	  compared	  with	  those	  receiving	  only	  1	  or	  >3	  treatments	  (Table	  12).	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   Mean	  treatment	  satisfaction	  Number	   of	  Treatments	  (number)	  
1	  (13)	   2-­‐3	  (21)	   3	  or	  more	  (26)	  
Month	  1	   65.0	   51.0	   53.1	  Month	  6	   66.5	   58.4	   56.8	  Month	  12	  (change	   in	  score	  from	  baseline)	  
63.0	  (-­‐2.0)	   66.8	  (+15.8)	   64.5	  (+11.4)	  
	  
Table	  12.	  The	  MacTSQ	  score	  over	  the	  course	  of	  the	  study,	  sub-­‐grouped	  by	  the	  number	  of	  treatments	  received.	  	  
4.4.3	   Correlations	   between	   visual	   acuity,	   well-­‐being	   and	   treatment	  
satisfaction	  	  Weak	  correlations	  were	  noted	  between	  VA	  and	  W-­‐BQ12	  general	  well-­‐being,	  VA	  and	  MacTSQ	  total	  score	  and	  W-­‐BQ12	  and	  MacTSQ).	  (Table	  13).	  	   	   r	   value	   	   at	   month	   12	   (p	  value)	  VA	  and	  W-­‐BQ12	   0.02	  (0.877)	  VA	  and	  MacTSQ	   0.02	  (0.877)	  W-­‐B12	  and	  MacTSQ	   0.08	  (0.537)	  
	  
Table	   13.	  The	  correlation	  co-­‐efficients	  and	   two	   tailed	  probability	   tests	   for	  correlations	  between	  VA,	  W-­‐BQ12	  and	  MacTSQ	  at	  month	  12.	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4.5	  Discussion	  
	  
4.5.1	   Patient	   reported	   outcome	   measurements	   in	   the	   treatment	   of	  
myopic	  CNV	  with	  ranibizumab	  
	  This	  study	  showed	  that	  patients	  treated	  with	  ranibizumab	  for	  mCNV	  over	  a	  12	  month	  study	  period	  on	  an	  ‘as	  required’	  basis	  had	  a	  small	  but	  statistically	  significant	  increase	  in	  overall	  well-­‐being	  as	  measured	  by	  the	  W-­‐QB12	  scale.	  There	   is	   no	   benchmark	  W-­‐BQ12	   data	   for	   mCNV	   treatment,	   or	   indeed	   for	  nvAMD	   for	   comparison,	   but	   the	   increase	   in	   well-­‐being	   observed	   with	  treatment	  would	  be	   in	   line	  with	   clinical	   expectation	  based	  upon	  a	  parallel	  improvement	  in	  visual	  acuity.	  The	  validity	  of	  the	  result	  is	  further	  supported	  by	  the	  12-­‐month	  observation	  that	  those	  who	  had	  achieved	  an	  increase	  in	  the	  VA	   had	   an	   increase	   in	   general	   well-­‐being	   but	   those	   who	   lost	   VA	  demonstrated	   a	  worsening	   of	  well-­‐being.	   Some	   caution	   has	   to	   be	   given	   to	  these	  conclusions	  as	  it	  is	  also	  noted	  that	  this	  was	  not	  the	  case	  in	  those	  losing	  vision	  at	  6	  months.	  The	  results	  show	  an	  improvement	  in	  energy	  and	  positive	  well-­‐being	   as	   well	   as	   a	   fall	   in	   negative	   well-­‐being,	   with	   only	   the	   later	  approaching	   significance.	   These	   changes	   in	   subscales	   are	   also	   in	   line	  with	  clinical	  expectation	  and	  therefore	   the	  explanation	   for	   their	   failure	   to	  reach	  statistical	  significance	  in	  likely	  to	  be	  that	  the	  study	  was	  underpowered.	  	  	  Treatment	   satisfaction	   as	  measured	   by	   the	  MacTSQ	   improved	   throughout	  the	  study	  both	  in	  terms	  of	  the	  treatment	  burden,	  and	  information	  provision	  and	   convenience	   subscales.	   Like	  with	   the	  W-­‐BQ12	   instrument	   there	   is	   no	  benchmark	   data	   in	   the	   use	   of	   the	   MacTSQ	   for	   the	   treatment	   of	   mCNV	   or	  nvAMD	  and	  the	  results	  on	  the	  IVAN	  study	  are	  awaited	  where	  it	  was	  used	  as	  an	   endpoint	   for	   treatment	   of	   nvAMD.	   Intravitreal	   injections	   can	   often	   be	  associated	  with	  considerable	  anxiety,	  but	  an	  increase	  in	  the	  MacTSQ	  can	  be	  interpreted	  as	  habituation	  to	  this	  in	  the	  context	  of	  this	  particular	  treatment	  regimen	  and	  study	  environment.	  Both	  impact	  of	  treatment,	  and	  information	  and	   convenience	   improved.	   Caution	   has	   to	   be	   taken	   in	   assuming	   these	  findings	   would	   be	   extrapolated	   into	   clinical	   practice,	   as	   routine	   clinical	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practice	  often	  does	  not	  involve	  the	  same	  degree	  of	  patient	  contact	  or	  indeed	  the	  same	  environment	  as	  clinical	  trial	  practice	  offers.	  	  By	  the	  definition	  used	  in	  this	  study	  more	  individuals	  were	  treated	  in	  a	  WSE	  than	  in	  the	  BSE.	  Improvements	  were	  marginally	  greater	  in	  those	  treated	  in	  their	   BSE.	   	   This	   small	   difference	   along	  with	   the	   small	   number	   in	   the	   BSE	  group	  makes	  interpretation	  of	  this	  finding	  difficult,	  although	  it	  is	  tempting	  to	  conclude	   it	   is	   explained	   by	   an	   improvement	   in	   the	   BSE	   having	   a	   greater	  impact	  on	  overall	  visual	  function.	  The	  concept	  that	  health	  utility	  scores	  are	  associated	  with	  the	  VA	  and	  in	  particular	  VA	  with	  their	  BSE	  is	  well	  founded	  one	   however.	   Brown	   et	   al	   studied	   80	   patients	  with	  macular	   degeneration	  and	  associated	  visual	  acuity	  with	   their	  BSE,	  reporting	   that	   those	  with	  mild	  visual	   loss	   (20/20-­‐20/25)	   were	   prepared	   to	   trade	   off	   11%	   of	   their	  remaining	   life	   and	   those	   with	   severe	   visual	   loss	   (Count	   fingers	   to	   Light	  perception)	  60%	  if	  normal	  vision	  could	  be	  restored	  (Brown,	  Sharma,	  Brown	  &	   Kistler,	   2000).	   This	   findng	   does	   not	   appear	   to	   be	   unique	   to	   AMD	   and	  mirrored	   findings	   in	   100	   consecutive	   patients	   with	   diabetic	   retinopathy	  with	   respective	   values	   of	   15%	   and	   41%	   (Brown,	   Brown,	   Sharma	   &	   Shah,	  1999).	  Using	  similar	  trade	  off	  utility	  values	  in	  a	  cohort	  of	  325	  vitreoretinal	  patients,	  Brown	  et	  al	  was	  able	  to	  find	  a	  closer	  correlation	  with	  VA	  in	  the	  BSE	  than	  the	  WSE	  (Brown,	  Brown,	  Sharma,	  Smith	  &	  Landy	  2001).	  	  	  There	  appears	   to	  be	  no	  easily	   identifiable	  explanation	   for	   the	  difference	   in	  month	   1	   MacTSQ	   results	   when	   subdivided	   by	   number	   of	   injections	   given	  during	   the	   study.	   It	  may	   be	   expected	   that	   the	  month	   1	  MacTSQ	  would	   be	  similar	   across	   the	   subgroups	   as	   at	   this	   time	   all	   participants	   would	   have	  received	   a	   single	   initiation	   treatment,	   however	   those	   	   receiving	   only	   1	  treatment	  was	  higher	  than	  in	  the	  groups	  recieivng	  more.	  An	  large	  imbalance	  in	   the	   numbers	   within	   each	   group	   may	   have	   distorted	   this	   result.	   Those	  participants	   having	   only	   1	   treatment	   had	   a	   fall	   in	  MacTSQ	  whereas	   those	  having	   2-­‐3	   or	   more	   than	   3	   had	   an	   increase.	   This	   appears	   to	   be	  counterintuitive	   but	   could	   be	   explained	   by	   those	   not	   requiring	   treatment	  beyond	  the	  first	  injection	  percieiving	  that	  no	  further	  attempt	  is	  being	  made	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to	  restore	  their	  vision	  and	  so	  being	  less	  content.	  No	  further	  subdivision	  on	  the	  subscales	  is	  valid	  here	  due	  to	  the	  low	  participant	  numbers	  but	  analyses	  from	  a	   larger	   scale	   trial,	   such	   as	   the	   anticipated	   IVAN	   study	  may	  be	  more	  informative	  (Chakravarthy	  et	  al,	  2012).	  	  	  	  
4.5.2	  The	  use	  of	  PROMS	  as	  an	  outcome	  measure	  	  Following	   on	   from	   the	   discussion	   in	   previous	   chapters,	   it	   is	   rational	   to	  conclude	   that	   mean	   VA	   over	   a	   treatment	   period	   is	   a	   reasonable	   way	   to	  assess	  the	  benefit	  of	  treatment	  of	  neovascular	  macular	  degeneration.	  It	  has	  also	   been	   concluded	   that	   CRT	   is	   a	   reasonable	   surrogate	  marker	   for	   visual	  acuity.	  In	  this	  chapter	  no	  correlation	  has	  been	  identified	  between	  the	  change	  in	  VA	  and	  the	  change	  in	  both	  well-­‐being	  and	  treatment	  satisfaction	  utilities	  studied.	   It	   is	   therefore	  not	  possible	   to	   conclude	  with	   a	  degree	  of	   certainty	  that	   the	  W-­‐BQ12	  and	  MacTSQ	  are	   valid	  PROMs	   tools	   in	   the	   assessment	   of	  treatment	   of	   mCNV	   with	   ranibizumab	   on	   an	   as	   required	   basis,	   and	  furthermore	   that	   VA	   is	   a	   marker	   of	   quality	   of	   life.	   It	   may	   that	   a	   study	  designed	  to	  specifically	  addressed	  this,	  with	  adequate	  powering	  may	  be	  able	  to	   conclude	   differently.	   The	   improvement	   in	   visual	   function	   as	  demonstrated	   by	   the	   NEI-­‐VFQ	   tool	   in	   the	   RADIANCE	   study	   adds	   further	  weight	   to	   the	   suggestion	   of	   the	   validity	   of	   PROMS	   however.	   It	   has	   to	   be	  appreciated	  that	  although	  broadly	  coming	  under	  the	  umbrella	  of	  	  ‘Quality	  of	  life’	   measurements	   these	   tools	   measure	   different	   concepts;	   the	   NEI-­‐VFQ	  measures	  perception	  of	  visual	  function,	  the	  MacTSQ	  perception	  of	  treatment	  satisfaction	  and	  the	  W-­‐BQ12	  overall	  perception	  of	  well-­‐being.	  	  The	  advantage	  of	  using	  a	  PROM	  is	  that	   is	  offers	  a	  new	  dimension	  to	  assess	  an	   outcome	   of	   treatment.	   Outcomes	   can	   be	   broadly	   divided	   into	   clinical	  (efficacy	  or	  safety),	  humanistic	  (performance	  of	  role,	  emotional	  status)	  and	  economical	  (expenses	  or	  saving)	  and	  the	  use	  of	  PROMs	  is	  a	  move	  away	  from	  using	  traditional	  clinical	  biomarkers	  of	  the	  improvement	  in	  ‘disease’	  such	  as	  VA	  alone	  (Deshpande	  et	  al,	  2011).	  The	  principle	  disadvantage	  of	  the	  use	  of	  PROMS,	  apart	   from	  their	  often	   time	  consuming	  nature	  and	  dependency	  on	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literative	  skills	  of	  the	  user,	  is	  that	  the	  questions	  posed	  are	  those	  of	  the	  study	  team.	  Although	  the	  development	  of	  the	  W-­‐BQ12	  and	  MacTSQ	  may	  have	  been	  informed	  by	  patients,	  ultimately	  the	  desgin	  was	  that	  at	  the	  discretion	  of	  the	  investigators	  (Riaz	  et	  al	  2006,	  Mitchell	  et	  al	  2007).	  A	  purer	  way	  of	  capturing	  perceptions	   of	   well-­‐being	   may	   be	   to	   take	   a	   more	   qualitative	   approach;	  however	  validating	  and	  interpreting	  such	  methods	  can	  prove	  more	  difficult.	  	  Overall,	   PROMs	  work	   synergistically	   with	   clinical	   markers	   reinforcing	   the	  use	   of	   all	   of	   these	   endpoints	   and	   as	   such	   they	   are	   becoming	   increasingly	  used	  to	  assess	  the	  outcome	  of	  treatments	  in	  a	  number	  of	  therapeutic	  areas.	  NHS	   England	   is	   currently	   using	   PROMs	   to	   assess	   the	   benefit	   and	   patient	  perceptions	   of	   orthopaedic	   and	   surgical	   procedures	   (NHS	   England,	   2015).	  Although	   as	   of	   yet	   no	   areas	   of	   eye	   health	   care	   are	   subjected	   to	   such	  mandatory	  study	  this	  is	  likely	  to	  become	  an	  important	  marker	  of	  the	  quality	  of	  services	  in	  the	  future.	  	  	  
4.6	  Conclusion	  	  	  The	  study	   in	   this	   chapter	  was	   the	   first	   time	   that	   the	  W-­‐BQ12	  and	  MacTSQ	  tools	   were	   used	   to	   evaluate	   outcomes	   in	   the	   treatment	   of	   mCNV	   with	   as	  required	   ranibizumab.	   Results	   show	   that	   both	   well-­‐being	   and	   treatment	  satisfaction	  improved	  over	  the	  12	  month	  study	  period	  and	  although	  subject	  to	  variability	  during	  the	  study	  and	  subscales	  being	  affected	  by	  low	  numbers,	  help	  to	  set	  a	  benchmark	  for	  their	  use.	  	  The	  study	  demonstrates	  that	  changes	  in	  PROMS	  are	  comparable	   to	   those	   in	  VA	  and	  CRT,	  and	  although	  provide	  a	  different	   dimension	   to	   measuring	   outcome,	   have	   the	   potential	   to	   work	  synergistically	  in	  evaluating	  such	  treatments.	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Chapter	  5.	  	  Change	  in	  retinal	  sensitivity	  following	  treatment	  of	  nvAMD	  
using	  anti-­‐VEGF	  therapy:	  using	  a	  lesion-­‐guided	  microperimetry	  retinal	  
sensitivity	  as	  an	  outcome	  measure	  
	  
5.1	  Introduction	  	  The	  previous	  chapters	  have	  discussed	  the	  use	  of	  visual	  acuity	  (VA),	  central	  retinal	   thickness	   (CRT)	  and	  patient	   reported	  outcomes	   (PROs)	  as	  outcome	  measures	   in	   the	   treatment	   of	   neovascular	   macular	   degeneration.	  Conclusions	  were	  made	  that	  VA,	  although	  useful	  when	  assessing	  cohorts,	  is	  not	  good	  at	  assessing	  point-­‐to-­‐point	  change	  in	  vision.	  CRT,	  as	  measured	  by	  Optical	   Coherence	   Tomography	   (OCT)	   is	   a	  more	   useful	   tool	   for	   individual	  assessments	  between	  single	  time	  points	  but	  still	  qualitative	  analysis	  of	  each	  image	   is	   required	   to	   aid	   the	   assessment	   of	   treatment.	   PROs	   are	   a	   usual	  adjunct	  in	  assessing	  the	  overall	  impact	  of	  therapies	  for	  macular	  disease	  but	  specific	  utilities	  are	  required	  to	  assess	  specific	  aspects	  of	  treatment	  and	  its	  outcome.	  VA	  provides	  a	  functional	  assessment	  of	  vision	  and	  OCT	  provides	  a	  morphological	   assessment	   of	   the	   macula.	   The	   chapter	   assesses	   and	  evaluates	  the	  use	  of	  microperimetry	  (MP)	  in	  determining	  retinal	  sensitivity	  as	  a	  part	  of	  an	  objective	  and	  functional	  outcome	  of	  treatment	  of	  neovascular	  AMD.	  	  
5.2	  Background	  	  Age-­‐related	  macular	   degeneration	   is	   the	   commonest	   cause	   of	   sight	   loss	   in	  the	   elderly	   population	   (Owen	   et	   al,	   2012).	   The	   neovascular	   subtype,	  representing	  about	  a	  fifth	  of	  incident	  cases	  is	  treatable	  with	  anti-­‐angiogenic	  intravitreal	  injections	  (Brown	  et	  al,	  2006;	  Rosenfeld	  et	  al,	  2006;	  Martin	  et	  al,	  2011;	  Charavarthy	  et	  al,	  2012,	  Schmidt-­‐Erfurth	  et	  al,	  2014).	  The	  majority	  of	  affected	   individuals	   require	   therapy	   in	   the	   long	   term	   in	   an	   attempt	   to	  maintain	  vision	  (Rofagha	  et	  al,	  2013;	  Tufail	  et	  al,	  2014;	  Airody	  et	  al,	  2014)	  with	  the	  maximal	  restoration	  of	  visual	  function	  being	  the	  goal	  of	  treatment.	  Once	  maximum	  visual	  potential	  has	  been	  reached,	  most	  individuals	  receive	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discontinuous	   therapy,	   being	   retreated	   either	   when	   there	   are	   signs	   of	  disease	   activity	   (reactive),	   or	   when	   activity	   is	   predicted	   to	   return	  (proactive)	   (Lalwani	   et	   al,	   2009;	   Berg,	   Pederson,	   Sandvik	   &	   Bragadottir,	  2015).	  As	  discussed	  in	  previous	  chapters	  these	  signs	  of	  disease	  activity,	  and	  so	   response	   to	   treatments,	   are	   commonly	   measured	   by	   distance	   visual	  acuity	   assessment	   using	   an	   Early	   Treatment	   Diabetic	   Retinopathy	   Study	  (ETDRS)	   chart	   and	   by	   assessment	   of	   retinal	   morphology	   as	   measured	   by	  optical	   coherence	   tomography	   (OCT).	   Visual	   acuity,	   because	   of	   its	   large	  coefficient	  of	  variability	  between	  measurements	  (Patel	  et	  al,	  2008;	  Aslam	  et	  al,	  2014)	  can	  be	  considered	  better	  placed	  to	  assess	  the	  response	  of	  a	  cohort	  of	   individuals	   or	   the	   mean	   response	   of	   an	   individual	   over	   a	   series	   of	  observations	  rather	  than	  judge	  response	  between	  single	  time	  points.	  Central	  Retinal	   Thickness	   (CRT)	   and	   in	   particular	   qualitative	   aspects	   of	   retinal	  morphology,	   as	  measured	   by	   OCT	   has	   good	   reproducibility	   and	   so	   can	   be	  considered	   well	   placed	   to	   measure	   outcomes	   between	   single	   time	   points.	  Despite	   being	   able	   to	   use	   these	   two	   biomarkers	   of	   visual	   function	  synergistically	  to	  aid	  the	  overall	  assessment	  of	  response	  to	  treatment	  there	  is	   still	   disconnect	   between	   patients’	   perceptions	   of	   visual	   change	   and	  conventional	   assessment	   methods	   such	   as	   VA	   (Legge,	   Ross,	   Isenberg	   &	  LaMay,	  1992)	  and	  CRT	  (Munk	  et	  al,	  2013;	  Cho	  et	  al,	  2013).	  	  Perimetry	   is	   a	   psychophysical	   method	   of	   assessing	   retinal	   sensitivity	  whereby	   a	   stimulus	   of	   given	   size	   and	   intensity	   is	   presented	   in	   the	   field	   of	  vision	  corresponding	  to	  the	  area	  of	  the	  retina	  under	  examination.	  An	  area	  of	  reduction	  in	  retinal	  sensitivity,	  termed	  a	  relative	  scotoma,	  or	  an	  area	  of	  total	  defect,	  an	  absolute	  scotoma,	  can	  be	  defined.	  Microperimetry,	  which	  enables	  the	  determination	  of	  a	  map	  of	  retinal	  sensitivity	  in	  a	  much	  smaller	  field	  and	  has	   shown	   promise	   as	   an	   objective	   tool	   of	   measuring	   macular	   function	  following	   treatment	   of	   nvAMD	  with	   anti-­‐angiogenic	   agents	   (Squirrel	   et	   al,	  2010;	   Baseler	   et	   al,	   2011;	   Munk	   et	   al,	   2013;	   Cho	   et	   al	   2013).	   Munk	   et	   al	  chose	   to	   observe	   the	   size	   of	   the	   absolute	   scotoma	   over	   time	   and	   found	   a	  trend	  towards	  a	  reduction	   in	   its	  size	  with	  treatment	  but	  this	  did	  not	  reach	  statistical	   significance	   (Munk	   et	   al,	   2013).	   Cho	   et	   al	   and	   Parravano	   et	   al	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however	  showed	  an	  increase	  in	  overall	  retinal	  sensitivity	  over	  time	  (Cho	  et	  al,	   2013,	   Parravano	   et	   al,	   2010).	   The	   common	   theme	   with	   each	   of	   these	  studies	  was	   that	  an	  area	  of	   the	  macula	  was	  predefined	  before	   that	  start	  of	  the	   study	  and	   then	  used	   for	   examination	  of	   each	  participant.	  This	   concept	  has	  some	  inherent	  weaknesses	  in	  particular	  that	  the	  size	  of	  the	  retinal	  lesion	  does	  not	  correspond	  exactly	  to	  the	  area	  of	  examination.	  	  Fixation	   is	   known	   to	   be	   impaired	   in	   individuals	  with	   AMD,	   particularly	   in	  late	   disease	   such	   as	   CNV	   (Tarita-­‐Nistor,	   Gonzalez,	  Markowitz	  &	   Steinback,	  2008;	   Pearce,	   Sivaprasad,	  &	   Chong,	   2011).	   In	   these	   circumstances	   fixation	  can	  be	  eccentric,	  can	  occupy	  one	  or	  more	  new	  preferential	  retinal	  locations	  (PRLs)	  or	  can	  be	  unstable	  (Fletcher	  &	  Schuchard,	  1997;	  Pearce	  et	  al,	  2011).	  Fixation	   stability	   or	   rather	   how	   unstable	   the	   fixation	   is,	   is	   known	   to	  correlate	   with	   day-­‐to-­‐day	   tasks	   such	   as	   reading	   (Ergun,	   Maar,	   Radner,	  Barbazetto,	   Schmidt-­‐Erfurth	   &	   Stur,	   2003;	   Crossland,	   Culham	   &	   Rubin.	  2005)	   and	   so	   is	  potentially	   an	   important	  measure	  of	   visual	   function	  when	  considering	  response	  to	  treatments.	  	  	  This	  chapter	  studies	  the	  change	  in	  retinal	  sensitivity	  following	  treatment	  of	  nvAMD	   using	   anti-­‐VEGF	   therapy	   using	   a	   lesion-­‐guided	   microperimetry	  technique	  to	  specifically	  study	  an	  area	  of	   interest.	   It	  also	  evaluates	  fixation	  stability	  as	  an	  exploratory	  outcome.	  	  
5.3	  Methods	  	  This	  research	   followed	   the	   tenets	  of	   the	  Declaration	  of	  Helsinki.	   	   Informed	  written	  consent	  was	  obtained	  from	  all	  participants	  following	  an	  explanation	  of	   the	   nature	   and	   possible	   consequences	   of	   the	   study.	   Experimental	  protocols	   were	   approved	   by	   the	   York	   Neuroimaging	   Research,	   Ethics	   and	  Governance	  Committee	  and	  the	  University	  of	  York	  Ethics	  Committee.	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5.3.1	  Patient	  population	  and	  treatment	  	  Treatment	  naïve	  patients	  that	  fulfilled	  the	  National	  Institute	  for	  Health	  and	  Clinical	  Excellence	  (NICE)	  criteria	  for	  treatment	  of	  nvAMD	  (Snellen	  VA	  6/12	  or	  less,	  nvAMD	  with	  evidence	  of	  recent	  disease	  progression)	  were	  recruited	  into	   the	   study.	   All	   participants	   had	   previously	   been	   assessed	  with	   Fundus	  Fluorescein	   Angiography	   as	   a	   part	   of	   routine	   care	   within	   2	   weeks	   of	  recruitment.	  Fluorescein	  angiography	  had	  been	  performed	  using	  a	  Carl	  Zeiss	  NM-­‐1	   camera	   with	   2mls	   of	   5%	   fluorescein	   being	   injected.	   Images	   were	  captured	   using	   a	   standard	   macular	   protocol	   in	   the	   choroidal,	   arterial,	  venous	  and	  late	  phases	  out	  to	  10	  minutes	  post-­‐injection.	  Participants	  were	  excluded	  if	  they	  were	  unable	  to	  give	  written	  consent.	  	  All	  participants	  underwent	  assessment	  with	  of	  Best	  Corrected	  Visual	  Acuity	  (BCVA)	   vision,	   CRT	   and	   retinal	   sensitivity	   (RS)	   at	   baseline	   (visit	   1).	  Treatment	   was	   subsequently	   commenced	   with	   the	   intravitreal	   anti-­‐VEGF	  agent	   that	  was	  requested	  by	  the	   local	  clinical	  commissioning	  group	  at	   that	  time	  (ranibizumab	  0.5mg	   in	  0.05mls,	  or	  Aflibercept	  2.0mg	   in	  0.05mls)	  and	  received	  monthly	  initiation	  doses	  under	  a	  standard	  aseptic	  technique	  via	  the	  pars	   plana.	   BCVA,	   CRT	   and	  RS	   assessments	  were	   performed	   following	   the	  subsequent	  three	  initiation	  doses	  making	  a	  total	  of	  4	  sessions	  per	  individual.	  At	  the	  same	  time	  as	  RS	  was	  measured,	  fixation	  stability,	  the	  ability	  of	  the	  eye	  to	  look	  at	  the	  target	  when	  the	  participant	  has	  been	  instructed	  to	  do	  so,	  was	  measured	  as	  an	  exploratory	  outcome.	  	  
5.3.2	  Best	  Corrected	  Visual	  Acuity	  assessment	  technique	  	  Participants	   had	   BCVA	   measured	   wearing	   their	   most	   up	   to	   date	   pair	   of	  distance	  glasses	  using	  an	  ETDRS	  chart	  (Pelli-­‐Robson,	  Precision-­‐Vision)	  at	  4	  metres.	  Each	  eye	  was	  assessed	  separately.	  If	  participants	  were	  able	  to	  read	  at	   least	  4	   letters	  on	  the	  top	   line	  at	  4	  metres	  then	  they	  were	  encouraged	  to	  read	  on	  until	   they	  were	  unable	   to	   read	  3	  or	  more	   letters	  on	  a	   subsequent	  line.	   A	   score	   of	   30	   was	   then	   added	   to	   the	   total	   number	   of	   letters	   read	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correctly	  (to	  compensate	   for	  the	  4	  metre	  testing	  distance)	  to	  give	  the	  total	  letter	  score	  used	  for	  the	  study.	  If	  participants	  were	  unable	  to	  read	  4	  letters	  or	  more	  on	  the	  top	  line	  of	  the	  chart	  at	  4	  metres,	  the	  chart	  was	  moved	  to	  1	  meter	  and	  the	  total	  letter	  score	  was	  then	  equal	  to	  the	  total	  number	  of	  letters	  correctly	   read	   with	   no	   score	   being	   required	   to	   be	   added	   to	   this	   number	  (Ferris	  et	  al,	  1982).	  	  
5.3.3	  Retinal	  Sensitivity	  assessment	  by	  Microperimetry	  	  Microperimetry	   was	   performed	   with	   the	   MP-­‐1	   micro-­‐perimeter	   (Nidek	  Advanced	   Vision	   Information	   System	   [NAVIS];	   Nidek	   Technologies,	   Padua,	  Italy)	   and	  was	   sequenced	   after	   BCVA	   assessment	   and	   before	   any	   other	   in	  order	   not	   to	   affect	   the	  measured	   retinal	   sensitivity.	   Participants	   had	   their	  pupils	   dilated,	   wore	   a	   patch	   on	   their	   fellow	   eye	   and	   undertook	   the	  assessment	  in	  a	  darkened	  environment.	  The	  fixation	  mark	  presented	  was	  in	  the	  form	  of	  a	  cross	  2o	  in	  diameter,	  which	  if	  necessary	  could	  be	  increased	  in	  size.	  	  The	  light	  stimulus	  was	  presented	  in	  a	  sequential	  random	  grid	  pattern	  and	  consisted	  of	  76	  test	  points.	  The	  stimulus	  intensity	  ranged	  from	  0-­‐20	  dB	  (0	  dB	  refers	   to	   the	   strongest	   signal	   intensity	  of	  127	  cd/m2)	   in	  1-­‐dB	  steps.	  The	   MP-­‐1	   proprietary	   software	   ‘follow-­‐up	   function’	   was	   used	   for	   every	  follow-­‐up	   visit	   ensuring	   the	   same	   areas	   of	   the	  macula	   were	   examined	   on	  successive	  occasions.	  	  
5.3.4	   Central	   Retinal	   thickness	   assessment	   with	   Optical	   coherence	  
tomography	  	  Following	   microperimetry	   assessment	   the	   1mm	   central	   subfield	   retinal	  thickness	  	  (micrometres)	  was	  measured	  using	  a	  spectral	  domain	  OCT	  with	  a	  standard	  macular	  cube	  assessment	  (Carl	  Zeiss	  Meditec).	  	  	  	  	  
	   109	  
5.3.5	  Identification	  of	  the	  Area	  of	  Interest	  	  Signs	   of	   the	   CNV	   and	   its	   sequelae	   (intraretinal	   fluid,	   subretinal	   fluid,	  pigment	   epithelial	   detachment)	   were	   identified	   anatomically	   both	   on	   the	  OCT	  and	  on	  a	  10	  minute	  frame	  of	  the	  FFA.	  An	  area,	  encompassing	  any	  of	  the	  activity	   seen	  with	   either	  OCT	  or	   FFA,	  was	   subsequently	  manually	  mapped	  onto	  the	  baseline	  MP	  grid	  pattern	  to	  identify	  which	  of	  the	  76	  points	  sampled	  were	  affected.	  This	  ‘lesion	  plus	  sequelae’	  area	  denoted	  the	  ‘area	  of	  interest’	  and	  was	  kept	  consistent	  throughout	  the	  subsequent	  data	  analyses.	  	  	  
5.3.6	  Fixation	  stability	  assessment	  	  As	  a	  part	  of	   the	   retinal	   sensitivity	  program,	   the	  MP	  automatically	  assesses	  eye	  fixation	  (that	  is	  if	  the	  eye	  is	  actually	  looking	  at	  the	  fixation	  target	  when	  the	  participant	  has	  been	  instructed	  to)	  about	  25	  times	  per	  second.	  The	  MP-­‐1	  then	   calculates	   the	  number	  of	   fixation	  assessments	   that	   are	  made	   that	   fall	  within	   2	   degrees	   or	   4	   degrees	   of	   the	   intended	   fixation	   target.	   Fixation	  stability	  is	  then	  defined	  in	  accordance	  with	  a	  study	  by	  Fujii	  and	  associates	  as	  follows:	  	   1. Stable	   fixation:	   More	   than	   75%	   of	   the	   fixation	   points	   inside	   the	   2-­‐degree-­‐diameter	  circle,	  2. Relatively	  unstable	  fixation:	  More	  than	  75%	  fixation	  points	  inside	  the	  4-­‐degree-­‐diameter	  circle	  and	  less	  than	  75%	  inside	  the	  2-­‐degree-­‐diameter	  circle	  and,	  3. Unstable	  fixation:	   	  Less	  than	  75%	  inside	  the	  4-­‐degree-­‐	  diameter	  circle.	  (Fujii,	  DeJuan,	  Humayun,	  Sunness,	  Chang	  T	  &	  Rossi	  2003).	  	  
5.3.7	  Statistical	  analysis	  	  The	  number	  of	  points	  in	  the	  area	  of	  interest	  was	  identified.	  Within	  this	  area	  the	   number	   and	   percentage	   of	   points	   that	   increased	   retinal	   sensitivity	   by	  2dB	  and	  4dB	  were	  calculated.	  Given	  that	  the	  co-­‐efficient	  of	  repeatability	  for	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the	   MP-­‐1	   has	   been	   described	   as	   1.45	   in	   Squirrel	   et	   al’s	   study	   and	   4.12-­‐	  4.37dB	  in	  Wu	  et	  al’s	  study,	  both	  a	  2dB	  change	  and	  a	  4dB	  change	  in	  RS	  were	  was	  chosen	  to	  be	  analysed	  at	  each	  location	  in	  the	  Grid	  (Squirrel	  et	  al,	  2010;	  Wu,	  Ayton,	  Guymer	  &	  Lu,	  2013).	  	  	  Pearson	  correlation	  coefficients	  were	  calculated	  between	  the	  treated	  eye	  VA	  or	  CRT	  and	  the	  number	  of	  points	  gaining	  2	  or	  4dBs.	  A	  two-­‐tailed	  probability	  was	  calculated	  and	  p	  <=	  0.05	  was	  taken	  as	  statistical	  significance.	  	  Data	   from	   participants	   that	  withdrew	   consent	  were	   not	   analysed.	  Missing	  data	   was	   handled	   by	   excluding	   that	   session	   from	   the	   analysis	   and	   the	  number	   of	   participants	   in	   a	   particular	   analysis	   was	   displayed.	   Fixation	  stability	   data	   is	   an	   exploratory	   outcome	   and	   so	   it	   is	   not	   appropriate	   to	  perform	  any	  statistical	  analyses.	  	  
5.4	  Results	  	  Sixteen	   participants	   were	   recruited	   into	   the	   study,	   of	   which	   6	   withdrew	  consent	  during	  the	  study.	  Of	  the	  remaining	  10	  participants	  all	  attended	  for	  VA	  and	  CRT	  assessments.	  Participant	  7	  had	  BCVA	  measured	  by	  the	  Snellen	  technique	  rather	  than	  ETDRS	  on	  the	  third	  visit	  so	  these	  data	  were	  excluded.	  Seven	   participants	   had	   a	   baseline	   MP	   assessment	   and	   only	   8	   had	   one	   or	  more	   further	  MP	   assessments.	   Of	   these	   follow	  up	   assessments	   only	   6	   had	  the	   first,	  8	   the	  second	  and	  one	   the	   final	   follow	  up	  assessments.	  Because	  of	  these	  low	  numbers	  data	  has	  only	  been	  analysed	  from	  the	  8	  participants	  with	  two	   of	   more	   MP	   assessments	   during	   the	   period	   of	   baseline	   (visit	   1)	   to	  second	   follow	   up	   (visit	   3)	   and	   missing	   data	   within	   these	   session	   was	  handled	   as	   described	   in	   the	   statisical	   analysis	   section	   of	   the	   methods.	  Reasons	  for	  this	  low	  MP	  rate	  included	  participants	  declining	  the	  assessment,	  technical	  failure	  and	  absence	  of	  staff.	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Mean	   participant	   age	   was	   76	   years	   (67-­‐87)	   with	   equal	   male:female	  distribution.	  There	  were	  6	   right	  eyes	  and	  2	   left	   eyes	   studied.	  The	  baseline	  charaterisitics	  are	  outlined	  below	  in	  table	  14.	  	   Participant	  number	  
Baseline	  BCVA	   for	  the	  Treated	  Eye	  (letters)	  
Baseline	  BCVA	   for	  the	  Untreated	  	  Eye	  (letters)	  
Baseline	  CRT	  for	  the	  Treated	  Eye	  (µm)	  
Baseline	  CRT	   for	   the	  Untreated	  	  Eye	  (µm)	  
Number	  of	  points	  in	   the	  area	   of	  interest	  (treated	  eye	  only).	  1	   75	   85	   309	   261	   76	  2	   62	   75	   269	   235	   51	  3	   79	   71	   292	   288	   55	  5	   40	   79	   314	   288	   29	  6	   55	   69	   272	   266	   50	  7	   69	   94	   335	   315	   57	  8	   70	   68	   260	   237	   (26	   at	  visit	  2)	  10	   28	   72	   738	   317	   29	  	  
Table	  14.	  The	  baseline	  (visit	  1)	  characteristics	  of	  the	  8	  participants	  (BCVA=	  best	   corrected	   visual	   acuity	   in	  ETDRS	   letters,	   CRT=	   central	   1mm2	   subfield	  retinal	  thickness	  in	  micrometers,	  and	  number	  points	  in	  the	  area	  of	  interest.	  Note	   that	   participant	   8	   had	   no	   baseline	  microperimetry	   performed	   so	   the	  area	  of	  interest	  was	  mapped	  onto	  the	  retinal	  sensitivity	  map	  at	  visit	  2.	  	  	  
5.4.1	  Best	  Corrected	  Visual	  Acuity	  	  The	  BCVA	  values	  for	  individual	  participants	  during	  the	  study	  (Table	  15)	  and	  the	  means	  of	  the	  cohort	  (Table	  16	  and	  Figure	  11)	  are	  presented	  below.	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Particpant	  number	   BCVA	  visit	  2	  for	   the	  Treated	  Eye	  (letters)	  
BCVA	   visit	   2	  for	   the	  Untreated	  Eye	  (letters)	  
BCVA	   visit	   3	  for	   the	  Treated	  Eye	  (letters)	  
BCVA	   visit	   3	  for	   the	  Untreated	  Eye	  (letters)	  
1	   64	   79	   75	   85	  2	   80	   79	   81	   79	  3	   80	   74	   80	   75	  5	   51	   90	   63	   80	  6	   48	   67	   74	   69	  7	   82	   89	   	   	  8	   77	   75	   78	   73	  10	   48	   80	   47	   83	  	  
Table	  15.	  	  Treated	  and	  untreated	  eye	  visual	  acuity	  (ETDRS	  letters)	  for	  the	  8	  participants	  over	   the	  2	   follow	  up	  sessions.	  A	  blank	  cell	   represents	  missing	  data.	  	   Mean	  (SD)	  BCVA	  Baseline	  for	   the	  	  Treated	  	  Eye	  (letters	  n=8)	  
Mean	   (SD)	  BCVA	  Baseline	  for	   the	  	  Untreated	  Eye	  (letters	  n=8)	  
Mean	  (SD)	  BCVA	  visit	   2	   for	  the	  	  Treated	  Eye	  (letters	  n=8)	  
Mean	  (SD)	  BCVA	  visit	   2	   for	  the	  	  Untreated	  Eye	  (letters	  n=7)	  
Mean	  (SD)	  BCVA	  visit	   3	   for	  the	  	  Treated	  Eye	  (letters,	  n=7)	  
Mean	  (SD)	  	  BCVA	   visit	  3	  	  for	  the	  Untreated	  Eye	  (letters	  n=8)	  
60	  (18.3)	   77	  	  (8.3)	   66	  (15.7)	   79	  (7.6)	   71	  (12.2)	   78	  (5.7)	  	  
Table	  16.	  	  Treated	  and	  untreated	  mean	  and	  standard	  deviation	  (SD)	  of	  best	  corrected	   visual	   acuity	   (ETDRS	   letters)	   for	   the	   8	   participants	   over	   the	   3	  sessions,	   visit	   1	   (baseline)	   to	   visit	   3.	  The	  number	  of	   sessions	   analysed	   (n)	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was	  8	   in	   all	   cases	   except	   for	   visit	   3	  when	   the	   figure	  was	  7	  due	   to	  missing	  data.	  	  
	  	  	  
Figure	   11.	   Mean	   (standard	   deviation)	   visual	   acuity	   (y-­‐axis,	   ETDRS	   letter	  score)	   at	   visit	   1	   (baseline)	   to	   visit	   3	   (x-­‐axis).	  Data	   from	   the	   treated	   eye	   is	  displayed	  in	  blue	  and	  data	  from	  the	  untreated	  eye	  in	  red.	  	  	  
5.4.2	  Central	  retinal	  thickness	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Participant	  number	   CRT	  visit	  2	  for	  the	  Treated	   	   Eye	  (μm)	  
CRT	  visit	  2	  for	  the	  Untreated	  Eye	  (μm)	  
CRT	  	  visit	   3	   for	  the	   Treated	  Eye	  (μm)	  
CRT	  visit	   3	   for	   the	  Untreated	  Eye	  (μm)	  
1	   357	   261	   305	   249	  2	   186	   235	   203	   234	  3	   289	   291	   278	   291	  5	   294	   285	   270	   281	  6	   260	   265	   259	   261	  7	   306	   316	   333	   318	  8	   234	   238	   233	   235	  10	   375	   318	   345	   313	  	  
Table	   17.	   	   Treated	   and	   untreated	   CRT	   (central	   1mm2	   subfield	   retinal	  thickness,	  micrometres)	  for	  the	  8	  participants	  over	  the	  2	  follow	  up	  sessions.	  	  	   Mean	  (SD)	  CRT	  Baseline	  for	  the	  Treated	  Eye	  (μm)	  
Mean	  (SD)	  CRT	  Baseline	  	  for	   the	  Untreated	  Eye	  (μm)	  
Mean	   (SD)	  CRT	  Visit	   2	   for	  the	  	  Treated	  Eye	  (μm)	  
Mean	   (SD)	  CRT	  Visit	   2	   for	  the	  	  Untreated	  Eye	  (μm)	  
Mean	   (SD)	  CRT	  Visit	   3	   for	  the	  	  Treated	  Eye	  (μm)	  
Mean	  (SD)	  CRT	  Visit	  3	  for	  the	  	  Untreated	  Eye	  (μm)	  349	  (159.4)	   276	  (31.7)	   288	  (61.9)	   264	  (50.9)	   278	  (48.3)	   273	  (33.1)	  	  
Table	   18.	   	   Treated	   and	  untreated	  mean	   and	   standard	  deviation	   (SD)	   CRT	  (central	   1mm2	   subfield	   retinal	   thickness,	   micrometres)	   for	   the	   8	  participants	  over	  the	  3	  sessions,	  visit	  1	  (baseline)	  to	  visit	  3.	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Figure	   12.	   Mean	   (standard	   deviation)	   1mm2	   central	   subfield	   retinal	  thickness	  (y-­‐axis,	  micrometres)	  at	  visit	  1	  (baseline)	  to	  visit	  3	  (x-­‐axis).	  Data	  from	  the	  treated	  eye	  is	  displayed	  in	  blue	  and	  data	  from	  the	  untreated	  eye	  in	  red.	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   Participant	  number	   Number	  of	  points	  in	   area	  of	  interest	  
Percentage	  (number)	  of	   points	  that	  increased	  by	   2dB	   or	  more	   in	  area	   of	  interest	   at	  visit	   2	  	  compared	  with	  baseline	  (n=6)	  
Percentage	  (number)	  of	   points	  that	  increased	  by	   4dB	   or	  more	   in	  area	   of	  interest	   at	  visit	   2	  	  compared	  with	  baseline	  (n=6)	  
Percentage	  (numbers)	  of	   points	  that	  increased	  by	   2dB	   or	  more	   in	   in	  area	   of	  interest	   at	  visit	   3	  	  compared	  with	  baseline	  (n=7)	  
Percentage	  	  (number)	  of	   points	  that	  increased	  by	   4dB	   or	  more	   in	  area	   of	  interest	   at	  visit	   3	  	  compared	  with	  baseline	  (n=	  7)	  1	   76	   14.5	  (11)	   11.8	  (9)	   44.7	  (34)	   22.4	  (17)	  2	   51	   	   	   29.4	  (15)	   19.6	  (10)	  3	   55	   63.0	  (34)	   24.1	  (13)	   78.7	  (37)	   42.5	  (20)	  5	   29	   27.6	  (8)	   13.8	  (4)	   58.6	  (17)	   34.5	  (10)	  6	   50	   44.0	  (22)	   20.0	  (10)	   62.0	  (31)	   46.0	  (23)	  7	   57	   33.3	  (19)	   28.1	  (16)	   77.2	  (44)	   54.4	  (31)	  8	   26	   	   	   73.1	  (19)	   38.5	  (10)	  10	   29	   13.8	  (4)	   13.8	  (4)	   	   	  	  
Table	   19.	   Number	   of	   microperimetry	   points	   in	   the	   area	   of	   interest.	  Percentage	  and	  number	  of	  points	  that	  increased	  in	  retinal	  sensitivity	  by	  2dB	  or	   more	   and	   4dB	   or	   more	   for	   the	   8	   participants	   over	   the	   2	   follow	   up	  sessions.	  A	  blank	   cell	   represents	  missing	  data.	  n	  =	   the	  number	  of	   sessions	  analysed.	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   Mean	  percentage	   of	  points	   that	  increased	   by	  2dB	   or	   more	   in	  acitve	   area	   at	  visit	   2	  	  compared	   with	  baseline	  (n=6)	  
Mean	   (SD)	  percentage	   of	  points	   that	  increased	  by	  4dB	  or	  more	  in	  acitve	  area	   at	   visit	   2	  	  compared	   with	  baseline	  (n=6)	  
Mean	   (SD)	  percentage	   of	  points	   that	  increased	  by	  2dB	  or	  more	  in	  acitve	  area	   at	   visit	   3	  	  compared	   with	  baseline	  (n=7)	  
Mean	   (SD)	  percentage	   	   of	  points	   that	  increased	   by	  4dB	   or	  more	   in	  acitve	   area	   at	  visit	   3	  	  compared	   with	  baseline	  (n=	  7)	  33	  (13.7)	   18	  (6.3)	   62	  (15.6)	   39	  (16.0)	  	  
Table	  20.	  Mean	  percentage	  and	  standard	  deviation	  of	  points	  that	  increased	  retinal	   sensitivity	  by	  2dB	  or	  more	   and	  4dB	  or	  more	   for	   the	  8	  participants	  over	  the	  2	  follow	  up	  sessions.	  A	  blank	  cell	  represents	  missing	  data.	  n	  =	  the	  number	  of	  sessions	  analysed.	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participants	   and	   change	   between	   baseline	   and	   first	   follow	   up	   may	   be	  affected	  by	  a	  significant	  learning	  effect	  (Wu	  et	  al,	  2013).	  	  	  
5.4.4	  Fixation	  stability	  
	  At	   baseline,	   6	   of	   7	   participants	   had	   relatively	   unstable	   fixation	   and	   1	   had	  stable	  fixation.	  Compared	  with	  baseline	  (visit	  2	  for	  subject	  8	  as	  baseline	  was	  missing),	   2	   subjects	   improved	   stability,	   5	  maintained	   stability	   and	  one	  got	  worse.	   In	   the	   case	   that	   fixation	   got	   worse	   data	   from	   visit	   3	   was	   missing	  (Table	  21).	  	  	   Participant	  number	   Fixation	   at	  baseline	   Fixation	   at	  visit	  2	   Fixation	   at	  visit	  3	   Change	   in	  fixation	  stability	  1	   R	   R	   S	   Better	  2	   R	   	   R	   Same	  3	   R	   S	   R	   Same	  5	   S	   R	   S	   Same	  6	   R	   R	   R	   Same	  7	   R	   R	   S	   Better	  8	   	   S	   S	   Same	  10	   R	   U	   	   Worse	  	  
Table	  21.	  fixation	  stability	  at	  baseline	  (visit	  1),	  visit	  2	  and	  visit	  3.	  S	  =	  stable	  fixation,	   R	   =	   relatively	   unstable	   fixation,	   U	   =	   unstable	   fixation	   (Fujii	   et	   al,	  2003).	  	  
5.4.5	  Correlation	  between	  VA,	  CRT	  and	  retinal	  sensitivity	  	  Neither	   VA	   or	   CRT	   correlated	   even	   at	   a	  weak	   trend	   level	  with	   percentage	  retinal	  sensitivity	  change	  of	  2dB	  or	  more	  or	  with	  4dB	  or	  more	  (Table	  22).	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VA	   vs	   CRT	  (N=6)	  	  
VA	  vs	  2dB	  	  (N=6)	   VA	  vs	  4dB	  (N=6)	   CRT	  vs	  2dB	  (N=6)	   CRT	  vs	  4dB	  (N=6)	  
-­‐0.573	  (P=0.234)	   -­‐0.323	  (p=0.532)	   0.030	  (p=0.955)	   0.607	  (p=0.201)	   0.582	  (p<0.226)	  
	  
Table	  22.	  Correlations	  between	  visual	  acuity	  of	  the	  treated	  eye	  (VA),	  central	  1mm2	   subfield	   retinal	   thickness	   of	   the	   treated	   eye	   (CRT)	   and	   percentage	  increase	   in	   retinal	   sensitivity	   of	   2dB	   or	  more	   or	   4dB	   or	  more	   (N=	   sample	  size).	  	  
5.6	  Discussion	  	  The	  mean	  increase	  in	  VA	  in	  this	  cohort	  of	  participants	  was	  11	  ETDRS	  letters	  following	  2	  treatments	  with	  anti-­‐VEGF	  agents.	  This	  is	  much	  larger	  than	  the	  mean	  gain	  approximately	  5.5	  to	  7.0	  ETDRS	  letters	  in	  the	  corresponding	  time	  points	  of	  much	  larger	  published	  clinical	  trial	  data	  sets	  of	  (Brown	  et	  al,	  2011;	  Chakravarthy	   et	   al,	   2013;	   Schmidt-­‐Erfurth	   et	   al	   2014).	   The	   mean	   CRT	  reduction	   was	   61	   micrometers,	   which	   is	   smaller	   than	   expected	   from	   the	  same	   clinical	   trials	   (range	   approximately	   -­‐120	   to	   -­‐180	   μm).	   At	   first	  assessment	  it	  may	  appear	  that	  the	  study	  cohort	  of	  patients	  is	  therefore	  not	  representative	  of	  a	  typical	  population	  but	  caution	  has	  to	  be	  taken	  with	  this	  view,	  as	  the	  sample	  size	  is	  small.	  	  	  
5.6.1	  The	  use	  of	  lesion-­‐guided	  microperimetry	  retinal	  sensitivity	  as	  an	  
outcome	  measure	  	  The	  mean	   retinal	   sensitivity	   (RS)	   increased	   following	   the	   first	   and	   second	  treatments.	  This	   is	   in	   line	  with	  other	  published	   studies,	   although	  different	  methods	   of	   assessing	   RS	   have	   been	   used	   and	   so	   caution	   has	   to	   be	   taken	  when	  making	  judgment.	  Munk	  et	  al	  reported	  an	  increase	  in	  RS	  when	  mean	  central	  retinal	  sensitivity	  was	  studied	  in	  64	  treatment	  naïve	  patients	  treated	  with	  monthly	  ranibizumab	  over	  a	  12	  month	  period	  (Munk	  et	  al,	  2013).	  On	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that	  occasion,	   the	  microperimetry	  map	  covered	  33	  points	  over	   the	   central	  12	  degrees	  of	   the	  macula	  and	  showed	   the	   largest	   increase	   in	  RS	  4	  months	  post	  treatment	  and	  thereafter	  the	  RS	  plateaued.	  Correlation	  between	  the	  RS	  and	  VA	  was	  not	  reported	  upon	  but	  a	  decrease	  in	  absolute	  scotoma	  size	  over	  the	  course	  of	  the	  study	  was	  only	  significant	  at	  a	  trend	  level	  (p	  =	  0.053).	  	  Paravanno	  et	  al	  performed	  microperimetry	  on	  5	  occasions	  over	  24	  months	  during	   the	   study	   of	   18	  patients	   that	  were	   treated	  with	   ranibizumab.	   They	  were	   given	   an	   initial	   3	   monthly	   treatments	   then	   retreated	   with	   an	   ‘as	  required’	   dosing	   regimen.	   The	   RS	   map	   consisted	   of	   37	   points	   over	   the	  central	  12	  degrees.	  On	  this	  occasion	  the	  VA	  improved	  up	  to	  24	  weeks	  then	  slowly	   declined	   whereas	   the	   mean	   RS	   continued	   to	   improve	   out	   to	   24	  months.	  In	  the	  second	  year	  the	  greatest	  disconnect	  between	  VA	  and	  RS	  was	  seen;	  the	  participants	  received	  a	  mean	  of	  6.2	  treatments	  achieving	  stable	  RS	  despite	  their	  VA	  slowly	  declining	  (Paravanno	  et	  al,	  2010).	  	  Cho	  et	  al	  used	  an	  OTI	  (Ophthalmic	  Technologies	  Inc.)	  microperimetry	  device	  to	  study	  28	  points	  in	  the	  central	  12	  degrees	  of	  the	  macula,	   in	  42	  eyes	  with	  newly	   presenting	   untreated	   nvAMD.	   Mean	   RS	   increased	   and	   the	   absolute	  scotoma	  decreased	  over	   the	  12-­‐month	   study	  period	  but	  no	  VA	   correlation	  data	  was	  reported.	  	  The	  three	  aforementioned	  studies	  all	  use	  the	  mean	  change	   in	  RS	  of	  a	   large	  retinal	  map	  with	  a	  predetermined	  size.	  This	  technique	  has	  the	  advantage	  of	  capturing	  the	  full	  extent	  of	  a	  large	  area	  affected	  by	  nvAMD	  but	  also	  has	  the	  disadvantage	   of	   diluting	   the	   effect	   of	   any	   change	   with	   the	   surrounding	  healthy	   retinal	   tissue	   that	   would	   not	   be	   expected	   to	   change.	   This	   effect	  would	   be	   particularly	   strong	   in	   lesions	   of	   a	   smaller	   size.	   Baseler	   et	   al	  evaluated	  retinal	  sensitivity	  across	  40	  degrees	  but	  only	  analysed	  the	  central	  10	  degrees	  as	  this	  was	  deemed	  to	  be	  the	  area	  where	  damage	  was	  most	  likely	  to	   be	   (Baseler	   et	   al,	   2011).	   In	   their	   study,	   in	   which	   a	   single	   case	   was	  reported	  upon,	  the	  scotoma	  decreased	  in	  size	  and	  the	  overall	  RS	  improved.	  Taking	   this	  concept	  of	   targeting	   the	  most	  appropriate	  area	  of	   the	  retina	   to	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be	   studied	   a	   step	   further,	   the	   technique	   used	   in	   this	   chapter	   of	   the	   thesis	  studied	  the	  affected	  area	  of	  the	  macula	  alone.	  The	  location	  of	  the	  CNV	  and	  its	  sequelae	  was	   determined	   by	   late	   frame	   FFA	   and	   OCT	  morphology	   and	   so	  defined	  an	  ‘area	  of	  interest’.	  Subsequently	  only	  RS	  change	  in	  this	  region	  was	  analysed.	  	  	  Squirrel	   et	   al	   (2010)	   performed	   a	   study	   similar	   in	   duration	   to	   the	   one	  reported	   in	   this	   thesis	  whereby	   10	   eyes	  were	   analysed	   by	  MP	   out	   to	   one	  month	  following	  3	  ranibizumab	  injections.	  They	  reported	  a	  mean	  increase	  in	  RS	  of	  2.9	  dB	  (SD	  +/-­‐1.5)	  over	   the	  45	  points	  measured	  within	  a	  central	  12-­‐degree	   map.	   Using	   repeatability	   measures	   it	   was	   determined	   that	   a	   2dB	  change	  was	  likely	  to	  be	  significant	  change.	  Subsequently	  they	  reported	  that	  9	  of	  the	  10	  individuals	  had	  a	  change	  of	  at	  least	  2	  dB	  in	  12	  or	  more	  of	  the	  45	  points	  studied	  (Squirrell	  et	  al,	  2010).	  This	   is	  a	   rather	  confusing	  statistic	   to	  report	  and	  even	  interpret,	  but	  the	  concept	  of	  how	  many	  points	  increase	  by	  2dB	  is	  an	  interesting	  one.	  However,	  the	  down	  side	  of	  reporting	  on	  how	  many	  points	  change	  by	  a	  certain	  figure	  is	  that	  the	  size	  of	  the	  lesion	  and	  therefore	  number	  of	  points	  within	  the	   lesion	  (26-­‐76	   in	  this	  case)	  will	  differ	  between	  individuals.	   The	   study	   in	   this	   chapter	   therefore	   used	   the	   percentage	   of	  points	  within	   the	  area	  of	   interest	   that	   changed	  by	  2dB	  and	   so	  attempts	   to	  correct	  for	  the	  size	  of	  the	  lesion.	  In	  fact	  the	  mean	  percentage	  of	  points	  that	  increased	  by	  2dB	  or	  more	   in	  active	  area	  was	  62%	  after	  2	   treatments.	  This	  seems	  an	  intuitively	  better	  way	  to	  represent	  the	  treatment	  effect.	  	  Neither	   VA	   change	   nor	   CRT	   change	   came	   close	   to	   correlating	   with	   the	  increase	  in	  percentage	  of	  points	  achieving	  2	  or	  4	  dB	  improvement.	  	  Because	  of	  the	  low	  sample	  size	  it	  is	  therefore	  hard	  to	  interpret	  whether	  this	  result	  is	  due	   the	   study	   being	   underpowered	   or	   indeed	  whether	   there	   is	   in	   fact	   no	  correlation.	  Based	  upon	  these	  results	  it	  is	  again	  hard	  to	  validate	  RS	  used	  in	  this	   way	   as	   a	   useful	   tool	   to	   measure	   visual	   function	   for	   an	   individual	  response	  to	  treatment	  on	  a	  visit-­‐to-­‐visit	  basis.	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Much	   as	   qualitative	   aspects	   of	   OCT	   morphology	   such	   as	   the	   presence	   of	  retinal	   fluid	   represent	  disease	   activity	   and	   so	   are	  used	   to	   guide	   treatment	  (Martin	  et	  al,	  2011;	  Chakravarthy	  et	  al,	  2012),	  future	  studies	  could	  be	  aimed	  to	   see	   if	   retreatment	   criteria	   could	   be	   based	   upon	   the	   signs	   of	   disease	  activity	  as	  represented	  by	  MP	  determined	  retinal	  function.	  	  The	  weaknesses	  of	  this	  study	  have	  to	  be	  acknowledged,	  in	  particular	  the	  low	  numbers	   and	   short	   duration	   of	   follow	   up,	   when	   interpreting	   the	   data.	  Furthermore	   it	   has	   to	   be	   acknowledged	   that	   the	   participants	   may	   have	  undergone	   a	   significant	   learning	   effect	   between	   the	   first	   and	   second	  evaluations,	   as	   was	   noted	   by	   the	   work	   of	   Wu	   and	   colleagues	   (Wu	   et	   al,	  2013).	   This	   potential	   bias	   was	   taken	   accounted	   for	   by	   not	   displaying	   the	  change	  between	   the	  baseline	  and	   first	   follow	  up	  examination	   in	   figure	  5.3.	  	  Pre	   planning	   analyses	   on	   the	   correlation	   of	   VA,	   CRT	   and	   absolute	  RS	  may	  have	  provided	  useful	  information	  in	  being	  able	  to	  validate	  RS	  as	  a	  useful	  tool	  help	   guide	   re	   treatment	   decisions	   and	   should	   be	   considered	   for	   future	  studies.	  	  Nonetheless	   this	   study	   demonstrated	   that	   there	   was	   improvement	   in	   RS	  within	  a	  high	  proportion	  of	  significant	  improvement	  points	  within	  the	  area	  of	   interest.	   These	   data	   would	   act	   as	   good	   pilot	   data	   for	   a	   larger	   study	   to	  confirm	   that	   this	   technique	   is	   a	   sensitive	   way	   of	   detecting	   RS	   change	  following	   therapeutic	   intervention	   for	   nvAMD.	   Demonstrating	   that	   RS	   can	  continue	   to	   improve	   or	   decline	   when	   VA	   and	   CRT	   plateau,	   particularly	   if	  individuals	  continue	  to	  notice	  a	  change	  in	  their	  visual	  function,	  adds	  to	  the	  argument	   for	   its	   routine	   evaluation	   in	   clinical	   practice.	   Alexander	   et	   al	  demonstrated	  that	  in	  5	  of	  21	  eyes	  in	  the	  ‘stability	  phase’	  of	  their	  treatment	  as	   determined	   by	   stable	   VA	   and	   CRT	   when	   ranibizumab	   was	   not	  administered,	   RS	   decreased	   (Alexander,	   Mushtaq,	   Osmond	   &	   Amoaku,	  2012).	   Retinal	   sensitivity	   as	   a	   functional	   outcome	   of	   MP	   could	   act	  synergistically	   along	   with	   VA	   and	   OCT	   to	   help	   determine	   outcomes	   or	  treatment	  response.	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The	  main	  disadvantage	  of	  using	  MP	  as	  a	  routine	  assessment	  tool	  is	  that	  the	  time	   required	   to	   perform	   the	   examination	   can	   often	   be	   8-­‐12	  minutes	   per	  eye.	  So	  to	  commit	  significant	  resources	  to	  do	  this	   its	  added	  value	  over	  and	  above	  OCT,	  which	  has	  an	  acquisition	  time	  of	  only	  around	  1	  minute	  per	  eye,	  would	  have	  to	  be	  certain.	  In	  addition,	  technical	  reliability	  and	  staff	  time	  need	  to	   be	   secured	   as	   both	   of	   these	   factors	   hampered	   data	   acquisition	   in	   this	  study.	  	  
5.6.2	  The	  evaluation	  of	  fixation	  stability	  as	  on	  outcome	  measure	  
	  Of	   the	   eight	   participants,	   two	   improved	   stability,	   five	  maintained	   stability	  and	   one	   got	   worse.	   The	   general	   trend	   is	   toward	   maintenance	   or	  improvement	  although	  it	  has	  to	  be	  noted	  that	  2	  already	  had	  stable	  fixation	  at	  their	   initial	   assessment	   and	   so	   were	   subject	   to	   the	   ceiling	   effect.	   These	  observations	  are	  broadly	  in	  line	  with	  other	  studies	  in	  the	  literature	  that	  also	  used	  the	  Fujii	  method	  of	  assessing	  fixation	  on	  the	  MPI-­‐1.	  Munk	  et	  al	  reports	  that	  63%	  of	  eyes	  had	  relatively	  stable	  fixation,	  27%	  unstable	  and	  10%	  stable	  fixation	   before	   anti-­‐VEGF	   treatment	   changing	   to	   72%,	   13%	   and	   15%	  respectively	  at	  12	  months	  (Munk	  et	  al,	  2013).	  The	  cross	  sectional	  study	  of	  102	   patients	   by	   Pearce	   et	   al,	   76	   of	   whom	   had	   ranibizumab	   treatment,	  demonstrated	  similar	  results	  in	  the	  treated	  group	  (Pearce	  et	  al,	  2011).	  	  	  Although	   the	   Fujii	   method	   of	   determining	   fixation	   stability	   is	   often	   used	  (Parravano	  et	  al,	  2010;	  Pearce	  et	  al,	  2011;	  Munk	  et	  al	  2013)	  it	  is	  a	  relatively	  crude	   measure	   in	   that	   it	   is	   only	   a	   three-­‐point	   scale	   (Fujii	   et	   al,	   2003).	  Crossland	   reports	   a	   potentially	   more	   accurate	   way	   of	   assessing	   fixation	  stability	  by	  capturing	  fixation	  using	  a	  bivariate	  contour	  ellipse	  area	  (BCEA).	  This	  gives	  a	  numerical	  value	  that	  has	  been	  showed	  to	  better	  correlate	  with	  reading	  speed	  than	  the	  Fujji	  method	  (Crossland,	  Dunbar	  &	  Rubin,	  2009).	  It	  was	  not	  possible	  to	  retrospectively	  capture	  raw	  numerical	  data	  necessary	  to	  calculate	   the	  BCEA	  or	  perform	  other	  analyses,	  but	  consideration	  should	  be	  given	  to	  using	  this	  method	  for	  future	  studies.	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Just	   as	   discussion	   about	   the	   qualitative	   aspects	   of	   OCT	   and	   MP	   have	  suggested	  their	  usefulness	  in	  retreatment	  decisions,	  the	  same	  argument	  can	  be	   applied	   to	   fixation	   data.	   If	   it	   was	   clear	   that	   disease	   activity	   was	  threatening	   a	   PRL	   then	   a	   physician	   may	   be	   more	   likely	   to	   administer	  treatment.	  	  
5.6.7	  Conclusion	  	  The	  use	  of	  microperimetry	  to	  assess	  RS	  and	  fixation	  stability	  has	  merits	   in	  potentially	   being	   able	   to	   explain	   disconnect	   between	   visual	   function	   and	  conventional	  methods	  of	  assessing	  disease	  activity	  such	  as	  OCT	  and	  VA.	  Both	  quantitative	   and	   qualitative	   aspects	   need	   further	   study	   to	   evaluate	   if	   the	  principle	  downside	  of	  these	  additional	  measurements,	  that	  is	  the	  time	  taken	  to	  acquire	  the	  data,	  is	  outweighed	  by	  its	  benefits.	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Chapter	   6.	   Functional	  MRI	  Blood	  Oxygen	   Level	  Dependency	   response	  
as	   an	   outcome	  measure	   of	   visual	   function	   following	   the	   treatment	   of	  
neovascular	  Age-­‐related	  Macular	  Degeneration:	  restoration	  of	  primary	  
visual	  cortex	  activity.	  
	  
6.1	  Introduction	  	  By	  performing	  specific	  studies	  the	  previous	  chapters	  have	  discussed	  the	  use	  of	  visual	  acuity	  (VA),	  central	  retinal	   thickness	  (CRT)	  and	  retinal	  sensitivity	  (RS)	  as	  outcome	  measures	  when	  assessing	  the	  affect	  of	  treating	  neovascular	  macular	   degeneration	   (nvMD).	   This	   chapter	   discusses	   the	  merits	   of	   using	  functional	   MRI	   as	   an	   outcome	   measure	   and	   compares	   it	   with	   these	  previously	  discussed	  methods.	  	  
6.2	  Background	  	  Treatment	   paradigms	   for	   neovascular	   Age-­‐related,	   Macular	   Degeneration	  (nvAMD)	   have	   been	   discussed	   in	   detail	   in	   previous	   chapters.	   After	   the	  ‘initiation	   phase’	   of	   treatment	   when	   monthly	   intravitreal	   injections	   are	  given,	  retreatment	  is	  in	  either	  a	  proactive	  or	  reactive	  manner	  (Brown	  et	  al,	  2006;	   Rosenfeld	   et	   al,	   2006;	   Martin	   et	   al,	   2011;	   Charavarthy	   et	   al,	   2012,	  Schmidt-­‐Erfurth	   et	   al,	   2014).	   Most	   patients	   can	   expect	   an	   initial	   gain	   in	  visual	   acuity	   followed	   by	   visual	   stability	   or	   a	   slow	  decline	   in	   the	   ‘stability	  phase’	   (Rofagha	  et	  al,	  2013;	  Tufail	  et	  al,	  2014;	  Airody	  et	  al,	  2014).	  Despite	  the	   routine	   use	   of	   VA	   measurement	   and	   OCT	   features	   these	   outcome	  measures	  do	  not	  give	  a	  complete	  representation	  of	  visual	  function	  or	  indeed	  the	  change	  in	  visual	  function	  in	  response	  to	  treatment.	  	  	  Functional	   activity	   of	   the	   visual	   cortex	   as	  measured	   by	   the	   Blood	   Oxygen	  Level-­‐Dependent	   (BOLD)	   response	   on	   MRI	   has	   the	   potential	   to	   be	   an	  objective	   measurement	   of	   visual	   response	   to	   retinal	   treatment	   and	  complement	  existing	  assessment	  modalities.	  As	  neuronal	  activity	   increases	  in	   the	   brain	   there	   is	   an	   increase	   in	   the	   amount	   of	   oxygenated	   blood	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compared	  to	  deoxygenated	  blood.	  This	  is	  because	  neuronal	  activity	  causes	  a	  release	  of	   the	  neuro-­‐transmitter	   glutamate,	   leading	   to	   the	   release	  of	   nitric	  oxide	   and	   ultimately	   dilation	   of	   blood	   vessels	   (Ogawa,	   Lee,	   Kay	   &	   Tank,	  1990).	  	  	  To	  enable	  the	  BOLD	  response	  to	  be	  a	  potential	  marker	  of	  visual	  function	  in	  those	   treated	   for	   nvAMD	   two	   principle	   assumptions	   need	   to	   be	   met.	   The	  first	  assumption	  is	  that	  there	  is	  the	  absence	  of	  significant	  re-­‐modeling	  of	  the	  visual	  cortex	  in	  those	  with	  AMD	  so	  that	  retinotopic	  (retina	  to	  cortex	  spatial	  mapping)	  relationships	  are	  maintained.	   	  This	  assumption	  would	  mean	  that	  any	   BOLD	   change	   that	   is	   observed	   would	   be	   due	   to	   the	   treatment	  intervention	   and	   not	   natural	   recovery.	   A	   number	   of	   studies	   have	   debated	  this	   point.	   	   Baker	   et	   al	   reported	  on	  preliminary	   fMRI	   investigations	   into	  2	  patients	   with	   severe	   AMD	   and	   suggested	   that	   visual	   processing	   could	   be	  reorganised.	   It	   was	   demonstrated	   that	   peripheral	   retinal	   stimulation	  activated	  the	  area	  of	  the	  visual	  cortex	  only	  normally	  represented	  by	  foveal	  stimulation	  (Baker,	  Peli,	  Knouf	  &	  Kanwisher,	  2005).	  Baker	  et	  al	  went	  on	  to	  qualify	  this	  statement,	  after	  replicating	  the	  study	  in	  3	  further	  individuals,	  by	  suggesting	  that	  this	  re-­‐organisation	  may	  only	  occur	  if	  there	  was	  severe	  loss	  of	   foveal	   function	   (Baker,	   Dilks,	   Peli,	   &	   Kanwisher,	   2008).	   	   To	   add	   to	   this	  argument	   Schumacher	   et	   al	   noted	   that	   this	   apparent	   degree	   of	   cortical	  plasticity	   could	   be	   related	   to	   eccentric	   viewing.	   (Schumacher	   et	   al,	   2008).	  This	   debate	   about	   cortical	   reorganisation	   has	   swung	   the	   other	   way	  more	  recently	  when	  Baseler	  et	   al	  performed	   fMRI	  assessments	  of	   a	  much	   larger	  cohort	  of	  patients.	  All	  had	  established	  bilateral	  macular	  degeneration	  and	  no	  significant	  activity	  in	  the	  foveal	  representation	  was	  observed	  (Baseler	  et	  al,	  2011).	   Studies	   in	   macaque	   monkeys	   with	   macular	   degeneration	   have	  confirmed	   this	   limited	   capacity	   for	   reorganisation	   in	   this	   so	   called	   lesion	  projection	   zone	   (that	   is	   the	   area	   of	   the	   cortex	   that	   represents	   the	   area	   of	  retinal	  defect)	  of	  the	  primary	  visual	  cortex	  (Smirnakis	  et	  al,	  2005;	  Shao	  et	  al,	  2013),	  but	  interestingly	  more	  extensive	  plasticity	  in	  the	  higher	  visual	  cortex	  zone	  V5	  was	  noted	  (Shao	  et	  al,	  2013).	  	  It	  is	  worth	  noting	  that	  this	  absence	  of	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significant	   reorganisation	   occurs	   in	   the	   presence	   of	   both	   monocular	   and	  binocular	   retinal	   lesions,	   a	   point	   particularly	   important	   when	   studying	  nvAMD,	   which	   typically	   has	   a	   unilateral	   onset	   (Murkami,	   Komatsu,	  Kinoshita,	   1997).	   So	   the	   balance	   of	   argument	   is	   now	   strongly	   in	   favour	   of	  concluding	   that	   there	   is	   no	   significant	   cortical	   re-­‐organisation	   in	   long-­‐standing	  retinal	  lesion	  acquired	  in	  adulthood.	  The	  second	  assumption	  that	  needs	  to	  be	  fulfilled	  is	  that	  the	  visual	  cortex	  has	  the	  ability	  to	  recover	  function.	  Boucard	  et	  al	  performed	  an	  MRI	  study	  of	  the	  posterior	   pole	   anatomy	   in	   9	  AMD	  patients,	   average	   age	   of	   72.6	   years,	   and	  demonstrated	   a	   reduced	   grey	  matter	   volume	   compared	  with	   age-­‐matched	  controls	   (Boucard	   et	   al,	   2009).	   A	   similar	   anatomical	   study	   in	   adults	   with	  long	   standing	   retinal	   defects	   also	   showed	   grey	   and	   white	   matter	   volume	  changes	   (Noppeney,	   Friston,	   Ashburner,	   Frackowiak	   &	   Price,	   2005).	  Although	   these	   studies	   seem	   to	  deny	   this	   second	   assumption	   they	  did	  not	  assess	  functional	  aspects	  of	  MRI	  and	  a	  direct	  relationship	  between	  structure	  and	   function	  may	  not	   be	   inevitable.	   To	   support	   the	   case	   that	   function	   can	  recover,	   Baseler	   et	   al	   has	   reported	   on	   a	   single	   case	   that	   showed	   clear	  improvement	   in	   the	   BOLD	   visual	   cortical	   response	   when	   nvAMD	   was	  treated	  with	  an	  anti-­‐VEGF	  agent	  (Baseler,	  et	  al,	  2011).	  	  	  So	  the	  way	  seems	  to	  be	  paved	  to	  allow	  further	  assessment	  of	  the	  use	  of	  the	  BOLD	  response	  in	  measuring	  outcomes	  of	  retinal	  treatment.	  The	  aim	  of	  the	  study	   in	   this	   chapter	   was	   to	   determine	   the	   BOLD	   response	   of	   the	   visual	  cortex	   in	   a	   cohort	   of	   individuals	  with	   nvAMD	  before,	   during	   and	   after	   the	  initiation	  phase	   of	   treatment	  with	   anti-­‐angiogenic	   therapy.	   Furthermore	   it	  aimed	   to	   determine	   how	   the	   BOLD	   response	   compares	  with	   the	   standard	  clinical	  methods	  of	  assessing	  vision	  and	  retinal	  anatomy.	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6.3	  Methods	  	  This	   research	   followed	   the	   tenets	   of	   the	  Declaration	   of	  Helsinki.	   Informed	  written	  consent	  was	  obtained	  from	  all	  participants	  following	  an	  explanation	  of	   the	   nature	   and	   possible	   consequences	   of	   the	   study.	   Experimental	  protocols	   were	   approved	   by	   the	   York	   Neuroimaging	   Research,	   Ethics	   and	  Governance	  Committee	  and	  the	  University	  of	  York	  Ethics	  Committee.	  	  
6.3.1	  Patient	  population	  and	  treatment	  	  This	  study	  ran	  in	  parallel	  with	  the	  study	  described	  in	  Chapter	  5	  and	  on	  the	  same	  cohort	  of	  individuals.	  To	  recap,	  treatment	  naïve	  patients	  that	  fulfilled	  the	  National	   Institute	   for	  Health	  and	  Clinical	  Excellence	   (NICE)	   criteria	   for	  treatment	   of	   nvAMD	   (Snellen	  VA	   6/12	   or	   less,	   nvAMD,	   evidence	   of	   recent	  disease	   progression)	   were	   recruited	   in	   to	   the	   study.	   Participants	   were	  excluded	   if	   they	   were	   unable	   to	   give	   written	   consent.	   All	   participants	  underwent	   assessment	   with	   best-­‐corrected	   visual	   acuity	   (BCVA)	   using	   an	  ETDRS	  chart,	  OCT	  (Cirrus,	  Carl	  Zeiss	  Meditec)	  and	  fMRI	  at	  baseline	  (visit	  1).	  	  All	   participants	   were	   commenced	   on	   the	   recommended	   intravitreal	   anti-­‐VEGF	   agent	   at	   that	   time	   (ranibizumab	   0.5mg	   in	   0.05mls,	   or	   Aflibercept	  2.0mg	  in	  0.05mls)	  and	  received	  3	  monthly	  initiation	  doses	  under	  a	  standard	  aseptic	  technique	  via	  the	  pars	  plana.	  Assessments	  (VA,	  OCT	  and	  MRI)	  were	  repeated	   following	   the	   three	   initiation	   doses	  making	   a	   total	   of	   4	   sessions	  (visit	  2-­‐4)	  per	  participant.	  	  
6.3.2	  Visual	  acuity	  technique	  	  This	  was	  as	  described	  in	  chapter	  5	  with	  participants	  having	  best	  corrected	  visual	   acuity	   (BCVA)	   measured	   using	   an	   ETDRS	   chart	   (Pelli-­‐Robson,	  Precision-­‐Vision)	   at	   4	  metres	   using	   their	  most	   up	   to	   date	   pair	   of	   distance	  glasses.	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6.3.3	  Ocular	  coherence	  tomography	  	  This	   was	   also	   as	   described	   in	   chapter	   5.	   	   Following	   pupillary	   dilation	   a	  standard	  macular	   cube	  assessment	  on	  a	   spectral	  domain	  OCT	   (Cirrus,	  Carl	  Zeiss-­‐Meditec)	  allowed	  the	  1	  mm2	  central	  subfield	  central	  retinal	  thickness	  to	  be	  recorded.	  	  
6.3.4	  Functional	  MRI	  technique	  	  At	  each	  visit	  there	  were	  two	  assessments	  of	  the	  treated	  eye	  and	  two	  of	  the	  untreated	   (control)	   eye	   giving	   a	   total	   duration	   of	   examination	   of	   up	   to	   30	  minutes.	  	  	  The	   stimulus	   was	   generated	   using	   MATLAB	   (Natick	   Laboratory;	   MATLAB	  and	   Statistics	   toolbox	   release,	   The	  Mathworks,	   Inc.,	  Natick,	  Massachusetts,	  USA.)	  and	  presented	  using	  an	  LCD	  projector	  (EPSON	  GB5900,	  60Hz	  refresh	  rate,	   maximum	   luminance	   =	   6000	   candelas	   per	   metre	   squared	   -­‐	   Minolta	  LS110	  photometer).	  A	  45	  degree-­‐tilted,	  front-­‐silvered	  mirror	  was	  placed	  in	  front	  of	  the	  subject's	  head,	  so	  the	  projection	  could	  occur	  onto	  the	  face	  from	  the	  light	  source.	  A	  diffusing	  acrylic	  film	  was	  fit	  to	  some	  clear	  acrylic	  goggles,	  which	  were	   placed	   over	   the	   subject's	   eyes.	   This	   film	   attenuated	   the	  mean	  luminance	   to	  1350	  cd/m2.	  Additionally,	  underneath	   the	  goggles,	   either	   the	  left	  or	  right	  eye	  of	   the	  subject	  was	  occluded	  with	  a	  sterile	   fabric	  eye	  patch	  while	   measurements	   from	   the	   other	   eye	   were	   made.	   Participants	   were	  instructed	   to	  keep	  both	  eyes	  open	  and	   to	  remain	  still	  during	   the	  scans;	  no	  fixation	  was	  required.	  Foam	  padding	  was	  used	  around	  the	  participant's	  head	  to	  minimise	  movement,	  with	  earplugs	  provided	  to	  protect	  from	  the	  noise	  of	  the	  scanner.	  	  	  The	  stimulus	  was	  a	  contrast	  reversing	  Ganzfield,	  reversing	  at	  6Hz.	   The	   stimulus	   was	   presented	   for	   18	   seconds	   and	   interleaved	   with	  periods	  of	  mean	  luminance	  (grey	  screen)	  of	  18	  seconds	  each.	  This	  36	  second	  stimulus	  cycle	  was	  repeated	  8	  times	  per	  scan.	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Structural	   data	   were	   acquired	   using	   high-­‐resolution	   T1-­‐weighted	   images	  and	  inplane	  structural	  images.	  Functional	  MRI	  data	  were	  acquired	  using	  an	  eight-­‐channel,	   phase-­‐array	   head	   coil	   tuned	   to	   127.4	   MHz,	   on	   a	   General	  Electric	   Signa	   HD	   Excite	   3T	   MRI	   scanner.	   Gradient	   recalled	   echo-­‐pulse	  sequences	   were	   used	   to	   measure	   T2*-­‐weighted	   blood	   oxygen	   level-­‐dependent	  (BOLD)	  data.	  The	  imaging	  parameters	  used	  for	  the	  T2*	  weighting	  were	  TR	  =	  3000ms,	  TE	  =	  30ms,	  Flip	  angle	  =	  90degrees,	  matrix	  size	  =	  64	  x	  64,	  field	  of	  view	  =	  192	  mm,	  slice	  thickness	  =	  3	  mm	  and	  voxel	  size	  =	  3	  x	  3	  x	  3mm3	  	  In	   additional	   to	   the	   functional	   data	   a	   whole	   head	   high	   resolution	   T1	  weighted	   anatomical	   image	   was	   acquired	   with	   the	   following	   parameters:	  	  TR	  =	  7.92ms,	  TE	  =	  2.9ms,	  matrix	  size	  =	  256	  x	  256	  field	  of	  view	  =	  290	  mm,	  slice	   thickness	   =	   1	   mm	   and	   voxel	   size	   =	   1	   x	   1.13	   x	   1.13mm3	   This	   high	  resolution	  brain	  image	  was	  used	  as	  a	  common	  space	  for	  comparison	  of	  data	  across	   sessions.	   To	   aide	   alignment	   of	   data	   across	   sessions	   an	   additional	  anatomical	   image	   was	   acquired	   as	   an	   intermediate	   step	   for	   aligning	  functional	   data	   to	   the	   high-­‐resolution	   whole	   brain	   dataset.	   This	   proton	  density	  weighted	  image	  was	  acquired	  with	  the	  same	  slice	  prescription	  as	  the	  functional	   data	   and	   with	   the	   following	   parameters:	   TR	   =	   2500ms,	   TE	   =	  34.9ms,	  matrix	  size	  =	  512	  x	  512	  field	  of	  view	  =	  192	  mm,	  slice	  thickness	  =	  3	  mm	  and	  voxel	  size	  =	  3	  x	  0.375	  x	  0.375mm3	  Pre-­‐processing	  stages	  included;	  MCFLIRT	   motion	   correction	   (Jenkinson,	   Bannister,	   Brady	   &	   Smith,	   2002)	  using	   FLIRT	   (FMRIB’s	   Linear	   Registration	   Tool),	   slice-­‐timing	   correction	  using	  Fourier-­‐space	   time-­‐series	  phase-­‐shifting	  and	   linear	  detrend	   filtering,	  to	   filter	   out	   any	   inconsistencies.	   Functional	   time-­‐series	   were	   high-­‐pass	  filtered	  to	  remove	  baseline	  drifts.	  	  	  Data	   analysis	   was	   performed	   primarily	   in	   MATLAB	   using	   the	   publicly	  available	  mrVista	   toolbox	   (http://white.stanford.edu/software).	  Data	  were	  averaged	   across	   scans	   for	   each	   participant	   and	   were	   aligned	   to	   the	   high-­‐resolution	  anatomical	  volume	  and	  visualised	  in	  3D.	  	  Based	   on	   anatomical	   criteria	   two	   regions	   of	   interest	   (ROI's),	   5	   mm	   in	  diameter	  were	  chosen	   in	  each	  hemisphere	   from	  each	  participant.	  One	  was	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chosen	  at	  the	  posterior	  occipital	  pole	  (PP),	  retinotopically	  representing	  the	  macula	   region,	   and	   the	   second	   in	   the	   mid-­‐calcarine	   (MC)	   region	  representing	   a	   peripheral	   location	   in	   V1	   to	   act	   as	   a	   control.	   The	   percent	  BOLD	  signal	  change	  was	  averaged	  across	  all	  voxels	  within	  a	  given	  ROI.	  The	  BOLD	  response	  (BR	  =	  a	  ratio)	  from	  the	  PP	  was	  controlled	  for	  the	  expected	  variation	  (Rosengarth	  et	  al,	  2013)	  in	  intersession	  response	  by	  correcting	  it	  by	   the	   MC	   activity.	   To	   further	   minimise	   this	   variation	   the	   treated	   eye	  response	  was	  also	  controlled	  by	  the	  untreated	  eye	  and	  so	  the	  final	  BR	  was	  calculated	  using	  the	  following	  equation:	  	  BR	   	   	  =	  	   	   (PP/MC)	  Treated	  /	  (PP/MC)	  Untreated	  	  
6.4.5	  Statistical	  analysis	  	  The	  stimulus	  driven	  amplitude	  of	   the	   signal	   recorded	  at	  each	  voxel	  within	  the	   ROI	   was	   computed	   via	   a	   vector	   mean	   calculation.	   Data	   was	   averaged	  across	  hemispheres	  within	  each	  scan	  session.	  	  	  Pearson	   correlation	   coefficients	   were	   calculated	   between	   the	   treated	   eye	  VA,	   the	   treated	   eye	   CRT	   and	   the	   BOLD	   response.	   A	   two-­‐tailed	   probability	  was	  calculated	  and	  P	  <=	  0.05	  was	  taken	  as	  statistical	  significance.	  	  Data	   from	   participants	   that	  withdrew	   consent	  were	   not	   analysed.	  Missing	  data	   was	   handled	   by	   excluding	   that	   session	   from	   the	   analysis	   and	   the	  number	  of	  participants	  analysed	  displayed.	  	  
6.5	  Results	  	  Sixteen	  patients	  were	  recruited	  into	  the	  study,	  of	  which	  6	  withdrew	  consent	  during	  the	  study.	  Data	  from	  the	  remaining	  ten	  patients	  were	  analyzed	  with	  seven	   right	   and	   three	   left	   eyes	   affected.	  Mean	   age	  was	   75.7	   years	   (67-­‐87)	  with	   equal	   male	   to	   female	   distribution.	   All	   patients	   attended	   for	   their	  treatment	  and	  VA/OCT	  assessments	  on	  schedule	  but	  only	   five	  attended	  all	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four	  neuroimaging	  sessions.	  Of	  the	  remaining	  five,	  all	  attended	  for	  their	  first	  assessment	  and	  two	  further	  assessments	  with	  one	  not	  attending	  the	  second	  and	  two	  not	  attending	  their	  third	  or	  fourth	  assessments.	  Participant	  number	  seven	  had	  BCVA	  measured	  by	  the	  Snellen	  technique	  rather	  than	  ETDRS	  on	  the	   third	   visit	   so	   this	   data	  was	   excluded.	   The	   baseline	  VA,	   CRT	   and	  BOLD	  characteristics	  are	  outlined	  in	  Table	  23.	  	   Participant	  number	   Baseline	  BCVA	  Treated	  (letters)	  
Baseline	  BCVA	  Untreated	  (letters)	  
Baseline	  CRT	  Treated	  (μm)	  
Baseline	  CRT	  Untreated	  (μm)	  
BOLD	  (PP/MC)Treated	  
BOLD	  (PP/MC)	  Untreated	  
1	   75	   85	   309	   261	   0.282	   0.591	  2	   62	   75	   269	   235	   1.462	   1.453	  3	   79	   71	   292	   288	   0.430	   0.459	  4	   60	   84	   366	   245	   0.132	   0.473	  5	   40	   79	   314	   288	   0.187	   0.388	  6	   55	   69	   272	   266	   1.991	   1.183	  7	   69	   94	   335	   315	   0.824	   1.190	  8	   70	   68	   260	   237	   0.337	   1.166	  9	   62	   74	   233	   258	   0.373	   0.479	  10	   28	   72	   738	   317	   0.439	   -­‐0.628	  	  
Table	   23.	   The	   baseline	   (visit	   1)	   characteristics	   of	   the	   10	   participants’	  treated	  and	  untreated	  eyes	  (BCVA=	  Best	  Corrected	  Visual	  Acuity	   in	  ETDRS	  letters,	  CRT=	  central	  1mm2	  subfield	  retinal	  thickness	  in	  micrometers,	  BOLD	  =	  Vector	  mean	  projected	  amplitude	  of	  Blood	  Oxygen	  Dependency	  Level).	  	  
6.5.1	  Visual	  acuity	  
	  The	  VA	  values	   for	   individual	  participants	   and	   the	  means	  of	   the	   cohort	   are	  presented	  below.	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Participant	  number	   BCVA	  visit	  2	  Treated	  (letters)	  
BCVA	   visit	  2	  Untreated	  (letters)	  
BCVA	  visit	   3	  Treated	  (letters)	  
BCVA	   visit	  3	  Untreated	  (letters)	  
BCVA	   visit	  4	  Treated	  (letters)	  
BCVA	   visit	  4	  Untreated	  (letters)	  1	   64	   79	   75	   85	   77	   76	  2	   80	   79	   81	   79	   78	   78	  3	   80	   74	   80	   75	   85	   78	  4	   60	   85	   60	   83	   55	   78	  5	   51	   90	   63	   80	   66	   85	  6	   48	   67	   74	   69	   76	   74	  7	   82	   89	   	   	   81	   89	  8	   77	   75	   78	   73	   78	   78	  9	   49	   73	   57	   75	   46	   78	  10	   48	   80	   47	   83	   45	   79	  	  
Table	  24.	   	  Treated	  and	  untreated	  eye	  visual	  acuity	  (ETDRS	  letters)	  for	  the	  participants,	   1-­‐10	   over	   the	   3	   follow	   up	   sessions.	   A	   blank	   cell	   represents	  missing	  data.	  	   Mean	  (SD)	  BCVA	  Baseline	  Treated	  (letters	  n=10)	  
Mean	  (SD)	  BCVA	  Baseline	  Untreated	  (letters	  n=10)	  
Mean	  (SD)	  BCVA	  visit	  2	  Treated	  (letters	  n=10)	  
Mean	  (SD)	  BCVA	  visit	   2	  Untreated	  (letters	  n=10)	  
Mean	  (SD)	  BCVA	  visit	  3	  Treated	  (letters,	  n=9)	  
Mean	  (SD)	  BCVA	  visit	   3	  Untreated	  (letters	  n=9)	  
Mean	  (SD)	  BCVA	  visit	  4	  Treated	  (letters	  n=10)	  
Mean	   (SD)	  BCVA	   visit	  4	  Untreated	  (letters	  n=10)	  
59.8	  (16.1)	   77.1	  	  (8.3)	   63.9	  (14.6)	   79.1	  	  (7.3)	   68.3	  (12.0)	   78.0	  	  (5.3)	   68.6	  (14.8)	   79.3	  (4.4)	  	  
Table	  25.	   	  Treated	  and	  untreated	  mean	  and	  standard	  deviation	  (SD)	  visual	  acuity	   (ETDRS	   letters)	   for	   the	  participants	  1-­‐10	  over	  all	  4	   sessions,	   visit	  1	  (baseline)	  to	  visit	  4.	  The	  number	  of	  sessions	  analysed	  (n)	  was	  10	  in	  all	  cases	  except	  for	  visit	  three	  when	  the	  figure	  was	  9	  due	  to	  missing	  data.	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  Figure	   14.	   Mean	   (standard	   deviation)	   visual	   acuity	   (y-­‐axis,	   ETDRS	   letter	  score)	  at	  visit	  1	  (baseline)	  to	  visit	  4	  (x-­‐axis)	  for	  the	  10	  participants.	  Treated	  data	  is	  displayed	  in	  blue	  and	  untreated	  data	  in	  red.	  See	  Table	  23.	  	  
6.5.2	  Central	  Retinal	  Thickness	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Participant	  number	   CRT	  visit	  2	  Treated	  (μm)	  
CRT	  visit	   2	  Untreated	  (μm)	  
CRT	  	  visit	   3	  Treated	  (μm)	  
CRT	  visit	   3	  Untreated	  (μm)	  
CRT	  	  visit	   4	  Treated	  (μm)	  
CRT	  	  visit	   4	  Untreated	  (μm)	  1	   357	   261	   305	   249	   294	   264	  2	   186	   235	   203	   234	   221	   233	  3	   289	   291	   278	   291	   274	   291	  4	   278	   246	   299	   245	   252	   144	  5	   294	   285	   270	   281	   278	   280	  6	   260	   265	   259	   261	   263	   160	  7	   306	   316	   333	   318	   285	   317	  8	   234	   238	   233	   235	   231	   236	  9	   219	   264	   217	   265	   209	   268	  10	   375	   318	   345	   313	   306	   314	  	  
Table	   26.	   	   Treated	   and	   untreated	   CRT	   (central	   1mm2	   subfield	   retinal	  thickness,	   micrometres)	   for	   the	   participants,	   1-­‐10	   over	   the	   3	   follow	   up	  sessions.	  	  	   Mean	  (SD)	  CRT	  Baseline	  Treated	  (μm)	  
Mean	  (SD)	  CRT	  Baseline	  Untreated	  (μm)	  
Mean	  (SD)	  CRT	  Visit	  2	  Treated	  (μm)	  
Mean	   (SD)	  CRT	  Visit	   2	  Untreated	  (μm)	  
Mean	  (SD)	  CRT	  Visit	  3	  Treated	  (μm)	  
Mean	   (SD)	  CRT	  Visit	   3	  Untreated	  (μm)	  
Mean	  (SD)	  CRT	  Visit	  4	  Treated	  (μm)	  
Mean	   (SD)	  CRT	  Visit	   4	  Untreated	  (μm)	  
338	  (145.5)	   271	  (29.9)	   279	  (56.7)	   271	  (29.5)	   274	  (47.5)	   269	  (30.6)	   261	  (32.4)	   270	  (29.9)	  	  
Table	   27.	   	   Treated	   and	  untreated	  mean	   and	   standard	  deviation	   (SD)	   CRT	  (central	  1mm2	  subfield	  retinal	   thickness,	  micrometres)	   for	  the	  participants	  1-­‐10	  over	  all	  4	  sessions,	  visit	  1	  (baseline)	  to	  visit	  4.	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Figure	   15.	   Mean	   (standard	   deviation)	   1mm2	   central	   subfield	   retinal	  thickness	  (y-­‐axis,	  micrometres)	  at	  visit	  1	  (baseline)	  to	  visit	  4	  (x-­‐axis)	  for	  the	  10	  participants.	  Treated	  data	  is	  displayed	  in	  blue	  and	  untreated	  data	  in	  red.	  	  	  
6.5.3	  Vector	  mean	  projected	  amplitude	  of	  BOLD	  responses	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Participant	  number	   BOLD	  visit	  2	  Treated	  (n=8)	  
BOLD	  visit	   2	  Untreated	  (n=8)	  
BOLD	  visit	   3	  Treated	  (n=9)	  
BOLD	   visit	  3	  Untreated	  (n=9)	  
BOLD	  visit	   4	  Treated	  (n=8)	  
BOLD	  visit	   4	  Untreated	  (n=8)	  1	   	   	   0.474	   0.746	   -­‐0.149	   0.915	  2	   1.024	   1.659	   	   	   1.622	   1.657	  3	   0.361	   0.247	   0.428	   0.522	   0.578	   0.497	  4	   0.285	   0.412	   0.019	   0.412	   	   	  5	   	   	   -­‐0.147	   0.143	   0.106	   0.161	  6	   1.862	   1.554	   1.312	   1.713	   1.761	   1.609	  7	   0.618	   0.868	   0.669	   0.918	   0.813	   0.614	  8	   0/152	   0.333	   0.763	   0.680	   0.472	   0.586	  9	   0.454	   0.622	   0.388	   0.589	   	   	  10	   0.112	   -­‐0.628	   -­‐0.263	   -­‐1.790	   -­‐2.622	   -­‐1.621	  	  
Table	  28.	   	  Treated	  and	  untreated	  BOLD	  (vector	  mean	  projected	  amplitude	  of	   BOLD	   responses)	   for	   the	   participants,	   1-­‐10	   over	   the	   three	   follow	   up	  sessions.	  A	  blank	  cell	   represents	  missing	  data.	  The	  number	  of	  participants	  analysed	   (n)	   was	   less	   than	   ten	   across	   all	   sessions	   after	   baseline	   due	   to	  missing	  data.	  	   Mean	  (SD)	  BOLD	  Baseline	  Treated	  (n=10)	  
Mean	   (SD)	  BOLD	  Baseline	  Untreated	  (n=10)	  
Mean	  (SD)	  BOLD	  visit	  2	  Treated	  (n=8)	  
Mean	   (SD)	  BOLD	  visit	   2	  Untreated	  (n=8)	  
Mean	  (SD)	  BOLD	  visit	  3	  Treated	  (n=9)	  
Mean	   (SD)	  BOLD	  visit	   3	  Untreated	  (n=9)	  
Mean	  (SD)	  BOLD	  visit	  4	  Treated	  (n=8)	  
Mean	   (SD)	  BOLD	  visit	   4	  Untreated	  (n=8)	  
0.646	  (0.644)	   0.676	  (0.604)	   0.608	  (0.584)	   0.626	  (0.753)	   0.141	  (1.123)	   0.437	  (0.888)	   0.322	  (1.459)	   0.551	  (1.025)	  	  
Table	  29.	   	  Treated	  and	  untreated	  mean	  and	  standard	  deviation	  (SD)	  BOLD	  (vector	  mean	  projected	  amplitude	  of	  BOLD	  responses)	   for	   the	  participants	  1-­‐10	  over	   the	  3	   follow	  up	  sessions.	  Following	  the	  baseline	  assessment,	   the	  number	  of	  participants	  analysed	  (n)	  was	  less	  than	  ten	  across	  the	  remaining	  sessions	  due	  to	  missing	  data.	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Figure	   16.	   Mean	   (standard	   deviation)	   BOLD	   response	   (y-­‐axis)	   at	   visit	   1	  (baseline)	  to	  visit	  4	  (x-­‐axis).	  Treated	  data	  is	  displayed	  in	  blue	  and	  untreated	  data	  in	  red.	  	  	   Participant	  number	   BOLD	  	  (Treated	   /	  Untreated)	  	  Baseline	  (n=10)	  	  
BOLD	  	  (Treated	   /	  Untreated)	  	  visit	  1	  (n=8)	  	  
BOLD	  	  (Treated	   /	  Untreated)	  	  visit	  2	  (n=9)	  	  
BOLD	  	  (Treated	   /	  Untreated)	  	  visit	  3	  (n=8)	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Table	   30.	   	   Mean	   treated	   divided	   by	   mean	   untreated	   BOLD	   (vector	   mean	  projected	  amplitude	  of	  BOLD	  responses)	  for	  the	  participants	  1-­‐10	  over	  the	  3	  follow	   up	   sessions.	   A	   blank	   cell	   represents	   missing	   data.	   Following	   the	  baseline	  assessment,	  the	  number	  of	  sessions	  analysed	  (n)	  was	  less	  than	  ten	  across	  the	  remaining	  sessions	  due	  to	  missing	  data.	  	   Mean	   	   (SD)	  BOLD	  (Treated	   /	  Untreated)	  	  Baseline	  (n=10)	  	  
Mean	  	  (SD)	  BOLD	  	  (Treated	   /	  Untreated)	  	  visit	  2	  (n=8)	  	  
Mean	  (SD)	  BOLD	  (Treated	   /	  Untreated)	  	  visit	  3	  (n=9)	  	  
Mean	  (SD)	  BOLD	  	  (Treated	   /	  Untreated)	  	  visit	  4	  (n=8)	  	  
0.593	  (0.615)	   0.682	  (0.484)	   0.579	  (0.715)	   0.937(0.535)	  	  
Table	   31.	   	   Mean	   and	   standard	   deviation	   (SD)	   treated	   /	   untreated	   BOLD	  (vector	  mean	  projected	  amplitude	  of	  BOLD	  responses)	   for	   the	  participants	  1-­‐10	   over	   the	   four	   sessions,	   visit	   1	   (baseline)	   to	   visit	   4.	   Following	   the	  baseline	  assessment,	  the	  number	  of	  sessions	  analysed	  (n)	  was	  less	  than	  ten	  across	  the	  remaining	  sessions	  due	  to	  missing	  data.	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Figure	   17.	  Mean	  BOLD	  response	  (treated	  over	  untreated,	  y-­‐axis)	  at	  visit	  1	  (baseline)	  to	  visit	  4	  (x-­‐axis).	  	  
6.5.4	  Correlations	  between	  psychophysical	  and	  anatomical	  measures	  	  The	  correlation	  between	  the	  treated	  eye	  VA	  and	  CRT	  was	  -­‐0.473	  (p=0.002).	  This	  was	  re	  analysed	  with	  the	  outlying	  results	  removed	  (VA	  28	  letters	  and	  CRT	   738)	   leading	   to	   a	   correlation	   of	   -­‐0.232	   (p=0.155).	   The	   correlation	  between	   the	   BOLD	   (treated	   /	   untreated)	   and	   VA	   was	   0.236	   (p=0.142).	  Correaltion	   of	   the	   full	   set	   between	   BOLD	   and	   CRT	   was	   -­‐0.410	   (p=0.009).	  Removing	  the	  outlier	  (CRT	  738	  and	  BOLD	  -­‐0.699)	  the	  correlation	  was	  -­‐0.143	  (p=0.385).	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Figure	  19.	  	  A	  scatter	  plot	  showing	  the	  relationship	  between	  the	  treated	  eye	  the	  BOLD	  response	  and	  the	  ETDRS	  Visual	  Acuity	  (number	  of	  letters).	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6.6	  Discussion	  
	  The	  mean	  VA	  improvement	  from	  pre	  treatment	  to	  after	  the	  third	  treatment	  of	   8.8	   ETDRS	   letters	   is	   in	   line	   with	   the	   expected	   response	   from	   larger	  published	   trials	   (Brown	   et	   al,	   2011;	   Chakravarthy	   et	   al,	   2013;	   Schmidt-­‐Erfurth	   et	   al	   2014).	   Similarly	   the	   corresponding	   reduction	   in	   central	  1mm	  subfield	  CRT	  of	  129.4	  microns	  was	  smaller	  but	  similar	  to	  that	  expected.	  This	  demonstrates	   that	   our	   subject	   population	   is	   broadly	   representative	   of	   a	  typical	  population	  of	  nvAMD	  patients.	  	  	  The	  BOLD	  response	  of	  both	  the	  treated	  and	  untreated	  eyes	  showed	  a	  mean	  decrease	   over	   the	   4	   sessions.	   At	   first	   glance	   this	   is	   surprisingly	  counterintuitive,	  but	  is	  a	  well-­‐documented	  phenomenon,	  thought	  to	  be	  due	  to	   habituation	   or	   attenuation	   possibly	   because	   the	   same	   stimulus	   is	  presented	  at	  each	  session	  (Rosengarth	  et	  al,	  2013).	   	  When	  the	  response	  of	  the	   treated	   eye	   was	   corrected	   for	   this	   expected	   variability	   by	   using	   the	  quotient	   of	   the	   untreated	   eye	   response,	   and	   the	   quotient	   of	   the	   MC,	   an	  improvement	   in	   activity	   was	   demonstrated	   from	   the	   first	   to	   the	   fourth	  session.	   This	   method	   of	   using	   a	   quotient	   is	   a	   logical	   step	   to	   take	   to	  counteract	  the	  habituation	  /	  attenuation	  effect.	  Just	  as	  Rosengarth	  had	  used	  during	  many	  of	  her	  experiments,	  the	  method	  used	  in	  this	  thesis	  employed	  a	  full	   field	   as	   a	   stimulus	   at	   each	   visit.	   This	   aimed	   to	   give	   consistency	   across	  sessions,	   but	   ultimately	   may	   have	   worked	   against	   the	   ability	   to	   show	   a	  greater	   effect.	   To	   counteract	   the	   habituation	   /	   attenuation	   effect	   an	  alternative	  method	  would	  have	  been	   to	  use	  either	  a	   stimulus	  appearing	   in	  multifocal	  locations	  over	  a	  short	  time	  sequence	  or	  to	  use	  randomly	  selected	  different	  patterns	  during	  and	  between	  sessions.	  Consideration	  needs	   to	  be	  given	  to	  this	  for	  future	  studies.	  In	  a	  similar	  vein	  the	  VA	  and	  CRT	  data	  could	  have	   been	   presented	   using	   quotients	   of	   treated	   eye	   divided	   by	   untreated	  eye,	   but	   because	   there	   are	   relatively	   small	   standard	   deviations	   associated	  with	  the	  mean	  values	  of	  the	  treated	  eyes	  this	  calculation	  seems	  unnecessary.	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Nonetheless,	  using	  the	  quotient	  the	  rise	  in	  BOLD	  is	  consistent	  with	  the	  effect	  shown	  in	  Baseler	  et	  al’s	  single	  case	  report	  (Baseler	  et	  al,	  2011).	  It	  supports	  the	  notion	  that	  the	  area	  of	  the	  primary	  visual	  cortex	  anatomically	  mapped	  to	  and	  so	  representing	  the	  central	  macula	  is	  able	  to	  increase	  its	  activity	  after	  a	  period	  of	  having	  reduced	  activity	  due	  to	  nvAMD.	  A	  degree	  of	  caution	  has	  to	  be	   applied	   to	   this	   conclusion	   though	   as	   the	   standard	   deviations	   are	   very	  large.	   It	  may	   be	   that	   a	   non-­‐parametric	   statistic	  would	   capture	   the	   overall	  trend	  in	  BOLD	  response	  change	  without	  displaying	  such	  high	  variance	  in	  the	  absolute	  quotient	   and	   this	   type	  of	   analysis	   should	  be	   considered	  as	   a	  pre-­‐planned	   outcome	   measure	   for	   future	   studies.	   The	   increase	   in	   cortical	  activity	  following	  treatment	  is	  an	  important	  finding	  in	  its	  own	  right	  but	  also	  allows	   the	   discussion	   about	   the	   place	   of	   using	   the	   BOLD	   response	   as	   an	  outcome	  measure	  of	  the	  treatment	  of	  AMD.	  The	  significant	  variability	  in	  the	  single	   subject	   BOLD	   response	   between	   sessions	   indicates	   that	   it	   is	   not	   a	  good	  measure	  of	  individual	  response	  to	  treatment	  from	  visit	  to	  visit.	  When	  a	  cohort	   is	   studied	   the	   mean	   change	   in	   BOLD	   is	   less	   vulnerable	   to	   this	  variability	  and	  so	  it	   is	  better	  to	  use	  mean	  values	  to	  demonstrate	  treatment	  effect.	  This	  conclusion	  is	  similar	  to	  that	  of	  the	  use	  of	  VA	  in	  chapter	  1,	  in	  that	  as	  an	  outcome	  measure	  it	  is	  also	  open	  to	  significant	  intersession	  coefficient	  of	  variability	  (Patel	  et	  al,	  2008;	  Aslam	  et	  al	  2014).	  	  	  What	  cannot	  be	  demonstrated	  is	  if	  the	  recovery	  of	  visual	  cortex	  function	  is	  back	  to	  its	  fully	  pre	  diseased	  state	  as	  we	  do	  not	  have	  BOLD	  data	  prior	  to	  the	  onset	  of	  the	  neovascularisation.	  One	  would	  estimate	  that	  there	  would	  be	  full	  recovery	  if	  the	  retinal	  function	  allowed	  it,	  and	  can	  extrapolate	  thinking	  from	  other	   disease	   processes.	   From	   studies	   of	   patients	   treated	   for	   nvAMD	   it	   is	  known	  that	  VA	  does	  not	  return	  to	  the	  pre-­‐diseased	  level	  (Airody	  et	  al,	  2014;	  Tufail	  et	  al,	  2014),	  but	  this	  is	  likely	  to	  be	  due	  to	  the	  incomplete	  amelioration	  of	  the	  retinal	  pathology	  as	  we	  see	  full	  visual	  recovery	  following	  treatment	  of	  other	  causes	  of	   reversible	  visual	   loss	  such	  as	   following	  cataract	   surgery.	   It	  has	   already	  been	  discussed	   that	   anatomical	   changes	   can	  occur	   in	   the	   grey	  matter	   in	   those	  having	  developed	  AMD	  and	   those	  with	   longer	   term	  retinal	  lesions	   (Noppeney	   et	   al,	   2005;	   Boucard	   et	   al,	   2009;	  Hernowo	   et	   al	   2013).	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Following	  on	  from	  this	  point,	  it	  is	  also	  not	  possible	  to	  conclude	  if	  there	  is	  a	  critical	  window	  of	  opportunity	  to	  protect	  the	  visual	  cortex	  from	  an	  inability	  to	   recover	   activity	   either	   fully	   or	   partially.	   This	   knowledge	   would	   have	  implications	  on	   the	   timing	  of	   treatments	   to	   try	   to	   recover	  vision	   following	  the	  onset	  of	  nvAMD	  and	  furthermore	  whether	  neuro-­‐protection	  strategies	  in	  new	  onset	  disease	  would	  be	  advisable.	  	  	  This	   study	   was	   open	   to	   bias	   in	   a	   number	   of	   areas	   in	   particular	   in	   the	  subjective	   selection	   of	   the	   Regions	   of	   Interest	   (ROIs).	   The	   ROIs	   were	  determined	   by	   selecting	  what	  was	   estimated	   to	   be	   the	   correct	   anatomical	  locations	   corresponding	   to	   the	   macula	   and	   to	   a	   region	   in	   the	   peripheral	  retina	   without	   any	   knowledge	   of	   their	   function.	   It	   is	   possible	   that	   the	  posterior	  pole	  and	  to	  a	  lesser	  extent	  the	  mid	  calcarine	  regions	  selected	  were	  not	  of	  the	  correct	  location,	  size	  or	  shape	  and	  therefore	  do	  not	  show	  the	  full	  effect	  of	  the	  change.	  To	  counteract	  this	  the	  ROIs	  could	  be	  selected	  to	  find	  the	  regions	   that	   have	   the	   greatest	   increase	   when	   the	   raw	   BOLD	   data	   is	  visualised,	  but	  this	  technique	  could	  be	  criticised	  in	  that	  one	  could	  ‘select	  the	  result	  to	  fit	  the	  question’.	  An	  alternative	  is	  to	  use	  line	  ROIs	  that	  join	  the	  PP	  and	  MC	  areas	  as	  done	  by	  Smirnakis	  et	  al.	  This	  captures	  a	  much	  larger	  cross	  section	   of	   the	   cortex	   which	   means	   that	   the	   location	   of	   the	   change	   in	   the	  BOLD	  response	  and	  not	  just	  its	  magnitude	  become	  the	  important	  end	  points	  (Smirnakis	  et	  al,	  2005).	  	  Further	  consideration	  should	  also	  be	  given	  to	  using	  larger	  regions	  of	  interest,	  even	  possibly	  the	  whole	  visual	  cortex,	  which	  may	  increase	  the	  chance	  of	  capturing	  change	  in	  activation.	  	  Another	   area	   of	   bias	   was	   that	   by	   the	   very	   nature	   of	   the	   duration	   and	  commitment	  required	  for	  fMRI,	  and	  particularly	  so	  in	  this	  older	  population,	  not	  all	  participants	  were	  able	  to	  attend	  all	  sessions.	  This	  could	  compromise	  the	  quality	  of	  the	  data.	  However	  given	  that	  only	  5	  sessions	  were	  missed	  in	  a	  total	  of	  40,	  and	  that	  no	  participant	  missed	  more	  than	  one	  session,	  the	  results	  are	   likely	   to	   be	   representative	   of	   a	   full	   dataset.	   The	   fact	   that	   participants	  were	  not	  always	  able	  to	  attend	  their	  session	  as	  well	  as	  the	  cost,	  duration	  and	  contraindications	  for	  the	  use	  of	  MRI,	  strengthens	  the	  argument	  that	  fMRI	  is	  
	   145	  
not	   a	   suitable	   tool	   for	   an	   assessment	   tool	   to	   guide	   re-­‐treatments.	   The	  reasons	   listed	   would	   have	   also	   contributed	   to	   slow	   recruitment	   into	   the	  study.	  Once	  again,	  all	  of	  these	  factors	  need	  to	  be	  taken	  into	  consideration	  for	  future	  studies.	  	  Correlations	   between	   the	   VA,	   CRT	   and	   BOLD	   response	   all	   missed	  significance,	  which	  could	  be	  due	  to	  the	  under	  powering	  of	  the	  study,	  but	  may	  also	  be	  due	   to	   the	   techniques	  being	   insufficiently	   sensitive	   to	  detect	   small	  change.	  	  	  Further	  work	  need	  to	  be	  done	  to	  refine	  the	  technique	  of	  both	  detection	  and	  analysis	  of	  the	  BOLD	  response,	  in	  order	  to	  increase	  its	  sensitivity.	  Although	  using	   the	   mid	   calcarine	   response	   and	   the	   fellow	   eye	   to	   control	   for	   the	  variation	  in	  the	  BOLD	  response	  seems	  logical,	  this	  quotient	  is	  in	  fact	  a	  ratio	  of	   a	   ratio	   and	   therefore	   has	   significant	   disadvantages.	   It	   may	   be	   an	  inherently	  unstable	  value	  particularly	  when	   there	  are	   large	  changes	   in	   the	  denominators.	   In	   addition	   to	   the	   drawback	   it	   may	   not	   be	   valid	   to	   use	  parametric	  analyses.	  Furthermore	   the	  use	  of	  negative	  values	   (as	  driven	  by	  some	   negative	   BOLD	   responses)	   appears	   intuitively	   inappropriate.	   These	  are	  all	  useful	  learning	  points	  for	  the	  design	  of	  future	  outcome	  analyses	  using	  the	  BOLD	  response.	  	  
6.7	  Conclusion	  	  The	   results	   of	   this	   study	   quite	   substantially	   confirm	   that	   the	   area	   of	   the	  primary	   visual	   cortex	   anatomically	   mapped	   to	   and	   so	   representing	   the	  central	  macula	  is	  able	  to	  increase	  its	  activity	  after	  a	  period	  of	  having	  reduced	  activity	  due	  to	  nvAMD.	  Furthermore	  measuring	  the	  BOLD	  response	  by	  fMRI	  appears	   to	   have	   potential	   to	   be	   a	   good,	   objective	   way	   assessing	   cortical	  function	   in	   response	   to	   treatment.	   However,	   due	   to	   its	   intersession	  variability	  and	  for	  practical	  reasons,	  the	  technique	  described	  in	  this	  thesis	  is	  best	   placed	   to	   assess	   cohorts	   of	   individuals,	   retrospectively	   over	  multiple	  scans,	  and	  at	  the	  moment	  in	  the	  research	  setting.	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Chapter	   7.	   Quantifying	   the	   adverse	   effects	   of	   macular	   degeneration	  
treatment:	   Short	   term	   intraocular	   pressure	   trends	   following	  
intravitreal	   Ranibizumab	   injections	   for	   neovascular	   Age-­‐related	  




	  The	   preceding	   chapters	   have	   focused	   attention	   on	  measuring	   the	   efficacy	  outcomes	  of	  the	  treatment	  of	  neovascular	  macular	  degeneration	  (nvMD).	  An	  equally	   important	   consideration	   of	   any	   treatment	   is	   the	   quantification	   of	  adverse	  events.	  This	  chapter	  studies	  the	  risk	  and	  implications	  of	  short	  term	  raised	  intraocular	  pressure	  (IOP)	  as	  a	  side	  effect	  of	  treatment	  of	  neovascular	  age-­‐related	  macular	   degeneration	   (nvAMD)	  with	   intravitreal	   ranibizumab.	  Furthermore	  the	  prevention	  of	  raised	  IOP	  with	  the	  use	  of	  oral	  acetazolamide	  is	  evaluated	  in	  a	  randomised	  controlled	  trial.	  	  
7.2.	  Background	  
	  As	   has	   been	   highlighted	   in	   previous	   chapters,	   nvAMD	   contributes	  substantially	   to	   the	   visual	   loss	   burden	   in	   society	   (Owen	   et	   al,	   2012).	  Following	  a	  ruling	  by	  the	  National	  Institute	  of	  Health	  and	  Clinical	  excellence	  (NICE)	   in	   2008,	   routine	   treatment	   is	   widely	   available	   in	   the	   UK	   and	   on	  average	  enables	  partial	  restoration	  of	  vision	  and	  its	  continued	  preservation	  in	   the	   longer	   term	   (NICE	   TA155,	   2008;	   Rofagha	   et	   al,	   2013;	   Tufail	   et	   al,	  2014;	  Airody	  et	  al,	  2014;	  Schmidt-­‐Erfurth	  et	  al,	  2014).	  	  All	   therapeutic	   interventions	  have	   associated	   side	   effects	   or	   complications	  and	   intravitreal	   injections	  with	   anti-­‐VEGF	   agents	   are	   no	   exception	   to	   this	  rule.	  The	  most	  feared	  complications	  are	  as	  a	  result	  of	  structural	  damage	  to	  the	   eye	   at	   the	   time	   of	   injection	   or	   as	   a	   result	   of	   an	   infection	   affecting	   the	  internal	  coats	  of	  the	  eye	  manifesting	  in	  the	  post	  injection	  period,	  a	  process	  termed	   endophthalmitis.	   Endophthalmitis	   often	   leads	   to	   a	   devastating	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outcome	  on	  final	  visual	  acuity	  and	  routine	  precautions	  such	  as	  prophylactic	  antiseptic	   treatments	   and	   a	   strict	   aseptic	   environment	   are	   routinely	  employed	   (Boyer,	   Heier,	   Brown,	   Francom	  &	   Ianchulev,	   2009;	   Hasler	   et	   al,	  2014).	  These	  events,	  although	  uncommon,	  have	  been	  well	  studied	  and	  occur	  at	  a	   frequency	  of	   less	   than	  1	   in	  a	  1000	   injections,	  with	  endophthalmitis	  at	  approximately	   1	   in	   3000	   injections,	   (Brown	   et	   al,	   2006;	   Rosenfeld	   et	   al,	  2006;	  Boyer	  et	  al,	  2009;	  Martin	  et	  al,	  2011;	  Chakravarthy	  et	  al	  2012).	  	  A	   less	  well-­‐studied	  side	  effect	   is	   the	  phenomenon	  of	  short	   term	  raised	  IOP	  following	   injection	   into	   the	   vitreous	   cavity.	   This	   unwanted	   effect	   is	  particularly	   relevant	   to	   patients	  who	  have	   glaucoma,	   a	   condition	  whereby	  there	   is	   progressive	   loss	   of	   the	   retinal	   nerve	   fibre	   layer	   manifesting	   as	   a	  ‘cupped’	   appearance	   of	   the	   optic	   nerve.	   This	   loss	   causes	   peripheral	   visual	  defects	  and	  as	  the	  condition	  progresses	  towards	  an	  advanced	  stage	  field	  loss	  encroaches	  on	  and	  then	  finally	  obliterates	  the	  nerve	  responsible	  for	  fixation.	  The	   principle	   risk	   factor	   for	   glaucoma	   is	   raised	   IOP,	   which	   untreated	   is	  usually	   above	   the	   normal	   range	   of	   10-­‐22mmHg.	   Treatment	   is	   aimed	   at	  pharmacologically,	   and	   occasionally	   surgically,	   lowering	   the	   IOP	   and	  reducing	  the	  diurnal	  variation	  of	  the	  pressure.	  	  	  At	  the	  time	  of	  an	  intravitreal	  injection	  of	  a	  therapeutic	  dose	  of	  and	  anti-­‐VEGF	  agent	  (usually	  0.05mls)	  a	  sharp	  rise	  in	  IOP	  occurs,	  raising	  it	  to	  a	  mean	  value	  of	   around	   44mmHg.	   After	   30	  minutes	   the	   IOP	   usually	   subsides	   to	   around	  30mmHg	   (Kim	   Manravadi,	   Hur	   &	   Covert,	   2008;	   Falkenstein,	   Cheng	   &	  Freeman,	  2007;	  Hollands,	  Wong,	  Bruen,	  Compbell,	  Sharma	  &	  Gale,	  2007).	  As	  commented	   upon	   by	   Mathalone	   et	   al,	   this	   effect	   may	   not	   be	   transient.	   In	  approximately	  11%	  of	  201	  eyes	  treated	  with	  bevacizumab	  the	  IOP	  rise	  was	  sustained,	  being	  defined	  at	  IOP	  greater	  than	  22mmHg	  or	  a	  rise	  of	  6mmHg	  or	  more	  from	  baseline	  for	  at	  least	  30	  days.	  Retreatment	  intervals	  of	  less	  than	  8	  weeks	  were	  found	  to	  be	  a	  risk	  factor	  (Mathalone	  et	  al,	  2012).	  	  	  With	   the	   knowledge	   that	   nvAMD	   is	   a	   chronic	   disease	   requiring	   multiple	  injections	   over	   a	   number	   of	   years	   (Rofagha	   et	   al,	   2013;	   Tufail	   et	   al,	   2014;	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Airody	   et	   al	   2014),	   concern	   has	   been	   raised	   as	   to	   the	  whether	   peripheral	  visual	   loss	   may	   be	   being	   promoted	   in	   those	   who	   have	   glaucoma	   and	   are	  being	   treated	   for	   nvAMD.	   Loss	   of	   peripheral	   vision	   has	   particular	  implications	   for	   those	   being	   treated	   for	   nvAMD	   who,	   by	   NICE	   guided	  criteria,	   must	   already	   have	   compromised	   central	   vision	   (Kim	   et	   al,	   2008;	  Falkenstein	  et	  al,	  2007).	  Furthermore	  debate	  exists	  as	  to	  whether	  those	  with	  glaucoma	  are	  more	  vulnerable	  to	  IOP	  rise	  following	  injection.	  In	  Kim	  et	  al’s	  study	   of	   213	   consecutive	   injections	   in	   120	   eyes	   a	   mean	   IOP	   immediately	  post	  injection	  of	  44	  mmHg	  (range	  4	  to	  87	  mmHg)	  was	  observed.	  Twenty	  of	  these	   patients	   had	   pre-­‐existing	   glaucoma	   and	   it	   was	   noted	   that	   these	  glaucomatous	   eyes	   took	   significantly	   longer	   to	   return	   to	   a	   pressure	   of	   30	  mmHg	  or	  lower	  (Kim	  et	  al.,	  2008).	  To	  support	  the	  opposing	  view	  Frenkel	  et	  al	   studied	   22	   patients	   receiving	   intravitreal	   pegaptanib	   injections	   (a	   less	  efficacious	  and	  so	  now	  a	  less	  commonly	  used	  anti-­‐VEGF	  agent)	  and	  showed	  no	   statistical	   significance	   between	   the	   2	   groups	   at	   any	   time	   interval.	   This	  study	  however	  only	  had	  9	  glaucoma	  patients	  and	  there	  was	  no	  clarity	  about	  which	   of	   the	   patients	   may	   have	   received	   prophylactic	   IOP	   lowering	  treatment	  (Frenkel	  et	  al.,	  2007).	  	  Similarly	   it	   is	   not	   clear	   if	   treatments	   to	   prevent	   raised	   IOP	   are	   useful.	  Frenkel	  et	  al	  reported	  upon	  another	  series	  of	  71	  patients	  being	  injected	  with	  one	  of	  three	  different	  types	  of	  anti-­‐VEGF	  agents:	  ranibizumab,	  bevacizumab	  and	  pegaptanib.	  Various	  types	  of	  prophylactic	  IOP	  lowering	  medication	  (the	  anti-­‐glaucoma	  drops	   timolol,	   brimonidine,	   aproclonidine	  and	  brinzolamide	  or	   oral	   acetazolamide)	   were	   administered	   1-­‐2	   hours	   prior	   to	   injection	   in	  around	   two	   thirds	  of	   cases.	   	   	  The	  report	  concluded	   that	  glaucoma	  patients	  behaved	   in	   a	   similar	   manner	   to	   non-­‐glaucoma	   patients	   and	   that	   IOP-­‐lowering	  medications	  were	  essentially	   ineffective	   (Frenkel,	  Haji	  &	  Frenkel,	  2010).	   The	   non-­‐randomised	   and	   inconsistent	   use	   of	   medications	   in	   this	  study	  casts	  doubt	  upon	  the	  validity	  of	  such	  a	  bold	  statement.	  Theoulakis	  et	  al	   however,	   reported	   on	   a	   prospective	   double-­‐blind	   placebo	   controlled	  study	  and	  concluded	  that	  use	  of	  Combigan	  (brimonidine	  and	  timolol)	  twice	  a	  day	  on	  the	  day	  before	  an	  intravitreal	  injection	  of	  Ranibizumab	  is	  effective.	  
	   149	  
Unfortunately	   on	   this	   occasion	   IOP	   was	   not	   measured	   immediately	   post	  injection	  missing	  the	  highest	  IOP	  spike	  (Theoulakis	  et	  al.,	  2010).	  All	  of	  these	  studies	  mentioned	   so	   far	  did	  not	   specifically	   study	   the	  population	  most	   at	  risk	   to	   losing	   peripheral	   visual	   field:	   those	   with	   glaucoma	   or	   glaucoma	  suspect.	  Any	  loss	  of	  the	  nerve	  fibre	  layer	  and	  associated	  visual	  field	  with	  single	  IOP	  spike	  is	  likely	  to	  be	  too	  small	  to	  be	  detectable	  with	  current	  technology	  and	  so	   ideally	  very	   long	   term	  studies	  of	   these	   indices	  should	  be	  performed.	  As	  with	  the	  studies	  described	  so	  far	  in	  this	  chapter	  raised	  IOP	  is	  often	  taken	  as	  a	   surrogate	   marker	   of	   potential	   visual	   field	   loss	   and	   so	   is	   the	   focus	   of	  investigation	   (McMonnies,	   2008;	   Kim	   et	   al,	   2008;	   Falkenstein	   et	   al,	   2007;	  Frenkel	  et	  al,	  2007;	  Frenkel	  et	  al,	  2010).	  	  The	  aim	  of	  the	  study	  in	  this	  chapter	  is	   to	   determine	   the	   effect	   of	   a	   single	   prophylactic	   medication,	   oral	  acetazolamide,	  on	   lowering	   the	  peak	  and	  duration	  of	   IOP	   rise	   in	  glaucoma	  and	   glaucoma	   suspect	   patients,	   following	   an	   injection	   of	   ranibizumab	   for	  nvAMD.	  Oral	   acetazolamide	  was	   chosen	  because	  of	   it	   known	  properties	   in	  being	  able	  to	  clear	  volume	  from	  so	  called	  ‘fourth	  spaces’	  such	  as	  the	  vitreous	  and	  its	  already	  established	  use	  in	  some	  nvAMD	  treatment	  clinics.	  	  
7.3.	  Methods	  
	  In	  accordance	  with	  the	  Declarations	  of	  Helsinki,	  York	  Teaching	  Hospital	  NHS	  Foundation	   Trust	   gave	   approval	   for	   the	   study	   and	   the	   trial	   was	   assigned	  EudraCT	  (European	  clinical	  trial	  database)	  number	  2010-­‐023037-­‐35.	  
	  
7.3.1	  Participant	  selection	  	  Participants	   were	   recruited	   from	   a	   single	   centre	   nvAMD	   treatment	   clinic,	  had	  to	  have	  been	  previously	  diagnosed	  with	  glaucoma	  or	  glaucoma	  suspect	  and	   to	   require	   an	   intravitreal	   injection	  of	   ranibizumab	   in	   accordance	  with	  NICE	  guidance	  (NICE	  TA155,	  2008).	  The	  full	  inclusion	  and	  exclusion	  criteria	  are	  listed	  in	  Table	  32.	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  Inclusion	  criteria:	  	  1.	  	  	  	  	  Patients	  with	  nAMD	  requiring	  Ranibizumab	  injections.	  2.	  	  	  	  	  Glaucoma	  or	  glaucoma	  suspect.	  3.	  	  	  	  	  Able	  to	  give	  written	  informed	  consent.	  	  Exclusion	  criteria:	  	  1.	  	  	  	  	  Baseline	  pre-­‐injection	  IOP	  of	  30	  mmHg	  or	  higher.	  2.	  	  Known	  allergy	  to	  sulphur/sulphonamide	  containing	  drugs	  or	  acetazolamide.	  3.	  	  	  	  	  Severe	  kidney	  or	  liver	  disease/dysfunction.	  4.	  	  	  	  	  Adrenal	  gland	  failure.	  5.	  	  	  	  	  Hyperchloraemic	  acidosis.	  6.	  	  	  	  	  Hepatic	  cirrhosis.	  7.	  	  	  	  	  Pregnancy/Pre-­‐menopausal.	  8.	  	  	  	  	  Concomitant	  use	  of	  other	  oral	  carbonic	  anhydrase	  inhibitors.	  9.	  	  	  	  Enrolment	  in	  a	  pre	  existing	  clinical	  trial	  	  
Table	   32.	  The	   inclusion	  and	  exclusion	  criteria	   for	  participation	   in	   the	   IOP	  rise	  prophylaxis	  study.	  	  
7.3.2	  Trial	  design	  	  Participants	  were	  randomised	  1:1	  to	  receive	  either	  500mg	  acetazolamide	  or	  no	   treatment	   60-­‐90	   minutes	   prior	   to	   treatment.	   The	   randomisation	  sequence	   had	   previously	   been	   software	   generated	   by	   an	   independent	  member	  of	  staff	  and	  was	  held	  by	  the	  trial	  pharmacist.	  In	  accordance	  with	  the	  Royal	   College	   of	   Ophthalmologists	   guidance	   on	   administration	   of	  intravitreal	   therapies,	   0.5mg	   in	   0.05mls	   of	   ranibizumab	  was	   administered	  via	  the	  pars	  plana	  (RCOphth,	  2009).	   	  The	  IOP	  was	  measured	  using	  a	  Tono-­‐Pen	  (Medtronic	  Xomed	  Ophthalmics	  Inc.,	  Mineapolis,	  Minnesota,	  USA)	  prior	  to	   injection	   to	   give	   the	   baseline	   (TB)	   reading.	   A	   second	   member	   of	   the	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research	   team	   verified	   the	   reading	   on	   the	   Tono-­‐Pen	   screen.	   Further	  readings	  were	  taken	  immediately	  after	  the	  injection	  (T0)	  and	  subsequently	  at	  5	  (T5),	  10	  (T10)	  and	  30	  (T30)	  minutes	  post	  treatment.	  	  	  
7.3.3	  Statistical	  methodology	  	  The	  primary	  end	  points	  were	  change	  in	  IOP	  from	  baseline	  to	  time	  points	  T0,	  T5,	   T10	   and	   T30.	   No	   published	   data	   existed	   on	   the	   anticipated	   treatment	  effect.	  An	  effect	  of	  9mmHg	  difference	  at	  T0	  was	   therefore	  estimated	  based	  upon	  clinical	  experience	  of	  the	  use	  of	  acetazolamide	  in	  other	  conditions	  with	  raised	  IOP	  by	  three	  ophthalmologists.	  	  To	  provide	  a	  power	  of	  80%	  with	  a	  5%	  significance	  level	  12	  participants	  in	  each	  arm	  were	  required.	  	  An	  intention	  to	  treat	  analysis	  was	  used,	  with	  repeated	  measures	  ANOVA	  to	  compare	  IOP	  over	  time	  and	  ANCOVA	  to	  compare	  between	  the	  arms	  at	  each	  time	   point.	   All	   analyses	  were	   adjusted	   for	   baseline	   IOP.	   All	   analyses	  were	  undertaken	  on	  SPSS	  version	  18.0	  (IBM,	  Portsmouth,	  UK)	  and	  p	  <	  0.05	  was	  considered	  to	  indicate	  statistical	  significance.	  	  An	   exploratory	   endpoint	  was	   to	   observe	   any	   treatment	   differences	   in	   the	  subtypes	   of	   glaucoma	   at	   baseline.	   These	   baseline	   observations	   along	  with	  age,	   sex	   and	   race	   were	   summarised	   using	   means	   (standard	   deviations),	  medians	  (inter-­‐quartiles	  ranges)	  and	  proportions	  (percentages).	  	  
7.4	  Results	  	  Twenty-­‐four	  participants	  were	  randomised	  and	  completed	  the	  study.	  Their	  baseline	  characteristics	  are	  displayed	  in	  Table	  33.	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   No	   aceta-­‐zolamide	  (12)	   Aceta-­‐zolamide	  (12)	   Total	  Age	   Mean	  (SD)	   84.9	  (7.4)	   80.8	  (4.6)	   82.9	  (6.4)	  Gender	   Male	   5	  (42%)	   9	  (75%)	   14	  (58%)	  Female	   7	  (58%)	   3	  (25%)	   10	  (42%)	  Ethnic	  group	   Caucasian	   12	  (100%)	   12	  (100%)	   24	  (100%)	  Eye	  injected	  with	  Lucentis	   during	  study	  
Right	  eye	   7	  (58%)	   6	  (50%)	   13	  (54%)	  Left	  eye	   5	  (42%)	   6	  (50%)	   11	  (46%)	  Type	   of	  Glaucoma	   or	  suspected	  glaucoma	  
Normal	  tension	  glaucoma	   0	  (0%)	   2	  (17%)	   2	  (8%)	  Primary	   /	  Chronic	  open	   angle	  glaucoma	   10	  (83%)	   8	  (67%)	   18	  (75%)	  Angle	  closure	  glaucoma	   1	  (8%)	   0	  (0%)	   1	  (4%)	  Glaucoma	  Suspect	   1	  (8%)	   2	  (17%)	   3	  (13%)	  Trabeculectomy	   No	   11	  (92%)	   10	  (83%)	   21	  (88%)	  Yes	   1	  (8%)	   2	  (17%)	   3	  (12%)	  Cataract	  surgery	   No	   6	  (50%)	   7	  (58%)	   13	  (54%)	  Yes	   6	  (50%)	   5	  (42%)	   11	  (46%)	  Number	   of	  concomitant	  medications	   for	  glaucoma	  
0	   1	  (8%)	   2	  (17%)	   3	  (13%)	  	  1	   	  7	  (58%)	  	   5	  (42%)	   12	  (50%)	  2	   4	  (33%)	   5	  (42%)	   9	  (38%)	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Table	  33.	  Baseline	  characteristics	  of	  study	  participants	  in	  the	  acetazolamide	  treated	  and	  non-­‐treated	  groups.	  	  A	  reduction	  in	  IOP	  was	  demonstrated	  from	  T0	  to	  T30	  (F(4)=72.97,	  p<0.001),	  although	   no	   difference	   between	   the	   two	   groups	  was	   observed	   (F(1)=0.57,	  p=0.459).	   Data	   is	   displayed	   in	   Table	   34	   and	   graphical	   representation	   in	  Figure	  18.	  	  
	   Mean	  (SD)	   	  Range	   95%	  CI	  Baseline	  (TB)	   No	  Acetazolamide	   15.1	  (5.5)	   [8-­‐26]	  	   12.0,	  18.2	  Acetazolamide	   15.8	  (4.8)	   [8-­‐26]	   13.1,	  18.4	  Post	   Lucentis	  injection	   	   at	   	   0	  minutes	  (mmHg)	  
No	  Acetazolamide	   44.5	  (19.8)	   [19-­‐86]	   33.3,	  55.7	  	  Acetazolamide	   42.2	  (10.2)	   [25-­‐58]	   36.4,	  48.0	  
Post	   Lucentis	  injection	   at	   5	  minutes	  (mmHg)	  
No	  Acetazolamide	   31.4	  (14.4)	   [13-­‐65]	   23.3,	  39.6	  Acetazolamide	   27.1	  (10.0)	   [14-­‐48]	   21.4,	  32.7	  
Post	   Lucentis	  injection	   at	   10	  minutes	  	  (mmHg)	  
No	  Acetazolamide	   24.5	  (11.7)	   [10-­‐50]	   17.9,	  31.1	  Acetazolamide	   21.3	  (7.0)	   [10-­‐35]	   17.4,	  25.3	  
Post	   Lucentis	  injection	   at	   30	  minutes	  	  (mmHg)	  
No	  Acetazolamide	   20.6	  (9.5)	   [11-­‐46]	   15.2,	  25.9	  Acetazolamide	   15.7	  (4.3)	   [8-­‐21]	   13.3,	  18.2	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Table	   34.	   Intraocular	   pressures	   in	   the	   acetazolamide	   and	   control	   group	  over	  each	  time	  point	  summarised	  with	  descriptive	  statistics.	  	  
	  	  
Figure	  21.	  Mean	  (SD)	   intraocular	  pressure	  (mmHg,	  y	  axis)	   for	  time	  points	  TB,	   T0,	   T5,	   T10,	   T30	   (minutes,	   x	   axis).	   The	   dashed	   line	   indicates	   the	  injection	  occured	  between	  TB	  and	  T0	  	  Single	  time	  points	  were	  analysed	  in	  an	  attempt	  to	  reveal	  data	  for	  potential	  future	  studies,	  such	  as	  observing	  IOP	  over	  a	  longer	  duration.	  	  No	  difference	  was	   seen	   between	   the	   two	   groups	   at	   time	   points	   T0,	   T5	   or	   T10	   but	   a	  difference	   at	   T30	   was	   noted	   (SD	   0.1,	   95%	   CI	   1.3-­‐9.8,	   p=	   0.013).	   Data	   for	  these	  time	  points	  is	  displayed	  in	  Table	  35.	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Absolute	  change	  from	  TB	   Difference	  between	  groups	  adjusting	   for	  baseline	  Mean	   (SD)	  (95%	  CI)	  
ANCOVA	   p-­‐value	  
No	  Acetazolamide	  (SD)	   Acetazolamide	  (SD)	  Change	   from	  TB	  to	  T0	   29.4	  (16.1)	   26.4	  (8.2)	   3.8	  (0.4)	  (-­‐6.2,	  13.7)	   0.440	  Change	   from	  TB	  to	  T5	   16.3	  (10.0)	   11.3	  (9.7)	   5.4	  (0.2)	  (-­‐2.7,	  13.5)	   0.183	  Change	   from	  TB	  to	  T10	   9.4	  (8.5)	   5.6	  (6.0)	   4.0	  (0.2)	  (-­‐2.3,	  10.3)	   0.201	  Change	   from	  TB	  to	  T30	   5.5	  (5.4)	   0.00	  (4.4)	   5.5	   (0.1)	   (1.3,	  9.8)	   0.013	  
	  
Table	  35.	  A	  comparison	  in	  the	  change	  in	  IOP	  from	  baseline	  to	  T0,	  T5,	  T10	  and	  T30	  between	  the	  treated	  and	  untreated	  groups.	  	  A	   post-­‐hoc	   analysis	   of	   area	   under	   the	   curve	   was	   calculated	   for	   the	   two	  groups:	  780.4	   for	   the	  group	  not	   receiving	  acetazolamide	  and	  665.0	   for	   the	  treated	  group.	  	  Throughout	   the	   short	   time	   participants	   were	   enrolled	   in	   this	   study	   no	  serious	  adverse	  or	  adverse	  events	  were	  reported.	  	  
7.5	  Discussion	  	  This	  study	  shows	  that	  transient	  IOP	  increase	  following	  intravitreal	  injection	  of	   ranibizumab	   for	   nvAMD	   is	   commonplace	   and	   can	   be	   substantial	   in	  glaucoma	   and	   glaucoma	   suspect	   patients.	   These	   results	   are	   in	   line	   with	  previous	   studies	   that	   have	   not	   specifically	   followed	   glaucoma	   patients	  (Frenkel	  et	  al,	  2007;	  Kim	  et	  al,	  2008;	  Schmidt-­‐Urfurth,	  2010;	  Frenkel	  et	  al,	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2010)	   although	   debate	   continues	   as	   to	   whether	   IOP	   behaves	   differently	  following	   an	   injection	   in	   those	  with	   glaucoma	   compared	   to	   those	  without	  (Kim	  et	  al,	  2008,	  Frenkel	  et	  al,	  2010).	  Nonetheless,	  given	  that	  IOP	  spikes	  are	  a	  risk	  factor	  for	  the	  development	  and	  progression	  of	  glaucoma	  (McMonnies,	  2008),	   and	   understanding	   that	   a	   substantial	   increase	   in	   IOP	   occurs	   with	  injections	  (and	  potentially	  worse	  still	  as	  treatments	  may	  be	  up	  on	  a	  monthly	  basis),	   precautionary	   measures	   must	   be	   considered	   in	   this	   at	   risk	  population.	  	  
	  The	  study	  in	  this	  chapter	  used	  oral	  acetazolamide	  as	  prophylactic	  treatment	  to	  try	  and	  address	  the	  issue	  of	  prevention	  of	  IOP	  rise	  following	  intravitreal	  injection.	  The	  treatment	  and	  non-­‐treatment	  groups	  were	  well	  balanced	   for	  baseline	   characteristics,	   although	   the	   non-­‐treatment	   group	   was	   slightly	  older	  and	  had	  a	  female	  propensity,	  so	  any	  differences	  in	  effect	  are	  likely	  to	  be	   due	   to	   the	   treatment.	   	   Overall,	   no	   statistical	   significant	   difference	   was	  observed	  between	  the	  group	  that	  received	  acetazolamide	  and	  the	  group	  that	  did	  not.	  	  In	  an	  attempt	  to	  look	  for	  data	  that	  may	  be	  useful	  to	  be	  able	  to	  power	  future	   studies	   an	   analysis	   of	   the	   single	   time	   points	   were	   performed.	   A	  	  	  	  statistically	  significant	  reduction	  in	  post	  injection	  IOP	  spike	  was	  seen	  at	  T0,	  T5	   or	   T10	   but	   a	   difference	   was	   observed	   at	   T30	   (20.6mmHg	   versus	  15.8mmHg).	   At	   first	   assessment	   the	   results	   therefore	   imply	   that	   the	   peak	  IOP	   is	   not	   affected	   by	   the	   treatment	   but	   the	   duration	   of	   IOP	   rise	   is	  shortened.	  This	  finding	  would	  need	  further	  examination	  to	  be	  confirmed.	  It	  can	   be	   argued	   that	   a	   modest	   reduction	   in	   IOP	   at	   30	  minutes	  may	   not	   be	  clinically	   significant	   in	   all	   but	   those	   patients	   with	   the	   most	   vulnerable	  retinal	  nerve	  fibre	  layers.	  	  	  	  There	  are	  two	  mechanisms	  whereby	  raised	  IOP	  can	  potentially	  cause	  nerve	  fibre	  layer	  damage;	  peak	  IOP	  and	  sustained	  raised	  IOP.	  	  Without	  the	  benefit	  of	   having	   measured	   the	   nerve	   fibre	   layer	   thickness	   at	   these	   time	   points	  using	   optical	   coherence	   tomography	   (and	   assuming	   the	   degree	   of	   change	  would	  in	  fact	  be	  measurable	  after	  a	  single	  injection),	  it	  is	  not	  easy	  to	  discern	  which	  of	  these	  factors	  is	  the	  most	  important.	  It	  may	  well	  be	  that	  both	  play	  a	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role	   and	   that	   the	   IOP	   reduction	   in	   the	   area	   under	   the	   curve	   is	   important	  (Figure	  18).	  Post	  hoc	  analysis	  showed	  a	  numerical	  difference	  suggesting	  that	  this	   could	   be	   a	   candidate	   measure	   for	   future	   studies.	   Furthermore	   an	  interesting	   observation	   to	   note	   is	   that	   at	   each	   time	   point	   the	   range	   of	  measured	  IOPs	  and	  the	  peak	  pressure	  was	  substantially	  lower	  in	  the	  treated	  group;	   this	   reduced	   chance	   of	   a	   very	   high	   peak	   pressure	  may	   be	   of	  more	  clinical	   significance	   in	   protecting	   the	   nerve	   fibre	   layer	   than	   the	   mean	  reduction	  in	  IOP	  and	  so	  the	  effect	  of	  the	  prophylactic	  acetazolamide	  may	  be	  more	  than	  it	  first	  appears.	  A	  larger	  sample	  size	  may	  have	  been	  able	  to	  detect	  this	  difference.	  	  If	  clinicians	  choose	  to	  use	  acetazolamide	  as	  prophylaxis	  against	  IOP	  rise	  they	  will	   need	   to	  debate	   the	   clinical	   significance	  of	   these	   findings.	   In	  particular	  there	   is	  a	  need	   to	  balance	   the	  apparent	   limited	  degree	  of	  efficacy	  with	   the	  potential	   side	   effects	   of	   treatment.	   Although	   no	   adverse	   events	   were	  reported	  in	  this	  study,	  acetazolamide	  can	  precipitate	  renal	  impairment	  and	  confusion,	   particularly	   in	   the	   elderly,	   which	   is	   of	   course	   the	   nvAMD	  population.	  	  Analysing	  the	  exploratory	  outcome	  of	  differences	  between	  the	  groups	  based	  upon	   the	   type	   of	   glaucoma	   was	   not	   valid	   as	   by	   far	   the	   majority	   of	  participants	  had	  primary	  open	  angle	  glaucoma.	  	  The	  design	  of	  the	  study	  in	  this	  chapter	  was	  robust	  in	  all	  but	  the	  method	  of	  informing	  the	  power	  calculation.	  	  Perhaps	  a	  larger	  group	  of	  clinical	  experts	  may	   have	   decided	   upon	   a	   lower	   peak	   reduction	   in	   IOP	   and	   so	   a	   larger	  sample	   size	   would	   be	   been	   used:	   the	   study	   appears	   under-­‐powered.	  Nonetheless	  the	  results	  of	  this	  study	  act	  as	  good	  pilot	  data	  to	  inform	  future	  studies.	  Furthermore,	  proving	  a	  statistical	  significance	  may	  not	  necessarily	  change	  its	  clinical	  relevance.	  	  	  Prophylactic	  medical	   treatments	  are	  unlikely	   to	  be	  able	   to	  prevent	   the	   full	  extent	  of	  the	  IOP	  spike	  as	  the	  globe	  is	  principally	  a	  rigid	  structure.	  A	  positive	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correlation	   has	   been	   described	   between	   rigidity	   coefficient	   and	   age	  suggesting	   that	   injection	   into	   an	   older	   more	   rigid	   eye	   would	   produce	   a	  higher	   peak	   IOP	   (Pallikaris,	   Kymionis,	   Gnis,	   Kounis	   &	   Tslimbaris	   2005;	  Kotliar	  et	  al,	  2007).	  Other	  factors	  have	  also	  been	  found	  to	  contribute	  to	  the	  degree	  of	  IOP	  rise	  such	  as	  the	  volume	  of	  the	  eye,	  needle	  bore	  size,	  vitreous	  reflux,	   and	   volume	   injected	   (Kim	   et	   al,	   2008;	  Kotliar	   et	   al,	   2007).	   In	   some	  eyes	  that	  are	  the	  most	  vulnerable	  to	  an	  IOP	  spike	  the	  only	  way	  to	  prevent	  an	  IOP	  rise	  may	  be	  to	  remove	  the	  equivalent	  volume	  from	  the	  eye	  immediately	  prior	   to	   injection.	  This	   is	  not	  a	  published	  technique	  and	  has	   the	  additional	  risk	  of	  requiring	  two	  punctures.	  	  	  
7.6	  Conclusion	  	  This	   chapter	   reports	   on	   the	   first	   randomised	   controlled	   trial	   studying	   the	  prophylaxis	   of	   IOP	   rise	   following	   intravitreal	   injection	   in	   glaucoma	   and	  glaucoma	  suspect	  patients.	  Oral	  acetazolamide	  given	  60-­‐90	  minutes	  before	  ranibizumab	   injection	   to	   treat	   nvAMD	   reduced	  mean	   IOP	  30	  minutes	   post	  injection	  by	  approximately	  5	  mmHg.	  Although	  this	  figure	  in	  itself	  it	  likely	  to	  be	  of	  little	  clinical	  significance,	  the	  reduction	  in	  peak	  IOP	  values	  immediately	  following	   injection	   and	   the	   reduced	   ‘area	   under	   the	   curve’	   may	   well	   be	  important	  to	  those	  most	  vulnerable	  to	  pressure	  rise.	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8.	   Summary	   and	   Conclusions:	   Quantification	   of	   neovascular	   macular	  
degeneration	  treatment	  
	  This	   thesis	   began	   by	   discussing	  macular	   degeneration	   and	  with	   particular	  emphasis	   on	   the	   neovascular	   form	   and	   its	   treatments.	   The	   common	   and	  some	  novel	  ways	  of	   quantifying	   treatment	   effect	  were	   then	   examined	   in	   a	  series	  of	  6	  studies.	  This	   final	  chapter	  summarises	  the	  context	  of	  the	  thesis,	  its	   findings	   and	   then	   discusses	   some	   alternative	   methods	   of	   assessing	  outcomes	  of	  treatments	  not	  studied	  here,	  before	  drawing	  final	  conclusions.	  
	  
8.1	  Overview	  of	  the	  context	  	  Neovascular	  macular	  degeneration,	  and	  in	  particular	  the	  age-­‐related	  form	  is	  a	   common	   cause	   of	   vision	   loss	   in	   the	   population	   (Owen	   et	   al,	   2012).	  Treatments	   are	   now	   available	   in	   the	   form	   of	   regular	   anti-­‐vascular	  endothelial	  growth	  factor	  (anti-­‐VEGF)	  injections	  into	  the	  vitreous	  of	  the	  eye,	  which	  not	  only	  restore	  a	  degree	  of	  the	  visual	  loss	  but	  also	  maintain	  vision	  in	  the	  long	  term	  (Martin	  et	  al,	  2011;	  Chakravarthy	  et	  al,	  2012;	  Schmidt-­‐Erfurth	  et	  al,	  2014;	  Tufail	  et	  al,	  2014;	  Airody	  et	  al,	  2014).	  Measuring	  the	  outcome	  of	  treatments	   is	   an	   important	   aspect	   of	   any	   care,	   not	   only	   to	   document	  progression	  through	  the	  disease	  journey,	  but	  also	  to	  aid	  treatment	  decisions	  such	   as	   which	   therapies	   to	   use	   and	   when.	   Documenting	   outcomes	   are	  equally	   important	   when	   describing	   the	   response	   to	   or	   side	   effects	   of	  treatments	  in	  populations,	  as	  effects	  are	  not	  always	  necessarily	  predictable	  in	  individuals.	  	  In	   a	   clinical	   setting	   the	   conventional	   way	   of	   reporting	   nvAMD	   treatment	  outcome	   is	   to	   use	   Visual	   Acuity	   (VA)	   (Brown	   et	   al,	   2006;	   Rosenfeld	   et	   al,	  2006;	  Tufail	  et	  al,	  2014).	  There	  is	  much	  discussion	  about	  the	  merits	  of	  doing	  this,	  in	  particular	  that	  VA	  alone	  may	  not	  be	  a	  comprehensive	  representation	  of	  vision	  and	  indeed	  could	  underestimate	  visual	  function	  (Scott	  et	  al,	  1994;	  West	   et	   al	   1997;	   Mangione	   et	   al,	   1999;	   Maclure	   et	   al,	   2000;	   Hazel	   et	   al,	  2000).	   Central	   retinal	   thickness	   (CRT)	   as	   measured	   by	   Optical	   Coherence	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Tomography	  (OCT)	  is	  also	  used	  as	  a	  routine	  outcome	  measure	  usually	  to	  aid	  retreatment	  decisions	  (Lalwani	  et	  al,	  2009;	  Martin	  et	  al,	  2011;	  Chakravarthy	  et	  al,	  2012;	  Airody	  et	  al,	  2014).	  In	  a	  similar	  way	  to	  the	  VA	  discussion,	  there	  is	  also	   comment	   that	   the	   use	   of	   OCT	   alone	   may	   not	   fully	   represent	   visual	  function	  change	  with	  treatment	  (Alexander	  et	  al,	  2012).	  	  	  	  	  This	  thesis	  aimed	  to	  assess	  these	  common	  forms	  of	  outcome	  measures	  and	  in	  addition	  aimed	  to	  explore	  the	  use	  of	  some	  functional	  measures	  including	  the	   use	   of	   Patient	   Reported	   Outcome	  Measures	   (PROMs),	   microperimetry	  (MP)	  and	   functional	  Magnetic	  Resonance	   Imaging	  (fMRI).	   	   In	   line	  with	   this	  theme,	   not	   just	   the	   positive	   aspects	   of	   therapy	   were	   studied,	   but	   also	   a	  negative	  aspect	  in	  the	  form	  of	  the	  prevention	  of	  short-­‐term	  pressure	  spikes	  following	  intravitreal	  injection.	  	  	  
8.2	  Overview	  of	  the	  findings	  	  
	  The	   studies	   presented	   comprise	   observational,	   interventional,	   randomised	  and	  open	  label	  methodology.	  	  
	  
8.2.1	  Visual	  acuity	  as	  an	  outcome	  measure	  
	  At	   the	   time	   of	   this	   study	   the	   principle	   treatment	   for	   nvAMD	   was	  ranibizumab	  administered	  monthly	  for	  3	  months	  and	  then	  as	  required	  on	  a	  monthly	  basis.	  (Lalwani	  et	  al,	  2009;	  NICE	  TA	  155,	  2008).	  	  As	  a	  part	  of	  service	  redesign,	   and	   in	   particular	   to	   try	   and	   ensure	   that	   patients	   received	  assessment	  on	  a	  monthly	  basis,	  a	  new	  treatment	  clinic	  was	  established.	  To	  evaluate	  the	  benefit	  of	  this	  change	  VA	  outcomes	  were	  assessed.	  Seventy-­‐two	  eyes	  of	  62	  patients	  with	  nvAMD	  who	  had	  already	   received	   the	  3	   initiation	  treatments	  of	  ranibizumab	  and	  were	  in	  the	  so	  called	  ‘stability	  phase’	  of	  their	  treatment	   were	   studied.	   	   Outcomes	   were	   assessed	   6	   visits	   before	   and	   6	  visits	   after	   their	  move	   to	   the	   new	   location	   (Tschour	   et	   al,	   2013).	   In	   the	   6	  visits	  prior	   to	   transfer	   the	  patients	  were	  seen	  at	  a	  mean	   frequency	  of	  56.8	  days	  (8	  weeks)	  and	  had	  a	  mean	   loss	   in	  VA	  of	  1.1	  ETDRS	   letters.	  Following	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transfer	   the	   patients	   were	   seen	   at	   a	   mean	   frequency	   of	   31.8	   days	   (4.3	  weeks)	   and	   subsequently	   VA	   improved	   by	   4.6	   letters.	   This	   information	  supports	  the	  notion	  that	  if	  their	  dosing	  regimen	  is	  to	  be	  on	  an	  ‘as	  required’	  basis,	   patients	  with	   nvAMD	   should	   have	   better	   outcomes	   if	   they	   are	   seen	  monthly	  rather	  than	  8	  weekly.	  	  In	   this	   case	   distance	   ETDRS	   letter	   score	   VA	   was	   used	   as	   the	   principle	  outcome	  measure.	   Its	  main	  advantages	  are	   that	   it	   is	   a	  quick	  and	  relatively	  simple	   assessment	   tool	   that	   produces	   a	   numerical	   value	   that	   can	   be	   used	  easily	   for	   statistical	   analysis.	   The	   principle	   disadvantages	   that	   were	  discussed	  were	   that	   it	  has	   a	   large	   co-­‐efficient	   in	   repeatability	   (Patel	  2008;	  Aslam,	   2014)	   meaning	   that	   it	   is	   not	   good	   at	   representing	   true	   responses	  between	  visits,	  and	  that	  it	  is	  not	  a	  full	  reflection	  of	  visual	  function	  (Scott	  et	  al,	  1994;	  West	  et	  al	  1997;	  Mangione	  et	  al,	  1999;	  Maclure	  et	  al	  2000;	  Haze	  et	  al,	  2000).	  Consequently	  basing	  re-­‐treatment	  decisions	  on	  VA	  alone,	  as	  was	  suggested	   in	   the	   product	   license	   of	   one	   anti-­‐VEGF	   treatment	   does	   not	  appear	  to	  be	  appropriate	  (SmPC	  Ranibizumab,	  2007).	  	  
8.2.2	  Central	  retinal	  thickness	  as	  an	  outcome	  measure	  	  Pathological	   myopia	   (PM)	   is	   the	   second	   commonest	   cause	   of	   macular	  degeneration	   and	   affects	   a	   younger	   population	   than	   its	   age-­‐related	  counterpart.	  Neovascular	  disease	  is	  a	  common	  complication	  of	  PM	  and,	  left	  untreated,	  has	  a	  poor	  natural	  history	  (Chan	  et	  al,	  2008;	  Montero	  et	  al,	  2010).	  At	   the	   time	   of	   study	   there	   was	   no	   licensed	   anti-­‐VEGF	   treatment	   for	   the	  treatment	   of	   CNV	   secondary	   to	   PM.	   The	   REPAIR	   study	   was	   aimed	   at	  evaluating	   the	   safety	   and	   efficacy	   of	   ranibizumab	   in	   the	   treatment	   of	   CNV	  secondary	   to	  PM.	  The	   local	  dataset	  was	  combined	  with	  a	  national	  data	   set	  and	  showed	  that	   there	  was	  a	  mean	   improvement	  of	  13.8	  (SD	  14.0)	  ETDRS	  letters	  at	  12	  months	  with	  a	  median	  number	  of	  treatments	  being	  3	  injections.	  The	   CRT	   as	   measured	   by	   spectral	   domain	   OCT,	   decreased	   by	   a	   mean	   of	  108μm	  (SD	  109)	  at	  this	  time	  point.	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The	   principle	   advantages	   of	   using	   CRT	   are	   that	   the	   information	   is	   quickly	  acquired	  by	  OCT,	  it	  is	  highly	  reproducible	  (Giana,	  Deiro	  &	  Staurenghi,	  2012)	  and	   a	   numerical	   value	   enables	   statistical	  manipulation.	   	   The	   CRT	  may	  not	  give	   complete	   information	   about	   the	   activity	   of	   neovascular	   disease	  however,	   as	   this	  may	   be	   governed	   by	   the	   exact	   site	   of	   the	   thickening	   and	  exactly	  what	  is	  measured	  within	  the	   ‘central	  retinal’	  area.	   	  Furthermore,	  to	  aid	  re-­‐treatment	  decisions	  qualitative	  aspects	  of	  the	  OCT	  scan	  are	  important	  (Martin	   et	   al,	   2012;	   Chakravarthy	   et	   al,	   2012)	   and	   training	   of	   those	   who	  interpret	   the	   image	   is	   required	   to	   given	   consistent	   results	   (Joeres	   et	   al,	  2007).	  	  
8.2.3	  The	  use	  of	  Patient	  Reported	  Outcome	  Measures	  	  Quality	   of	   life	   measurements	   give	   a	   holistic	   approach	   to	   outcomes	   of	  treatment	   and	   have	   been	   suggested	   to	   be	   more	   important	   than	   clinical	  outcomes	  (Deshpande	  et	  al,	  2011).	  Chapter	  4	  used	  the	  same	  REPAIR	  cohort	  of	  individuals	  as	  in	  the	  CRT	  study	  but	  analysed	  outcomes	  using	  a	  well-­‐being	  questionnaire	   (W-­‐BQ12)	   (Riazi	   et	   al,	   2006)	   and	   a	   treatment	   satisfaction	  questionnaire	   (MacTSQ)	   (Mitchell	   et	   al,	   2007).	   	   The	   results	   showed	   that	  individuals	   had	   a	   small	   but	   statistically	   significant	   improvement	   in	   their	  well-­‐being	  and	  an	  improvement	  in	  treatment	  satisfaction	  over	  the	  12	  month	  study	  period.	  	  Both	   the	   W-­‐BQ12	   and	   MacTSQ	   only	   correlated	   weakly	   with	   mean	   VA	  improvement	   in	   the	   cohort.	   This	   gives	   hope	   that	   a	   specifically	   powered	  study	   would	   give	   validity	   to	   these	   tools	   and	   also	   that	   VA	   could	   act	   as	   a	  biomarker	   for	   quality	   of	   life	   under	   this	   circumstance.	   PROMs	   give	   a	   new	  dimension	  to	  the	  assessment	  of	  outcomes	  and	  intuitively	  a	  change	  in	  quality	  of	  life	  measurement	  is	  more	  relevant	  to	  those	  receiving	  the	  treatment	  than	  a	  surrogate	  biomarker.	  Collecting	  and	  interpreting	  W-­‐BQ12	  and	  MacTSQ	  data	  is	  time	  consuming	  and	  not	  practical	  for	  all	  patients	  in	  a	  high	  volume	  clinical	  setting,	   however.	   PROMS	   are	   well	   placed	   to	   retrospectively	   evaluate	  interventions,	   but	   given	   their	   nature	   they	   do	   not	   directly	   help	   treatment	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decisions.	  At	  present	  they	  are	  best	  placed	  as	  a	  research	  or	  service	  evaluation	  tool.	  	  
8.2.4	  The	  use	  of	  microperimetry	  as	  tool	  for	  outcome	  measurement	  	  Data	   from	  eight	  participants	  undergoing	   routine,	  NICE	  approved	  NHS	  care	  for	   treatment	  of	  nvAMD	  were	  analysed	   in	   the	  study.	  All	  eight	  had	  VA,	  OCT	  and	   microperimetry	   (MP)	   assessments	   followed	   by	   treatment	   with	   anti-­‐VEGF	  therapy	  at	  baseline.	  Visual	  acuity,	  CRT	  and	  MP	  were	  repeated	  prior	  to	  re-­‐treatment	  at	  two	  further	  subsequent	  monthly	  visits.	  Due	  to	  missing	  data	  only	  the	  first	  three	  time	  points	  were	  analysed.	  The	  mean	  VA	  improved	  by	  11	  ETDRS	  letters	  and	  the	  CRT	  decreased	  by	  61	  micrometers.	  	  
8.2.4.1	  Retinal	  sensitivity	  	  Retinal	   sensitivity	   (RS)	  was	  analysed	   from	  within	  an	   ‘area	  of	   interest’	   that	  was	  defined	  as	  the	  area	  of	  CNV	  and	  sequelae	  guided	  by	  late	  frame	  FFA	  and	  OCT	   images.	   The	   percentage	   of	   points	   within	   the	   area	   of	   interest	   that	  increased	  by	  2dB	  or	  more	  or	  4dB	  or	  more	  was	  used	  as	  the	  principle	  outcome	  measure.	  One	  month	  following	  the	  first	  treatment	  a	  mean	  of	  33%	  of	  points	  increased	   by	   2dB	   or	   more	   and	   18%	   by	   4dB	   or	   more.	   At	   two	   months,	  following	   the	   second	   treatment	   the	   figures	   rose	   to	   62%	   and	   39%	  respectively.	  	  	  Despite	  the	  main	  set	  back	  of	  this	  study	  being	  low	  participant	  numbers	  and	  a	  short	   study	   duration	   (12	   months	   would	   have	   been	   better),	   RS	   has	   the	  potential	   to	   be	   used	   as	   an	   outcome	   measure	   not	   only	   for	   populations	  analysis,	  but	  also	  to	  aid	  visit-­‐to-­‐visit	  re-­‐treatment	  decisions.	  Alexander	  et	  al,	  studying	  visit-­‐to-­‐visit	  change,	  albeit	  not	  with	  an	  ‘area	  of	  interest’	  guided	  MP	  technique,	  and	  demonstrated	  that	  change	   in	  RS	  may	  precede	  change	   in	  VA	  or	   OCT	   measures.	   (Alexander	   et	   al,	   2012).	   The	   principle	   disadvantage	   of	  using	   RS	   is	   that	   data	   acquisition	   takes	   8-­‐12	   minutes	   per	   eye,	   which	   is	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difficult	   for	   frail	   individuals	   to	   achieve	   and	   would	   necessitate	   substantial	  resources.	  	  
8.2.4.2	  Fixation	  stability	  	  Fixation	  is	  impaired	  in	  late	  stage	  AMD	  (Pearce	  et	  al,	  2011).	  Fixation	  stability	  is	  potentially	  an	   important	  measure	  of	  visual	   function	  as	   it	  correlates	  with	  day-­‐to-­‐day	  tasks	  such	  as	  reading	  (Ergun	  et	  al,	  2003;	  Crossland	  et	  al,	  2005).	  	  	  In	   parallel	   with	   the	   MP	   assessment	   of	   RS,	   fixation	   stability	   data	   was	  gathered	   as	   an	   exploratory	   outcome.	   It	   was	   analysed	   using	   the	   method	  described	   by	   Fujii	   (Fujii	   et	   al,	   2003)	   but	   in	   hindsight	   using	   the	   bivariate	  contour	   ellipse	   area,	   as	   described	   by	   Crossland	   may	   have	   proved	   more	  sensitive	  to	  detect	  change	  (Crossland,	  et	  al,	  2005).	  Five	  of	  the	  8	  participants	  demonstrated	   no	   change	   in	   the	   fixation	   stability	   (of	   these	   2	   already	   had	  stable	   vision),	   2	   had	   an	   improvement	   in	   their	   fixation	   and	   1	   showed	   a	  decline.	   These	   results	   are	   broadly	   in	   line	   with	   other	   larger	   published	  datasets	  although	  study	  designs	  were	  not	  directly	  comparable	  (Pearce	  et	  al	  2011;	  Munk	  et	  al	  2013).	  The	  relatively	  small	  numbers	  of	  participants,	  short	  study	   duration	   and	   the	   analysis	  method	   precluded	  meaningful	   correlation	  analysis	   with	   VA,	   OCT	   and	   RS.	   Capturing	   FS	   data	   could	   be	   useful	   in	  determining	   the	   preferred	   retinal	   location	   and,	   in	   combination	   with	  qualitative	  aspects	  of	  OCT	  such	  as	  the	  presence	  of	  retinal	  fluid,	  can	  inform	  if	  retreatment	  is	  appropriate.	  	  
8.2.5	  Functional	  MRI	  and	  the	  BOLD	  response	  	  This	  study	  looked	  at	  cortical	  response	  to	  retinal	  treatment	  for	  nvAMD.	  Data	  from	  10	  participants	   from	  the	  same	  cohort	  as	   in	   the	  MP	  study	  undergoing	  routine,	  NICE	  approved	  NHS	  treatment	  were	  analysed.	  All	  had	  VA,	  CRT	  and	  fMRI	  assessments	  prior	  to	  their	  first	  treatment	  and	  then	  on	  a	  further	  three	  occasions,	   prior	   to	   re-­‐treatment.	   The	   Blood	   Oxygenation	   Level	   Dependent	  (BOLD)	   response	   from	   predefined	   Regions	   of	   Interest	   (ROI)	   of	   the	   visual	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cortex,	  which	  corresponded	  either	  to	  the	  macular	  or	  peripheral	  retina,	  were	  studied.	   Averaging	   of	   two	   scans	   in	   a	   session	   and	   averaging	   across	  hemispheres	  corrected	  data	  for	  the	  anticipated	  normal	  variation.	  	  	  The	  VA	   improved	  and	  CRT	  decreased	  broadly	   in	   line	  with	   larger	  data	   sets	  (Martin	  et	  al,	  2011,	  Chakravarty	  et	  al,	  2012,	  Schmidt-­‐Urfurth,	  2014).	  	  There	  was	   a	   decline	   in	   BOLD	   across	   the	   four	   sessions	   however,	   in	   both	   mean	  treated	  and	  untreated	  eyes	  This	  is	  a	  well-­‐documented	  phenomenon,	  thought	  to	  be	  due	  to	  habituation	  or	  attenuation,	  possibly	  because	  the	  same	  stimulus	  is	   presented	   at	   each	   session	   (Rosengarth	   et	   al,	   2013).	   This	   decline	   was	  accounted	   for	  by	  correcting	   the	   treated	  eye	  response	  by	   the	  untreated	  eye	  response	   and	   subsequently	   the	  mean	   treated	   /	   untreated	   BOLD	   response	  increased	  across	   the	  4	  sessions.	  Correlation	  with	  VA	  and	  CRT	  both	  missed	  significance	  and	   this	  may	  be	   explained	  by	  under	  powering	  of	   the	   study	  or	  the	  technique	  itself.	  	  	  The	  main	  conclusions	  of	  this	  aspect	  of	  this	  study	  were	  two	  fold.	  Primarily	  it	  demonstrated	  that	  reactivation	  of	  the	  visual	  cortex	  is	  possible	  after	  a	  period	  of	  inactivity	  due	  to	  nvAMD.	  This	  confirmed	  the	  findings	  from	  the	  single	  case	  reported	  by	  Baseler	  et	  al	  (Baseler	  et	  al,	  2012).	  It	  was	  not	  possible	  however,	  to	   establish	   to	  what	   extent	   the	   visual	   cortex	   is	   able	   to	   recover,	   if	   this	  was	  limited	  by	   retinal	   function	   recovery	  or	   indeed	   if	   there	   is	  a	   critical	  window	  where	   recovery	   is	   possible.	   Different	   study	   designs	   would	   be	   required	   to	  address	  these	  issues.	  Secondarily,	  the	  range	  of	  BOLD	  response	  was	  so	  great	  that	  even	  if	  fMRI	  was	  practical	  to	  perform	  routinely	  it	  would	  not	  be	  a	  useful	  tool	   for	  measurement	   of	   activity	   from	   visit-­‐to-­‐visit	   and	   therefore	   to	   guide	  retreatment.	   It	   may	   have	   potential	   in	   the	   clinical	   setting	   as	   a	   tool	   to	  investigate	  if	  the	  cause	  of	  ‘non	  response’	  to	  treatment	  is	  cortical	  or	  retinal.	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8.2.6	   Measuring	   the	   side	   effects	   of	   treatment.	   The	   amelioration	   of	  
short-­‐term	  intraocular	  pressure	  fluctuations	  with	  oral	  acetazolamide	  	  Chapter	   7	   appreciated	   that	   outcomes	   of	   nvAMD	   treatment	   are	   not	   always	  positive	  (Brown	  et	  al,	  2006;	  Rosenfeld	  et	  al,	  2006)	  and	  that	  thought	  needs	  to	  be	   give	   as	   to	   how	   side	   effects	   are	   measured.	   Side	   effects	   with	   anti-­‐VEGF	  therapy	  can	  be	  classified	  as	  either	  systemic	  or	  ocular	  and	  the	  transient	  rise	  in	   intraocular	   pressure	   (IOP)	   at	   the	   time	   of	   and	   after	   an	   intravitreal	  treatment	   is	   a	   well-­‐documented	   example	   of	   the	   latter.	   (Falkenstein	   et	   al,	  2007;	  Kim	  et	  al,	  2008).	  Individuals	  with	  glaucoma,	  who	  are	  already	  at	  risk	  of	  peripheral	   visual	   loss	   due	   to	   raised	   pressure,	   were	   studied.	   The	   study	   in	  chapter	   7	   was	   a	   randomized	   controlled	   trial	   aimed	   to	   establish	   if	   oral	  acetazolamide,	   a	   diuretic,	   was	   able	   to	   reduce	   pressure	   rise	   following	  intravitreal	  injection	  in	  a	  group	  of	  glaucoma	  and	  glaucoma	  suspect	  patients	  having	  treatment	  for	  nvAMD.	  	  Of	   the	   24	   participants	   studied,	   12	  were	   randomized	   to	   receive	   treatment.	  This	   group	   showed	   a	   numerical	   reduction	   in	   peak	   IOP	   measurement	  (42.2mmHg,	   SD	   10.2)	   compared	   with	   the	   control	   group	   (44.3	   mmHg,	   SD	  19.8).	   All	   points	   out	   to	   the	   end	   of	   the	   study	   at	   30	  minutes	   demonstrated	  similar	   numerical	   difference	   and	   using	   ANOVA	   testing	   no	   difference	  between	   the	   groups	   was	   identified.	   At	   the	   30-­‐minute	   single	   time	   point	  measure	   a	   difference	   in	   the	   two	   groups	   did	   reach	   statistical	   significance	  (15.7mmHg,	  SD	  4.3,	  versus	  20.6	  mmHg,	  SD	  9.5,	  p	  =	  0.013).	  This,	  along	  with	  the	   area	   under	   the	   curve	   post	   analysis,	   provides	   useful	   information	   in	  designing	   future	  studies.	  Despite	   this	  statistical	  difference	  there	   is	  unlikely	  to	  be	  clinical	  significance	  in	  such	  a	  small	  difference	  in	  all	  except	  those	  that	  are	  extremely	  vulnerable	  to	  an	  IOP	  spike.	  	  	  Discussion	  followed	  as	  to	  whether	  it	  is	  the	  IOP	  that	  is	  important	  to	  measure	  or	   in	   fact	   the	   visual	   loss	   caused	  by	   the	   raised	  pressure	   that	   should	  be	   the	  outcome	   of	   interest.	   As	   progression	   of	   visual	   fields	   is	   very	   slow	   and	   can	  sometimes	   be	   unreliable,	   a	   study	   of	  much	   longer	   duration	  with	   numerous	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intravitreal	   injections	  and	  multiple	  visual	   field	  analyses	  would	  be	  required	  to	   address	   the	   issue	   (Choy,	   Kwun,	   Han	   &	   Kee,	   2015).	   Given	   the	   time	   and	  resource	   available,	   studying	   the	   IOP	   change	   as	   a	   proxy	   of	   potential	   visual	  change	  was	  appropriate.	  	  	  
8.3	   Outcome	   measures	   of	   neovascular	   Macular	   Degeneration	   not	  
addressed	  in	  this	  thesis	  	  Outcomes	   of	   any	   treatment	   can	   be	   broadly	   divided	   into	   the	   following	  categories:	   clinical	   (e.g.	   efficacy,	   side	   effects),	   humanistic	   (e.g.	   role	  performance,	   emotional	   status)	   and	   economical	   (e.g.	   expenses,	   saving)	  (Deshpande	  et	  al,	  2011).	  This	  thesis	  has	  mainly	  addressed	  clinical	  and	  some	  humanistic	  outcomes	  and	  has	  not	  aimed	  to	  address	  economic	  outcomes.	  The	  main	  focus	  has	  been	  on	  VA,	  CRT	  and	  IOP	  as	  commonly	  used	  outcomes	  and	  PROMS,	   MP	   and	   fMRI	   in	   what	   could	   be	   considered	   as	   primarily	   research	  tools.	   Other	   ways	   of	   assessing	   vision	   are	   the	   topic	   of	   the	   following	  discussion.	  	  	  
8.3.1	  Near	  (reading)	  visual	  acuity	  and	  reading	  speed	  	  The	   effect	   on	   reading	   performance	   (reading	   visual	   acuity	   and	   speed)	   has	  been	   studied	   in	   depth	   in	  AMD	   (Legge	   et	   al,	   1997;	   Stifter,	   Sacu,	   Benesch	  &	  Weghaupt,	   2005;	   Richter-­‐Mueksch,	   Stur,	   Stifter	   &	   Radner,	   2006;	   Cacho,	  Dickinson,	  Smith	  &	  Harper,	  2010).	  Reading	  performance	  has	  been	  shown	  to	  be	   significantly	   impaired	   in	   AMD	  with	   60%	   of	   the	   impairment	   in	   reading	  speed	  being	  due	   to	   reduced	  near	  acuity	  and	   scotomas	   (Cacho	  et	   al,	   2010).	  This	   is	   in	   contrast	   to	   distance	   acuity,	   which	   only	   has	   a	   10%	   influence	   on	  reading	  performance	  (Legge	  et	  al,	  1992).	  Late	  stage	  AMD	  disproportionately	  affects	   reading	   performance	   more	   than	   distance	   visual	   acuity	   (Richter-­‐Mueksch	   et	   al,	   2006).	   Furthermore	   reading	   acuity	   has	   been	   shown	   to	  improve	   more	   than	   distance	   VA	   when	   nvAMD	   is	   treated	   (Frennesson,	  Nilsson,	  Peebo	  &	  Nilsson,	  2010).	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8.4.2.	  Contrast	  sensitivity	  	  Contrast	   is	   the	   luminance	   or	   colour	   of	   an	   object	   that	   makes	   its	  distinguishable	  from	  its	  background.	   	  Contrast	  sensitivity	  (CS)	  is	  the	  ability	  to	  discern	  the	  difference	  in	  luminance	  between	  objects.	  It	  has	  also	  been	  well	  studied	   in	   AMD	   (Mones	   &	   Rubin,	   2005;	   Bansback	   et	   al,	   2007;	   Patel	   et	   al,	  2011).	  In	  a	  study	  of	  209	  patients	  with	  AMD,	  CS	  correlated	  more	  closely	  with	  visual	   function	   and	   quality	   of	   life	   utility	   than	   did	   distance	   visual	   acuity	  (Bansback	   et	   al,	   2007).	   Contrast	   sensitivity	   was	   reported	   to	   be	   a	   more	  sensitive	  test	  of	  visual	  function	  change	  than	  distance	  VA	  when	  121	  nvAMD	  patients	  were	  treated	  with	  bevacizumab	  in	  the	  ABC	  trial	  (Patel	  et	  al,	  2011).	  Furthermore	   OCT	   morphology	   correlated	   well	   with	   CS,	   in	   particular	   CS	  decreasing	   with	   an	   increasing	   amount	   of	   subretinal	   tissue	   (Keane	   et	   al,	  2010).	  It	  may	  be	  expected	  that	  CS	  would	  correlate	  well	  with	  RS,	  however	  in	  a	  small	  study	  of	  23	  participants	  no	  relationship	  was	  identified.	  The	  authors	  feel	   that	   this	   may	   be	   because	   the	   study	   was	   underpowered	   (Hautamaki,	  Oikkonen,	  Onkamo	  &	  Immonen,	  2014).	  	  
8.4	  	  Conclusions	  	  There	  are	  numerous	  ways	  of	  assessing	  outcomes	  of	  the	  treatment	  of	  nvMD.	  Ultimately	  the	  goal	  of	  any	  therapeutics	  is	  to	  maintain	  or	  improve	  quality	  of	  life	  and	  this	  can	  be	  measured	  directly	  with	  health	  utility	  scores.	  Given	  their	  nature,	   such	   indicators	   would	   perform	   poorly	   in	   assessing	   the	   effects	   of	  immediate	   treatment	   are	   so	   best	   used	   to	   retrospectively	   assess	  interventions.	  To	  assess	  immediate	  effect	  proxy	  measurements	  of	  quality	  of	  life	   are	   required.	   	   It	   is	   clear	   that	   this	   principal	   proxy	   outcome	   measure	  should	   be	   governed	   by	   the	   reason	   for	  measuring	   the	   change.	   The	   reasons	  include	  the	  need	  to	  describe	  the	  response	  of	  a	  population,	  in	  which	  case	  VA	  or	  CRT	  are	  appropriate,	  or	   to	  help	  guide	  treatment	  decision,	   in	  which	  case	  OCT	  morphology	  or	  RS	  are	  better	  suited.	  Even	  within	  these	  categories	  some	  measures	   may	   outperform	   others.	   For	   example	   CRT	   is	   a	   more	   objective	  measure	  than	  VA,	  but	  in	  some	  individuals	  may	  be	  of	  less	  relevance	  than	  VA.	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Resources	   and	   practical	   issues	   are	   important	   to	   consider;	   the	   time	   and	  ability	   to	   perform	   complex	   technology	   dependent	   measures,	   even	   though	  they	   are	   very	   sensitive,	   may	   render	   them	   better	   as	   research	   tools.	   An	  example	  of	  this	  is	  the	  use	  of	  fMRI.	  	  	  The	  acquisition	  of	  many	  outcome	  measures	  can	  enable	  a	  composite	  view	  of	  response	   to	   treatment.	   In	   this	  way	   the	   individual	   outcome	  measurements	  can	  work	   synergistically.	   This	   process	   requires	   an	   individual	   to	   assimilate	  all	   the	   pieces	   of	   relevant	   information	   and	   put	   them	   into	   context	   of	   the	  question	  to	  be	  addressed.	  	  There	   are	  many	   aspects	   of	   this	   thesis	   that	   have	   provided	   insight	   into	   the	  successful	  delivery	  of	  high	  quality	  research;	  the	  importance	  of	  study	  design,	  methodology,	   attention	   to	   the	   recruitment	   window	   and	   a	   focus	   on	  participant	   retention	   have	   been	   particularly	   pertinent.	   Taking	   this	   into	  account	  and	  as	  is	  often	  the	  case	  in	  research,	  accepting	  that	  there	  are	  many	  new	   questions	   that	   have	   been	   generated,	   this	   thesis	   has	   generated	   useful	  insights	  in	  assessing	  the	  outcomes	  of	  nvMD	  treatment.	  	  Understandably	  there	  is	  a	  tendency	  for	  early	  phase	  clinical	  trials	  to	  focus	  on	  easily	  quantifiable	  measure	  of	   success	  such	  as	  VA	  or	   retinal	  morphology.	   I	  would	   hope	   that	   earlier	   phases	   of	   evaluation	   of	   therapeutic	   interventions	  would	   also	   explore	   alternative	   outcomes	   such	   as	   retinal	   sensitivity.	   As	  clinical	  trials	  begin	  to	  develop	  for	  treatment	  of	  conditions	  where	  the	  natural	  history	   is	   for	   visual	   acuity	   to	   change	   very	   slowly,	   such	   as	   Geographic	  Atrophy,	  clearly	  new	  study	  endpoints	  are	  required.	  Again,	  retinal	  sensitivity	  may	  be	  more	  appropriate.	  Visual	  cortex	  outcomes	  may	  also	  be	  appropriate	  in	   these	   circumstances,	   particularly	   in	   the	   knowledge	   that	   there	  may	  be	   a	  loss	  of	  volume	  or	  activity	  of	  the	  cortex	  in	  the	  long	  term	  and	  that	  putatively	  neuroprotection	  could	  play	  an	   important	  role.	  Ultimately,	  and	  in	  particular	  for	  the	  later	  phase	  clinical	  trials,	  quality	  of	  life	  utilities,	  which	  are	  the	  most	  important	  outcomes	  for	  individuals,	  should	  be	  given	  higher	  priority.	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Appendices	  
	  
Appendix	  A.	  The	  W-­‐BQ12	  Well-­‐being	  questionnaire	  
	  
	  Item	   Negative	  well-­‐being	   Energy	   Positive	  well-­‐being	  I	  have	  episodes	  of	  crying	  or	  wanting	  to	  cry	   	   	   	  I	  feel	  down	  hearted	  and	  sad	   	   	   	  I	  feel	  fear	  for	  no	  reason	   	   	   	  I	  become	  easily	  upset	  and	  panic	   	   	   	  I	  feel	  energetic,	  active	  and	  full	  of	  vitality	   	   	   	  I	  feel	  without	  energy	  and	  weak	   	   	   	  I	  feel	  tired,	  worn	  out	  or	  exhausted	   	   	   	  I	  wake	  up	  felling	  fresh	  and	  rested	   	   	   	  I	  am	  happy,	  satisfied	  or	  content	  with	  my	  personal	  life	   	   	   	  I	  have	  the	  type	  of	  life	  I	  wanted	   	   	   	  I	  feel	  enthusiastic	  to	  get	  on	  with	  daily	  tasks	  or	  take	  new	  decisions	   	   	   	  I	  feel	  I	  can	  easily	  deal	  with	  any	  serious	  problem	  or	  big	  change	  in	  my	  life.	   	   	   	  
	  
	  
Appendix	  B.	  The	  MacTSQ	  Treatment	  satisfaction	  questionnaire	  	  1. How	  satisfied	  are	  you	  with	  the	  treatment	  for	  your	  MD?	  2. How	   bothered	   are	   you	   by	   any	   side	   effects	   or	   other	   effects	   you	  experienced	  with	  the	  treatment	  for	  your	  MD?	  3. How	  bothered	  are	  you	  by	  any	  discomfort	  or	  pain	  from	  the	  treatment	  for	  your	  MD?	  4. How	  do	  you	  feel	  the	  treatment	  for	  your	  MD	  is	  working?	  5. How	  unpleasant	  did	  you	  find	  the	  treatment	  for	  your	  MD?	  
	   171	  




	   172	  
Appendix	  C.	  Raw	  BOLD	  data	  for	  participants	  1-­‐10-­‐	  Left	  and	  right	  hemisphere	  projected	  amplitude	  across	  all	  4	  sessions	  for	  both	  the	  treated	  and	  untreated	  eye.	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   PP_Left	  Hem_ProjAmp	  	  	   Treated	  Eye	   Untreated	  Eye	  Participant	   Session	  1	   Session	  2	   Session	  3	   Session	  4	   Session	  1	   Session	  2	   Session	  3	   Session	  4	  1	   0.199852	   	   0.177254	   0.028077	   0.445891	   	  	   0.541926	   0.120751	  2	   1.587112	   1.142707	   	   1.970797	   1.462461	   1.433796	   	   1.634187	  3	   0.197924	   0.191190	   0.273981	   0.211132	   0.241968	   0.299090	   0.146287	   0.362546	  4	   0.300632	   0.340123	   0.168455	   	   0.437856	   0.498992	   0.510980	   	  	  5	   0.035295	   	   0.144161	   0.102315	   0.121328	   	   0.105470	   0.179376	  6	   0.584713	   0.909950	   0.388482	   0.574210	   0.187114	   0.213241	   0.138982	   0.490987	  7	   0.648770	   0.382172	   0.656346	   0.745081	   0.706105	   0.370161	   0.509113	   0.307332	  8	   0.015962	   0.026680	   0.166332	   0.250102	   0.298358	   0.145402	   0.212310	   0.283924	  9	   0.154021	   0.394266	   0.183401	   	   0.344309	   0.738739	   0.528823	   	  	  10	   -­‐0.456334	   0.053861	   1.143094	   1.456971	   0.615644	   0.708574	   1.150516	   1.198214	  	   	   	   	   	   	   	   	   	  
PP_Right_Hem_ProjAmp	  Treated	  Eye	   Untreated	  Eye	  Session	  1	   Session	  2	   Session	  3	   Session	  4	   Session	  1	   Session	  2	   Session	  3	   Session	  4	  	  	  0.190795	   	  	   0.245601	   0.098371	   0.276177	   	  	   0.331438	   0.20571	  0.595263	   0.889731	   	   0.738290	   0.266001	   1.097948	   	   1.099594	  0.299272	   0.196710	   0.20282	   0.375874	   0.313938	   0.032305	   0.422897	   0.157396	  	   0.179509	   0.061465	   0.15052	   	   0.124951	   0.150538	   0.010907	   	  	  0.233128	   	   -­‐0.05200	   0.222557	   0.556975	   	   0.373369	   0.329240	  2.710465	   2.314634	   1.882082	   2.126247	   1.062131	   1.874393	   1.599101	   2.504829	  0.386992	   0.252248	   0.377487	   0.388136	   0.506045	   0.344709	   0.340193	   0.276683	  0.276350	   0.178966	   0.294250	   0.209231	   0.632990	   0.220506	   0.236842	   0.271296	  0.760945	   1.288191	   1.241026	   	  	   0.871843	   1.430766	   1.389128	   	  	  0.203453	   0.006687	   -­‐0.36734	   0.003686	   0.042165	   0.066416	   0.121872	   0.010442	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Line_Right_Hem_ProjAmp	  Treated	  Eye	   Untreated	  Eye	  Session	  1	   Session	  2	   Session	  3	   Session	  4	   Session	  1	   Session	  2	   Session	  3	   Session	  4	  0.890321	   	  	   0.880818	   0.276000	   0.601474	   	  	   0.947429	   0.200337	  0.945582	   1.299540	   	   1.030788	   0.556175	   1.353398	   	   1.340461	  0.448729	   0.236317	   0.354217	   0.472443	   0.275876	   0.268415	   0.473296	   0.278034	  0.603537	   0.846508	   0.415649	   	  	   0.398622	   -­‐1.123799	   0.495722	   	  	  0.270391	   	   -­‐0.083958	   0.099623	   0.744949	   	   0.592507	   -­‐0.504903	  1.265250	   0.897362	   -­‐1.127648	   1.018246	   0.418475	   1.322228	   0.745803	   1.351727	  0.656800	   0.411092	   -­‐0.611596	   -­‐0.614306	   -­‐0.654271	   0.393036	   0.499581	   0.452691	  0.543412	   0.693411	   0.489000	   0.512592	   -­‐0.696131	   0.636431	   0.569816	   0.607865	  -­‐1.032286	   1.796397	   1.696452	   	  	   1.227540	   1.696585	   1.694391	   	  	  0.328651	   0.120536	   0.037389	   0.080819	   0.358883	   0.269647	   0.138510	   0.150211	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Definitions	  	  ABC	   Bevacizumab	  for	  Neovascular	  Age-­‐related	  Macular	  Degeneration	  trial	  ANCHOR	   Anti-­‐VEGF	  antibody	  for	  treatment	  of	  predominantly	  classic	  choroidal	  neovascularisation	  in	  AMD	  study	  ANOVA	   Analysis	  of	  Variance	  Anti-­‐VEGF	   Anti-­‐Vascular	  endothelial	  Growth	  Factor	  AMD	   	   Age-­‐related	  Macular	  Degeneration	  AREDS	  	   Age-­‐related	  Eye	  Disease	  Study	  Group	  BCVA	   	   Best	  Corrected	  Visual	  Acuity	  BH	   	   Base	  Hospital	  BOLD	   	   Blood	  Oxygen	  Level	  Dependent	  BSE	   	   Better	  seeing	  eye	  CATT	   	   Comparison	  of	  anti-­‐VEGF	  Treatment	  Trial	  CEC	   	   Community	  Eye	  Clinic	  CRT	   	   Central	  Retinal	  Thickness	  CNV	   	   Choroidal	  Neovascular	  Membrane	  dB	   	   Decibels	  ETDRS	  	   Early	  Treatment	  Diabetic	  Retinopathy	  Study	  FDA	   	   Food	  and	  Drug	  Administration	  FFA	   	   Fundus	  Fluorescein	  Angiography	  fMRI	   	   Functional	  Magnetic	  Resonance	  Imaging	  GA	   	   Geographic	  Atrophy	  ICG	   	   Indocyanine	  angiography	  IOP	   	   Intraocular	  Pressure	  IVAN	   	   Investigation	  of	  anti-­‐VEGF	  Agents	  in	  Neovascular	  AMD	  Trial	  LGN	   	   Lateral	  Geniculate	  Nuclei	  LogMAR	   Logarithm	  of	  Minimum	  Angle	  of	  Resolution	  MARINA	   Minimally	  Classic/Occult	  Trial	  of	  the	  Anti-­‐VEGF	  Antibody	  Ranibizumab	  in	  the	  Treatment	  of	  Neovascular	  AMD	  MacTSQ	   Macular	  Treatment	  Satisfaction	  Questionnaire	  MD	   	   Macular	  Degeneration	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MMD	   	   Myopic	  Macular	  Degeneration	  MP	   	   Microperimetry	  MPS	   	   Macular	  Photocoagulation	  Study	  MRI	   	   Magnetic	  Resonance	  Imaging	  NEI	  VFQ	   National	  Eye	  Institute	  Visual	  Function	  Questionnaire	  NHS	   	   National	  Health	  Service	  NICE	   	   National	  Institute	  for	  Health	  and	  Clinical	  Excellence	  OCT	   	   Optical	  Coherence	  Tomography	  nvAMD	   Neovascular	  Age-­‐related	  Macular	  Degeneration	  nvMD	   	   Neovascular	  Macular	  Degeneration	  PCV	   	   Polypoidal	  Choroidal	  Vasculopathy	  PDT	   	   Photodynamic	  Therapy	  PED	   	   Pigment	  Epithelial	  Detachment	  PlGF	   	   Placental	  Derived	  Growth	  Factor	  PM	   	   Pathological	  Myopia	  	  
prn	   	   Pro	  re	  nata	  /	  as	  required	  PRO	   	   Patient	  Reported	  Outcome	  PROM	   	   Patient	  Reported	  Outcome	  Measure	  RADINACE	   A	  randomized	  controlled	  study	  of	  ranibizumab	  in	  patients	  with	  choroidal	  neovascularisation	  secondary	  to	  pathological	  myopia.	  RAP	   	   Retinal	  Angiomatous	  Proliferation	  RPE	   	   Retinal	  Pigment	  Epithelium	  SAE	   	   Serious	  Adverse	  Events	  SAILOR	   Safety	  of	  ranibizumab	  in	  subjects	  with	  nvAMD	  trial	  SmPC	   	   Summary	  of	  Product	  Characteristics	  SPSS	   	   Statistical	  Package	  for	  the	  Social	  Sciences	  SD	   	   Standard	  Deviation	  TAP	   Treatment	  of	  Age-­‐related	  Macular	  degeneration	  with	  Photodynamic	  therapy	  study	  TAG	   Technology	  appraisal	  guidance	  TTT	   Transpupillary	  Thermotherapy	  V1	   	   Primary	  Visual	  Cortex	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V2	   	   Secondary	  Visual	  cortex	  V3	   	   Tertiary	  Visual	  Cortex	  V4	   	   Quaternary	  Visual	  Cortex	  V5	   	   Fifth	  Visual	  Cortex	  VA	   	   Visual	  Acuity	  VEGF	   	   Vascular	  Endothelial	  Growth	  Factor	  VIP	   	   Verteporfin	  in	  Pathological	  Myopia	  study	  W-­‐BQ12	   12	  Item	  Well-­‐Being	  Questionnaire	  WSE	   	   Worst	  seeing	  eye	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